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Abstract 
 
Myeloproliferative Neoplasms (MPNs) are a group of clonally derived stem-cell disorders of 
haematopoietic progenitors resulting in a proliferation of differentiated myeloid cell types. They 
include polycythaemia vera (PV), essential thrombocythaemia (ET), and myelofibrosis (MF). JAK2 
encodes a non-receptor tyrosine kinase and mutations in this gene are found in a large percentage of 
MPN cases. It is present in approximately 95% of PV and between 50-60% of ET and PMF cases. JAK2 
plays a key role in cell proliferation and differentiation of haematopoietic stem cells to mature blood 
cells. 
Expression of key haematopoietic genes were studied along with their relationship to haematological 
parameters and JAK2 mutational status. Anagrelide was used to target the haematopoietic 
transcription factor, GATA1, in MPN model cell lines. The effect of this drug on downstream effectors 
of megakaryocytic differentiation was also studied to determine potential mechanisms for its anti-
platelet activity in essential thrombocythaemia. Ruxolitinib, a JAK1/2 inhibitor, was used to block JAK2 
and the downstream effects on STAT, SOCS and interferon-gamma target proteins were quantified. 
Global proteomic changes were studied, using isobaric tagging and relative quantification and LC-
MS/MS. This inhibitor was also used to examine the importance of JAK2 signalling in erythropoiesis 
and colony growth in primitive progenitor cells isolated from MPN patients.  
GATA1 expression was found to be dysregulated in the PBMCs of ET patients. In cell lines, expression 
of downstream GATA1 targets were found to be downregulated during inhibition of megakaryopoiesis 
using anagrelide. Functional protein analysis showed that STAT1 and associated key molecular 
pathways involved in interferon signalling were the target of JAK2 inhibition by ruxolitinib. 
The results in this study suggest a potential role for GATA1 as a disease biomarker, independent of 
JAK2 mutational status. The activity of the anti-platelet drug, anagrelide, may in part be due to 
targeting of GATA1 downstream targets. STAT1 is likely to play a key role in MPN pathogenesis and 
response to JAK inhibitor therapies. 
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1.1: Background 
 
Myeloproliferative neoplasms (MPN) are a group of bone marrow diseases arising from clonal 
disorders of haematopoietic stem cells (Nangalia et al., 2016). They manifest in the overproduction of 
one or more types of mature blood cell. Traditionally, they have been classified into one of two groups, 
Philadelphia chromosome positive (Ph1+) or negative (Ph1-), depending on the presence or absence 
of a chromosomal translocation (t(9;22) (q34;q11)), resulting in the expression of a constitutively 
active fusion gene product, breakpoint cluster region-Abelson tyrosine kinase 1(BCR-ABL1).   
1.2: BCR-ABL1 
 
A chromosomal abnormality present in patients with chronic myeloid leukaemia (CML), but not in 
those with acute myeloid leukaemia (AML), was identified in 1960 (Hungerford and Nowell, 1960). 
Rowley (1973) determined that this abnormality was the result of a reciprocal translocation between 
chromosome 9 and 22. The ABL1 gene on chromosome 9 is fused with the breakpoint cluster region 
(BCR) gene to generate a fusion gene BCR-ABL1. The resulting chimeric BCR-ABL1 protein that is 
expressed is a constitutively active tyrosine kinase. There are three main variants of the BCR-ABL1 
protein, p190, p210 and p230, which are each associated with a particular disease phenotype and 
kinase activity, with p210 the subtype found primarily in CML (Li et al., 1999). 
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Figure 1: Diagram of reciprocal translocation in CML and the generated Philadelphia Chromosome 
(Lydon, 2009). 
1.3: The BCR-ABL negative MPN 
 
“Myeloproliferative disorders” were first described as a distinct group by Dameshek in the 1950s to 
describe several disorders that he speculated shared a common origin (Dameshek, 1951, Tefferi, 2008). 
Essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (MF) had all been 
identified by the early twentieth century, and trilineage myeloproliferation had been recognised in PV 
and other MPDs (Dameshek, 1951, Tefferi, 2008). These were formally classified CML, PV, ET and MF 
along with erythroleukaemia (later redefined as acute erythroid leukaemia forming a subtype of AML) 
(Dameshek, 1951). Dameshek recognised that despite these disorders being primarily associated with 
one cell type, it often coincided with proliferation of others. Further to this, he proposed that the 
various manifestations of disease occurred as a result of differential stimulatory activity on bone 
marrow cells. At the time, the source of the myelostimulatory activity was speculated to be 
endogenous steroid hormones (Dameshek, 1951). 
1.4: Myeloproliferative Neoplasms: WHO Classification (2001 – 2016) 
 
In 2001, the World Health Organisation attempted to classify the numerous myeloproliferative 
disorders resulting in four groupings, 1) chronic myeloproliferative disorders (CMPD), 2) 
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myelodysplastic syndromes (MDS), 3) MDS/MPD crossover diseases and 4) mast cell disease (MCD). 
CMPD included PV, ET, MF, CML, as well the rarer chronic neutrophilic leukaemia (CNL), chronic 
eosinophilic leukaemia (and the hypereosinophilic syndrome) (CEL/HES) and CMPD unclassified. The 
principal criteria for classification in the CMPD group was a shared effective clonal myeloproliferation 
(Tefferi and Vardiman, 2008). 
The discovery of molecular disease markers, including the JAK2V617F somatic mutation in 2005, led to 
the revised 2008 WHO classification, with myeloproliferative diseases renamed myeloproliferative 
neoplasms (MPNs) (Tefferi and Vardiman, 2008). The major changes to the 2001 classification included 
a separate grouping outside of MPN for myeloid neoplasms associated with eosinophilia and 
abnormalities of PDGFRA, PDGFRB and FGFR1 (Bain, 2010). MCD was grouped with the MPNs, in 
recognition that like other MPNs it arises from a clonal stem cell disorder (Tefferi and Vardiman, 2008). 
Diagnostic criteria for the MPNs were also further defined in the 2008 WHO classification, the 
aforementioned JAK2V617F mutation providing additional information to assist with diagnosis 
(Vardiman et al., 2009). The JAK2V617F mutation is not in itself specific to any of the MPNs but can be 
used along with other diagnostic criteria to eliminate other causes (Bench et al., 2013). 
Although the 2008 diagnostic criteria and associated algorithms appear to provide a mechanism for 
clearly distinguishing between different MPNs, there remained debate concerning patients whose 
symptoms overlap more than one of these conditions, in particular whether patients diagnosed with 
ET should be categorised as having either “true ET” or “pre-fibrotic MF”. Campbell et al. (2009a) 
demonstrated that the reticulin grade at diagnosis was a prognostic marker for disease activity and 
duration. However, these findings were disputed by Thiele (2009), who questioned whether a 
significant cohort of these patients should have been classified as MF with thrombocythaemia rather 
than “true” ET. Counter to this, the Campbell group argued that 17% of their patients did not meet 
the strict WHO guidelines for either ET or MF diagnosis, but clearly had a myeloproliferative neoplasm 
(Campbell et al., 2009b). The major issue of contention between the groups would appear to concern 
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whether narrow diagnostic criteria, such as that for prefibrotic MF have a clinical utility over broad 
categories that aim to capture all patients. Barosi et al. (2012) demonstrated that prefibrotic MF was 
aligned in a biological and clinical continuum with myelofibrosis. It has previously been proposed that 
all the classic Ph1- MPNs form a continuum, where progression from a chronic to an accelerated 
chronic and finally acute phase of disease is represented by PV and ET developing to MF and finally 
AML (Campbell et al., 2005).  
In an attempt to address the issues surrounding ET and MF diagnoses, the WHO have released updated 
criteria distinguishing pre-MF from “true” ET (Arber et al., 2016). The diagnostic criteria for ET, pre-
MF and overt MF have now also been updated to recognise the CALR mutation (Klampfl et al., 2013, 
Nangalia et al., 2013). Guidance has also been provided to myelofibrosis grading, which is used in 
distinguishing between the ET, pre-MF, and overt-MF disease continuum. 
Potential under-diagnosis of PV has also been addressed in the 2016 revision to MPN classification of 
myeloid neoplasms. A study of patients with the JAK2V617F mutation and bone marrow morphology 
consistent with the 2008 WHO criteria but haemoglobin levels lower than the major diagnostic criteria 
showed significantly increased risk of disease transformation to MF and acute leukaemia compared 
to diagnosed PV patients (Barbui et al., 2014). It is not yet known whether this is an early form of PV 
or whether it represents an initial myelofibrosis stage given its poorer prognosis (Barbui et al., 2014). 
For now the diagnostic criteria for haemoglobin levels have been reduced and greater importance is 
attached to bone marrow morphology (now a major criteria) meaning these cases are grouped with 
PV (Arber et al., 2016). A typical flow chart for the steps involved in MPN diagnosis is illustrated in 
Figure 2.  
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Figure 2: Typical diagnostic algorithm for MPNs (Tefferi and Pardanani, 2014). 
1.4.1: Polycythaemia Vera (PV) 
 
PV is a myeloproliferative neoplasm characterised by an elevated number of erythrocytes, greater 
than 25% red cell mass above normal (Arber et al., 2016). This overproduction of red blood cells can 
lead to vascular and thrombotic complications which can have serious implications for the patient’s 
quality of life (Stein et al., 2014). Some of the symptoms commonly encountered in PV include pruritus, 
fatigue, night sweats, bone pain, thrombosis, and bleeding (Griesshammer et al., 2015). Median age 
of diagnosis of patients is between 55 and 60 years old (Harrison and Keohane, 2013). Annual 
incidence rate has been estimated at 0.86 per 100,000 based on pooled data from European studies 
(Titmarsh et al., 2014). The risk for transformation to myelofibrosis (MF) and acute myeloid leukaemia 
over 10-15 years is 10-15% and 5-10% respectively (Harrison and Keohane, 2013).  
7 
 
Table 1: 2016 WHO Diagnostic Criteria for PV. A diagnosis of PV is determined by the presence of all 
three major criteria or the 1st two major criteria and the minor criteria (Arber et al., 2016). 
  POLYCYTHAEMIA VERA 
Major Criteria 
1 
Haemoglobin > 165/160 g/L (men/women) 
OR 
Haemocrit > 49/48% (men/women) 
OR 
Elevated red cell mass > 25% above mean normal predicted value 
2 
BM biopsy showing hypercellularity for age with trilineage growth 
(panmyelosis) including prominent erythroid, granulocytic, and 
megakaryocytic proliferation with pleomorphic, mature megakaryocytes 
(differences in size). This criterion may not be required in cases with sustained 
absolute erythrocytosis, haemoglobin levels > 185/165 g/L and haematocrit 
> 49.5% 
3 Presence of JAK2V617F or similar mutation 
Minor Criteria 1 Subnormal serum EPO level 
 
1.4.2: Essential Thrombocythaemia (ET) 
 
ET is defined by an elevated circulating platelet count (> 450 x 109 /L) and increased numbers of 
megakaryocytes (Tefferi and Vardiman, 2008). Diagnosis also requires elimination of other 
myeloproliferative disorders. The presence of a clonal marker such as JAK2V617F is indicative, as well as 
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ruling out secondary or reactive thrombocytosis as a cause of elevated platelet counts. Overall median 
survival (19.8 years) is longer than seen in PV (13.5 years) but still lower than the age-matched control 
population (Tefferi et al., 2014a). Reflecting the longer survival rates, the risk of disease 
transformation, myeloid or leukaemic, is low in the first decade of life (9.1% and 1.4% respectively) 
but increases significantly into the second (28.3 and 8.1%), and third decades after diagnosis (58.5% 
and 24.0%)  (Wolanskyj et al., 2006).  
Table 2: 2016 WHO Diagnostic Criteria for ET. All four major criteria required for diagnosis or first 
three major criteria and the minor criteria (Arber et al., 2016). 
  ESSENTIAL THROMBOCYTHAEMIA 
Major Criteria 
1 Platelet count ≥ 450 x 109 /L 
2 
BM biopsy showing proliferation mainly of the megakaryocyte lineage with 
increased numbers of enlarged, mature megakaryocytes with hyperlobulated 
nuclei. No significant increase or left shift in neutrophil granulopoiesis or 
erythropoiesis and very rarely minor (grade 1) increase in reticulin fibres 
3 Not meeting WHO criteria for CML, PV, MF, MDS or other myeloid neoplasm 
4 Presence of JAK2, CALR, or MPL mutation 
Minor Criteria 
1 
Presence of a clonal marker or absence of evidence for reactive 
thrombocytosis 
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Table 3: 2016 WHO Diagnostic Criteria for pre-MF. Diagnosis requires meeting all three major and one 
minor criteria. Minor criteria to be confirmed twice on consecutive investigations (Arber et al., 2016). 
  PRE-MF 
Major Criteria 
1 
Megakaryocytic proliferation and atypia, without reticulin fibrosis > grade 1, 
accompanied by increased age-adjusted BM cellularity, granulocytic 
proliferation, and often decreased erythropoiesis 
2 
Not meeting WHO criteria for CML, ET, PV, MF, MDS, or other myeloid 
neoplasm 
3 
Presence of JAK2, CALR, or MPL mutation or in the absence of these 
mutations, presence of another clonal marker, or absence of reactive 
myelofibrosis 
Minor Criteria 
1 Anaemia not attributed to a comorbid condition 
2 Leucocytosis: ≥ 11 × 109/L 
3 LDH increased to above upper normal limit of institutional reference range 
4 Palpable splenomegaly 
 
1.4.3: Myelofibrosis (MF) 
 
Myelofibrosis is the least common of the three main non-CML myeloproliferative neoplasms, 
accounting for approximately 0.47 new cases per 100,000 (Titmarsh et al., 2014). It is nonetheless the 
most serious and has a worse prognostic outcome than either PV or ET (Tefferi et al., 2014a). Median 
survival in MF is 5.9 years (Tefferi et al., 2014a). Blast transformation and progression to AML occurs 
in up to 25% of MF patients (Harrison and Keohane, 2013). Constitutional symptoms have a significant 
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negative impact on quality of life, these arise as a result of bone marrow failure or splenomegaly and 
include sweating, pruritus, fever and bone pain (Harrison and Keohane, 2013). 
Table 4: 2016 WHO Diagnostic Criteria for overt MF. Diagnosis requires meeting all three major and 
one minor criteria. Minor criteria to be confirmed twice on consecutive investigations (Arber et al., 
2016). 
  MYELOFIBROSIS 
Major Criteria 
1 
Presence of megakaryocytic proliferation and atypia, accompanied by either 
reticulin and/or collagen fibrosis grades 2 or 3 
2 Not meeting WHO criteria for CML, ET, PV, MDS, or other myeloid neoplasm 
3 
Presence of JAK2, CALR, or MPL mutation or in the absence of these 
mutations, presence of another clonal marker, or absence of reactive 
myelofibrosis 
Minor Criteria 
1 Anaemia not attributed to a comorbid condition 
2 Leucocytosis: ≥ 11 × 109/L 
3 LDH increased to above upper normal limit of institutional reference range 
4 Palpable splenomegaly 
5 Leucoerythroblastosis 
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1.5: Janus Kinases (JAK) 
 
Janus kinases (JAK) are a family of four cytoplasmic non-receptor tyrosine kinases, comprising of JAK1-
3 and TYK3 (Yamaoka et al., 2004). Janus kinase family members, despite their structural similarities, 
play crucial and non-redundant roles in multifunctional areas such as embryonic development, 
haematopoiesis, and immune regulation. JAK1, JAK2 and TYK2 are ubiquitously expressed, while JAK3 
is found mostly in haematopoietic cells (Ghoreschi et al., 2009). The four JAK kinases share a common 
structure: receptor-binding domains are located at the N-terminal, while the catalytic active kinase 
and pseudokinases are at the C-terminal (Degryse et al., 2014). They are responsible for transmitting 
signals from extracellular stimuli across the cell membrane and through the cytoplasm to the nucleus. 
Cytokine receptors on the cell surface lack protein kinase domains and rely on the catalytic activity of 
non-receptor tyrosine kinases, such as JAK2, for phosphorylation and recruitment of other signal 
transducing proteins (Babon et al., 2014). JAK2, as with other members of the JAK protein family, is 
comprised of seven homology domains (Figure 3). JH1 is located closest to the carboxyl end and JH7 
nearest the N-terminal end. JH1 contains the catalytic activity while JH7 is responsible for receptor 
binding (Figure 3). 
 
Figure 3: Homology domains of JAK2. Receptor binding occurs at the N-terminus while kinase activity 
(JH1) is at the carboxyl end. 
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JAK is activated by cytokine binding to the receptor, resulting in dimerization or a conformational 
change leading to increased kinase activity (Furqan et al., 2013). Activated JAKs can then in turn 
phosphorylate tyrosine residues on the cytoplasmic portion of the receptor. JH2 shares much 
homology with JH1 domain but lacks enzymatic activity and is regarded as a pseudokinase domain 
(Furqan et al., 2013). It has an inhibitory effect on JH1 through the phosphorylation of two negative 
regulatory sites in JAK2, Ser523 and Tyr570 (Ungureanu et al., 2011). 
Experiments have shown that both JAK1 and JAK2 knockout result in a lethal phenotype. JAK1 null 
mice (JAK-/-) are smaller in size and die a few hours after birth (Rodig et al., 1998, Sakamoto et al., 
2016). Experiments with cells from JAK1 knockout mice showed a lack of biologic responses to type II 
cytokine receptors, including those for interferon-α (IFN-α) and interferon-γ (IFN-γ) (Rodig et al., 1998), 
and JAK1 deficient LSK cells do not respond to type 1 interferons (Kleppe et al., 2016). Knockout of 
JAK2 in mice produces an embryonic lethal phenotype by 12.5 days; conditional knockout from E12.5 
to 4 days post-natal also resulted in death due to impaired haematopoiesis (Park et al., 2013). Deletion 
of JAK2 in adult mice (> 2 months) resulted in severe impairment of erythropoiesis and thrombopoiesis, 
and lethality in 20% of cases (Park et al., 2013). 
Mutations in JAK2 are found in a wide range of haematological malignancies. Most frequently, 
mutations in the pseudokinase domain or in the nearby exon 12 are associated with myeloproliferative 
neoplasms, PV, ET, and MF (Lundberg et al., 2014). Mutations are also found in some rare cases of de-
novo acute myeloid leukaemia (AML) (Fröhling et al., 2006, Lee et al., 2006, Steensma et al., 2006). 
Translocations of the JAK2 gene locus, resulting in a JAK2 fusion protein have also been reported in 
cases of AML and CML (Ho et al., 2010). Mutations and translocations in the 9p24 region of the JAK2 
gene have been detected in over 30% of Hodgkin’s lymphomas (HLs) (Meier et al., 2009, Van 
Roosbroeck et al., 2011). 
TYK2 knockout in mice, whilst not lethal, results in a partial reduction in response to cytokine signalling 
from both type I and type II interferons (Karaghiosoff et al., 2000). Severe combined 
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immunodeficiency results from JAK3 knockout, with a reduction in the number of functional T and B 
cells (Ward et al., 2000). Myelopoiesis is also adversely affected, JAK3 null mice shows signs of 
splenomegaly and have increased numbers of neutrophils (Grossman et al., 1999). Mutations in the 
pseudokinase domain of JAK3 have been identified in patients with acute megakaryoblastic myeloid 
leukaemia (Walters et al., 2006). 
1.6: JAK signalling and STAT 
 
Cytokine signalling through transmembrane receptors and downstream signalling through 
intracellular pathways are important modulators for cell proliferation, differentiation, and growth. 
Haematopoietic cytokine receptors are divided into 5 groups (Figure 4) depending on the number of 
subunits or the presence of shared subunits (Baker et al., 2007).  
 
 
Figure 4: Diagram showing the five main haematopoietic cytokine receptor groups and their 
associated cytokines (Baker et al., 2007). 
Receptors for erythropoietin (EPO), thrombopoietin (TPO), granulocyte colony stimulating factor (G-
CSF) as well as some interleukins (IL), and type II interferons are lacking in intrinsic catalytic activity 
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(Staerk and Constantinescu, 2012), and therefore require additional signalling downstream from the 
initial cytokine-receptor binding. 
As described previously, JAK2 is activated by receptor-ligand binding and dimerization which in turn 
leads to phosphorylation of tyrosine residues on the cytoplasmic ends of the membrane bound 
receptor. The confirmation change induced by this phosphorylation allows the binding of SH2 domain 
containing molecules, including signal transducers and activators of transcription (STATs), src kinases 
and protein phosphatases. In the case of STAT proteins, a conserved tyrosine residue is located at the 
C-terminal and this is phosphorylated by JAK2. Phosphorylation of STAT leads to dimerization and 
translocation to the nucleus, where it acts as a transcription factor (Figure 5). 
 
Figure 5: Mechanism of JAK2/STAT5 signalling through erythropoietin binding the EPO receptor 
(Zhang et al., 2014). 
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There are seven STAT proteins identified in humans, STAT 1-4, 5a, 5b and 6, ranging in size from 73 to 
95 kDa (Steelman et al., 2004). The protein structure of members of this family consists of an N-
terminal domain, a central DNA binding domain, an SH2 domain and a transactivation domain located 
near the C-terminal (Steelman et al., 2004).  The N-terminal contains an oligomerization domain which 
is phosphorylated by JAK activity, this phosphorylation allows interaction with SH2 domains on other 
STAT proteins and resulting dimerization in the cytoplasm. STAT dimers can then translocate to the 
nucleus and bind recognised sequences of DNA (Chen et al., 1998), where they act as transcription 
factors, affecting the expression of one or more genes. 
STAT activity is controlled through a number of different mechanisms, both constitutive and inducible. 
Constitutive suppressors include tyrosine phosphatases, SHP1 and 2 in the cytoplasm and a family of 
STAT inhibitors called protein inhibitors of activated STATs (PIAS) (Valentino and Pierre, 2006). 
Suppressors of cytokine signalling proteins (SOCS) are inducible negative regulators of JAK/STAT 
activity (Tamiya et al., 2011). Members of this family of proteins contain a central src-homology 2 
(SH2) domain and a carboxyl terminal end of forty amino acids known as a SOCS box, which is required 
for proteosomal degradation of SOCS binding partners (Zhang et al., 1999). There are eight members 
of the SOCS protein family, SOCS1-7 and cytokine-inducible SH2 protein (CIS) (Yoshimura and 
Yasukawa, 2012). Downregulation of SOCS1 and inactivating mutations are linked to a wide range of 
solid tumours, as well as haematological malignancies, including AML, multiple myeloma, B-cell 
lymphomas and HL (Inagaki-Ohara et al., 2013, Mottok et al., 2009). Two members of the SOCS family 
(SOCS1 and SOCS3) are known to interact directly with JAK2 (Trengove and Ward, 2013). Both SOCS1 
and SOCS3 have a kinase inhibitory region (KIR), located with the N-terminal domain (Tamiya et al., 
2011). Adjacent to the KIR, they can also target JAK2 for ubiquitination and degradation by the 
previously described SOCS box (Hookham et al., 2007). SOCS1, 2 and 3 are unable to control the 
increased kinase activity of JAK2V617F expressing cells and SOCS3 enhances JAK2V617F induced 
proliferation (Hookham et al., 2007). Hypermethylation of CpG islands located in the promoter regions 
of SOCS1 and 3 genes have been identified in PV and ET patients, including those positive and negative 
16 
 
for the JAK2V617F mutation (Teofili et al., 2008). Silencing of genes involved in tumour suppression and 
cell cycle control is a characteristic of CpG island methylation (Melzner and Möller, 2003). 
As well as the STAT pathways, other mechanisms of downstream signalling can be affected by changes 
to JAK2. JAK2 itself can also translocate to the nucleus and affect chromatin structure through 
phosphorylation of Tyr41 on histone H3 (Dawson et al., 2009). This prevents binding of H1 alpha to 
this region. Inhibition of JAK2 results in the down-regulation of a haematopoietic oncogene, LMO2, 
reduction in H3Y41 phosphorylation at the LMO2 promoter site and an increase in H1 alpha binding 
at the same site (Dawson et al., 2009). 
1.6.1: PI3K/Akt 
 
The PI3K/Akt pathway is a major cytokine signalling axis responsible for many functions in 
haematopoiesis. Tyrosine kinase receptors in the plasma membrane bind their respective ligands and 
activate P13K in the cytoplasm. PI3K phosphorylates the 3-OH position on the inositol ring of 
phosphatidylinositol, generating the second messenger phosphatidylinositol-3,4,5-trisphosphate 
(Fresno Vara et al., 2004). This indirectly acts upon a serine/threonine kinase, protein kinase B/Akt, 
attracting it to the cell surface where it can be phosphorylated and activated by phosphoinositide 
dependent kinases 1 and 2 (Vivanco and Sawyers, 2002). Activated Akt can then work downstream via 
its pathway to effect the expression of a number of genes affecting proliferation, apoptosis and growth 
(Vivanco and Sawyers, 2002, Fresno Vara et al., 2004). 
Mutations in this pathway, both upstream and downstream have been implicated in a wide range of 
cancers, but are seen at low frequency in haematological malignancies and none at all linked to 
myeloproliferative neoplasms (Khwaja, 2010, Kleppe and Levine, 2012). Despite this, there appears to 
be a clear link between increased JAK2 tyrosine kinase activity and aberrant activation of this pathway 
(James et al., 2005). Constitutive activation of STAT5 in MPN as a result of deregulated JAK signalling 
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may result in a complex formed with the p85 subunit of PI3-kinase and also the scaffolding adapter 
protein Gab2 and results in increased Akt phosphorylation (Harir et al., 2007). 
1.6.2: Mitogen Activated Protein Kinase (MAPK) pathway 
 
Mitogen activated protein kinase (MAPK) pathway, also referred to as the RAS/RAF/MEK/ERK pathway 
is another important cytokine signalling pathway through which JAK2 may impact. RAS lies upstream 
from this pathway and others, including the previously mentioned PI3K/Akt.  On cytokine-receptor 
binding, RAS, a GTPase, can activate MAPK and trigger the signalling cascade. RAF migrates to the 
plasma membrane where it is activated and dimerises – active RAF, a serine/threonine kinase, can 
then phosphorylate MEK which in turn phosphorylates ERK (Chang et al., 2003). ERK can act on both 
cytosolic and nuclear protein and impact transcriptional regulation, including a number of cell cycle 
regulatory proteins (Downward, 2003). There are several different mechanisms via which activated 
JAK2V617F can affect the MAPK pathway. Phosphorylation of ERK 1 and 2 kinases has been identified in 
JAK2V617F MPNs (James et al., 2005, Levine et al., 2005). There are three encoded forms of RAS, H-, K- 
and N-RAS. K-RAS plays a role in normal erythropoiesis, homozygous deletion in mice results in a fatal 
phenotype (Johnson et al., 1997). Oncogenic gain of function mutations in K-RAS along with N-RAS are 
found in approximately 30% of myeloid malignancies (Kleppe and Levine, 2012). Although mutations 
in RAS are rarely observed in MPNs, they occur in 7-14% of post MPN acute myeloid leukaemia cases 
(Beer et al., 2010, Kleppe and Levine, 2012), suggesting they may play an important role in leukaemic 
transformation. Deletions of NF1, a gene coding for a negative regulator of RAS signalling, have also 
been found in some patients with MF after previous PV or ET disease (Stegelmann et al., 2010), 
indicating the potential impact this pathway has on MPN progression. When a constitutively active 
form of MEK was introduced to haematopoietic stem cells in mice it resulted in a myeloproliferative 
type disorder (Chung et al., 2011).  
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1.7: Mutations in MPN 
 
1.7.1: JAK2V617F mutation 
 
In 2005 several independent groups discovered a somatic gain of function mutation in JAK2 (Baxter et 
al., 2005, James et al., 2005, Kralovics et al., 2005, Levine et al., 2005). A single valine to phenylalanine 
substitution at position 617 in the JH2 domain of JAK2 results in constitutive kinase activity in the 
absence of cytokine binding to the membrane-bound receptor. This mutation has been found in nearly 
all (> 95%) cases of PV (Pardanani et al., 2007) and up to 60% of ET and MF (Harrison and Vannucchi, 
2016). Mutations in this domain, including JAK2V617F in MPN patients, reduce Tyr570 phosphorylation 
and the ability to negatively control JH1 activity (Ungureanu et al., 2011). 
Since the discovery of the JAK2V617F mutation, the key unanswered question has been how a single 
mutation can result in three distinct disease phenotypes. Animal model experiments using mice 
suggest the importance of the JAK2V617F mutation in the disease phenotype (Li et al., 2011). Lacout et 
al. (2006) demonstrated that over-expression of JAK2V617F via retroviral transduction in mice resulted 
in a myeloproliferative disorder with a PV-like phenotype and secondary myelofibrosis. Transgenic 
and knock-in models also supported these findings and further research suggests a possible link 
between allele burden and the resulting MPN type disease. Shide et al. (2008) generated the first line 
of transgenic mice with JAK2V617F ectopically expressed, which resulted in erythrocytosis, 
thrombocytosis and eventual progression to myelofibrosis. Another group reported similar findings 
expressing human JAK2V617F in mice under the control of a tissue specific promoter (Xing et al., 2008). 
Following on from these, Tiedt et al. (2008) generated a transgenic construct where it was possible to 
vary levels of JAK2V617F expression. Higher levels of JAK2V617F were found to correlate with a PV-like 
phenotype, whereas when JAK2V617F levels were lower than the endogenous JAK2WT, an ET-like 
phenotype was found (Tiedt et al., 2008). A switch from ET to a PV-like phenotype was observed in 
mice with acquired JAK2V617F homozygosity and the severity of the phenotype correlated with the 
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homozygous allele burden (Li et al., 2014). These results along with the animal model studies support 
the gene-dosage hypothesis, where disease phenotype is determined by mutant allele burden 
proportion to wild-type (Passamonti and Rumi, 2009). PV patients have an overall higher percentage 
(48%) of mutant allele to wild-type versus ET (26%) and levels are even higher in secondary MF (74%) 
(Vannucchi et al., 2008). 
Although these studies may point to JAK2V617F homozygosity being the principle driver of phenotype, 
it has also been shown that homozygous clones are present in large numbers of ET patients and 
undetected in a small number of PV patients (Godfrey et al., 2012). This is noteworthy, since it was 
also shown that the principal distinguishing factor between the two phenotypes was the expansion of 
a dominant homozygous subclone in PV (Godfrey et al., 2012). Disease phenotype does not appear to 
be simply determined by loss of heterogeneity but rather the clonal selection of a homozygous 
JAK2V617F progenitor stem cell. 
Gene expression profiles also differ between JAK2V617F heterogenous erythroid cells from PV and ET 
patients, with increased STAT1 signalling observed in ET (Chen et al., 2010) supporting a key role for 
STAT1 in determining disease phenotype in JAK2V617F patients. 
The role that the JAK2V617F mutation plays in disease transformation is also not fully understood. 
JAK2V617F only occurs in approximately 1% of cases of de-novo acute myeloid leukaemia (AML) with no 
known previous history of MPN, but is present in 50% of cases of AML secondary to MPN (Steensma 
et al., 2006). It has also been shown that the majority of leukaemic blasts in transformed JAK2V617F 
patients are negative for the JAK2V617F mutation (Theocharides et al., 2007). The significance of JAK2 
allele burden in blast transformation and overall survival has been widely studied. Several groups have 
shown no overall prognostic value in JAK2V617F mutational status as a marker for either blast 
transformation or overall survival (Cervantes et al., 2009, Tefferi et al., 2005). However, others have 
claimed to show that low allele burden in MF is associated with poorer overall survival (Guglielmelli 
et al., 2009, Tefferi et al., 2008). More recently, with the discovery of the calreticulin (CALR) mutation 
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in ET and MF, poorer prognosis has been associated with JAK2 mutations versus CALR (Tefferi et al., 
2014c). The role of mutated JAK2 in disease progression is likely to be a consequence of molecular 
events which favour leukaemogenic events in the wild-type clones and, as mentioned earlier, the 
presence of additional mutations and the order in which they occur (Ortmann et al., 2015). 
1.7.2: Calreticulin (CALR) 
 
Calreticulin is a protein located in the endoplasmic reticulum which sequesters Ca2+ (Luo and Lee, 
2013). Knockout of calreticulin in mice results in death at the embryonic stage due to impaired cardiac 
development, which is dependent on Ca2+ signalling pathways (Guo et al., 2002, Mesaeli et al., 1999). 
It also plays a role in post-translational modifications of proteins in the ER, recognising N-linked glycans 
on glycoproteins and processing them for further folding or degradation (Michalak et al., 2009, van 
Leeuwen and Kearse, 1996). In addition to its ER chaperone functions, calreticulin has also been found 
expressed at the surface of tumour and apoptotic cells where it is believed to promote phagocytosis 
(Gardai et al., 2005, Obeid et al., 2007).  
In 2013, two independent groups discovered mutations in exon 9 of the CALR gene (Klampfl et al., 
2013, Nangalia et al., 2013). Over 50 different mutations have been identified to date, with a 52-bp 
deletion (type 1 mutation) and a 5-bp insertion (type 2) most frequently seen (Cazzola and Kralovics, 
2014). Mutations in calreticulin have been identified in 33% and 25% of ET and MF patients 
respectively (Andrikovics et al., 2014). Evidence suggests that ET patients bearing a calreticulin 
mutation (as opposed to a JAK2 or MPL mutation) have a lower risk of thrombosis (Rotunno et al., 
2014). Notably, CALR mutated ET patients do not have a polycythaemic transformation compared to 
29% of JAK2 mutated patients over a 15 year time period (Rumi et al., 2014a). Myelofibrotic 
transformation risk over 15 years was reported to be higher (13.4%) in CALR-mutated ET versus JAK2 
(8.4%) and leukaemic transformation lower, 2.5% in CALR versus 4.3% in JAK2, although these 
differences were non-significant when adjusted for age (Rumi et al., 2014b). Survival rates for CALR-
mutated MF have been reported to be favourable compared to JAK2 mutated or triple-negative 
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patients (Rumi et al., 2014b, Tefferi et al., 2014a), with median survival of 17.7 years for CALR versus 
9.2 years for JAK2, 9.1 years for MPL and 3.2 years for triple-negative patients (Rumi et al., 2014b). 
Calreticulin mutants have been shown to activate the thrombopoietin receptor (MPL) and result in 
ligand-independent signalling through JAK-STAT, PI3K and MAPK pathways (Chachoua et al., 2016). 
The mechanism has been demonstrated to be linked to activation by CALR mutants of N-glycosylation 
sites on the extracellular portion of the MPL receptor (Figure 6) (Chachoua et al., 2016, Cazzola, 2016). 
Experiments in mice have also shown that the presence of MPL but not TPO is required for activation 
by CALR mutants (Marty et al., 2015). 
 
Figure 6: Diagram of pathogenic mechanism of CALR mutant MPN. Mutant calreticulin associates 
with MPL in the ER and is exported to the cell surface. This results in cytokine independent activation 
of MPL and JAK2 phosphorylation (Cazzola, 2016). 
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1.7.3: MPL 
 
Megakaryocyte development is regulated by the binding of the cytokine thrombopoietin (TPO) to the 
membrane receptor MPL (Figure 7), and circulating levels of TPO are associated with platelet levels 
indicating a feedback loop mechanism between the two (de Graaf and Metcalf, 2011). In addition to 
its role in megakaryopoiesis, TPO signalling has also been implicated in haematopoietic stem cell (HSC) 
regulation, inhibition of TPO/MPL signalling results in reduction of the quiescent HSC population while 
stimulation with TPO increases the proportion of quiescent cells (Yoshihara et al., 2007). 
 
Figure 7: TPO/MPL signalling pathway. TPO binding causes dimerisation of the membrane-bound 
MPL receptor. This leads to phosphorylation and activation of JAK2 and STAT signalling molecules as 
well as other signalling pathways (MAPK/PI3K). Phosphorylated STAT translocates to the nucleus and 
results in altered gene transcription (de Graaf and Metcalf, 2011). 
 
Mutations in exon 10 of the gene encoding the thrombopoietin receptor (MPL) have been recorded 
in between 3-10% of ET and MF cases (Tefferi, 2010, Vainchenker et al., 2011). These mutations result 
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in the substitution of a tryptophan at position 515 to a leucine, lysine, asparagine, or alanine (Pikman 
et al., 2006, Vainchenker et al., 2011). Mutations in MPL can contribute to altered spatial confirmation 
of the receptor resulting in auto-phosphorylation of JAK2 and constitutive activation of the JAK/STAT 
pathway (Chaligné et al., 2008). MPL mutations are not found in PV and are believed to enhance 
primary megakaryocyte proliferation (Tefferi, 2010). 
1.7.4: Exon 12 
 
Most of the 5% of JAK2V617F negative PV cases have mutations located in exon 12 of JAK2 (Passamonti 
et al., 2011, Scott et al., 2007). This is not directly located in the negative regulatory pseudokinase 
domain, but is located in a loop close to the interface between the pseudokinase and kinase domains 
(Scott, 2011). Patients with exon 12 mutations have higher haemoglobin levels but lower platelet and 
leukocyte counts at diagnosis than in JAK2V617F patients, however overall survival, incidence of 
thrombosis and myelofibrotic/leukaemic transformations are similar (Passamonti et al., 2011).  
1.8: Transcription factor and epigenetic modifications 
 
Downstream from cell surface signalling and the cytoplasmic pathways described previously, gene 
expression is regulated by transcription factors (TFs) within the nucleus binding to recognised 
sequences of DNA. Transcription factors also play an important role in determining the differentiation 
and expansion of haematopoietic stem cells into mature myeloid cells. The impact of TFs is further 
dependent on what lineage the cell is at and interactions with other transcription factors acting as 
repressors or enhancers of expression. TFs play a critical role in controlling differentiation of 
haematopoietic stem cells and determining lineage specification (Nakajima, 2011). A number of the 
most important transcription factors in haematopoiesis are discussed below. 
1.8.1: GATA1 
GATA1, plays an essential role in the development of normal erythroid cells and megakaryocytes 
(Crispino, 2005). It is expressed in primitive and mature erythroid cells, as well as megakaryocytes, 
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eosinophils, and mast cells (Ferreira et al., 2005). Animal experimental studies have shown that 
GATAnull mice die during embryonic development, between embryonic day 10.5 and 11.5 due to severe 
anaemia (Fujiwara et al., 1996). In adult mice, conditional knockout of GATA1 results in impaired 
erythroid cell differentiation, where maturation is arrested at the proerythroblast stage (Gutiérrez et 
al., 2008). Experiments where GATA1 expression is knocked out in megakaryocyte progenitors have 
shown significantly reduced platelet levels (Shivdasani et al., 1997). Mutations in GATA1 are seen in 
almost all cases of acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative 
disorder (TMD) accompanying Down’s syndrome (Greene et al., 2003). Other studies have suggested 
that increased GATA1 expression in AML is associated with a worse prognosis (Ayala et al., 2009, 
Shimamoto et al., 1995). GATA1 has three functional domains, two zinc fingers and an N-terminal 
activational domain (Crispino, 2005). One of the zinc fingers (C) is responsible for binding to the 
consensus sequence on the DNA. The other zinc finger (N) also has DNA binding activity, specific to a 
palindromic consensus sequence, as well as being important for the recruitment and binding of a co-
factor, friend of GATA1, (FOG1) (Tsang et al., 1997). 
1.8.2: FOG1 
FOG1 has been identified as being expressed in erythroid and megakaryocytic progenitors and is 
essential for normal erythropoiesis and megakaryopoiesis (Tsang et al., 1998). In the mast cell lineage, 
GATA1 is expressed independently to FOG1 (Cantor et al., 2008). Experiments with FOG1 constitutively 
expressed in progenitor cells led to a block on eosinophil production, and forced expression in 
eosinophils resulted in a loss of specific eosinophilic cell surface markers and a reverting to a 
multipotent progenitor phenotype (Querfurth et al., 2000). FOG1 has also been shown not only to 
have a synergistic effect on gene expression with GATA1 but is also responsible for inhibiting 
expression of some genes, most likely through the recruitment of co-repressors such as CtB2 (Katz et 
al., 2002). GATA1 has been found to be overexpressed in ET and PV but not in other MPNs, and this is 
independent of the JAK2V617F mutation (Rinaldi et al., 2008). CD61+ cells from myelofibrosis patients 
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had similar GATA1 transcript levels to controls but significantly reduced protein expression (Vannucchi 
et al., 2005). 
1.8.3: GATA2 
GATA2 also plays a critical role in haematopoiesis, in particular during the early stages of HSC 
proliferation and survival but is dispensable during later erythroid and myeloid terminal 
differentiation (Tsai and Orkin, 1997). It binds an overlapping set of genes with its related family 
member, GATA1, at several distinct sites. The mechanism of switching from GATA2 to GATA1 
occupation at these locations may act as a balance between proliferation and differentiation (Doré et 
al., 2012). Mutations in GATA2 have been linked to chronic myeloid leukaemia and transformation to 
AML (Zhang et al., 2008) and overexpression has been associated with poorer prognostic outcomes in 
AML (Vicente et al., 2012). Inherited missense mutations in the DNA-binding region of GATA2 have 
been linked to a predisposition for the development of familial MDS/AML (Hahn et al., 2011).  
1.8.4: PU.1 
PU.1 is an ETS transcription factor family member and is encoded by the Sfp1 (Sp-1) gene (Burda et al., 
2010). Along with GATA1, it is responsible for lineage stage determination in early HSC (Figure 8). PU.1 
transgenic mice were found to develop a multistep erythroleukaemia, where differentiation was 
partially blocked at the pro-erythroblast level (Moreau-Gachelin et al., 1996). Levels of PU.1 were 
found to be raised in MPN patients and this correlated with the JAK2V617F allele burden. In cellular 
models, overexpression of JAK2V617F in HEL cells resulted in increased Sp1 expression but this was not 
observed in wild type JAK2 expression in K562 cells. In addition, it was also demonstrated that 
inhibition of ABL1 with imatinib reduced PU.1 levels in K562 but not BCR-ABL1 negative / JAK2V617F 
positive HEL cells, suggesting that this transcription factor may be a common downstream target for 
both JAK2 and ABL1 oncogenic signalling (Irino et al., 2011).  
1.8.5: NFE2 
Nuclear factor erythroid-2 (NFE2) is a haematopoietic transcription factor and is essential for normal 
platelet formation (Shivdasani et al., 1995). Overexpression of NFE2 has been found in the vast 
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majority of PV patients (Goerttler et al., 2005). Increased NFE2 is also responsible for delayed 
erythroid maturation and results in an increase in the number of mature erythroid cells deriving from 
a single progenitor (Mutschler et al., 2009). It has also been found over expressed in other MPN 
patients, independent of JAK2V617F mutation status (Goerttler et al., 2005, Wang et al., 2010). Analysis 
of the promoter sequence upstream from NFE-2 has suggested a potential role for AML1 in modulating 
the levels of this transcription factor. AML1 binds the NFE2 promoter at three locations and increased 
NFE-2 and AML1 levels are found in MPN patients (Wang et al., 2010). Furthermore, point mutations 
in AML1 have been implicated in leukaemic transformation in MPN patients (Ding et al., 2009), 
suggesting that it, along with NFE2, may play a role in the pathogenesis of MPNs. 
 
Figure 8: Diagram showing role of GATA-1 and PU.1 transcription factors have on lineage 
determination (Tenen, 2003). 
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There are three basic epigenetic mechanisms which interact with each other to affect gene expression 
in the nucleus: 
1) DNA methylation. 
2) Histone modifications including acetylation, methylation, phosphorylation and ubiquitination. 
3) Chromatin remodelling. 
1.8.6: DNA methylation 
Studies on individual genes (SOCS1, SOCS3, and PTPN6) involved in negatively regulating JAK2 have 
shown an increase in methylation of SOCS1 in ET patients compared to control (Födermayr et al., 2012). 
However, no differences were seen for PV patients and methylation of either SOCS or PTPN did not 
correlate with any clinical outcome (Födermayr et al., 2012). Another group utilised a genome wide 
array and found an aberrant methylation pattern for the MPNs centred around a gene network for 
NF-κB (Pérez et al., 2013). Interestingly, it was also noted that this difference was increased for 
transformed MPNs, suggesting that DNA methylation may play a role in the pathogenesis of the 
disease. 
Mutations in the gene for DNA methyltransferase-3 (DNMT3A) have also been identified in 
myeloproliferative neoplasms (Stegelmann et al., 2011). DNMT3A has previously been found at a high 
frequency (22%) and is associated with a poor prognosis in acute myeloid leukaemia patients (Ley et 
al., 2010). The role of DNMT3A may be in the advanced phase of the myeloproliferative disease. 
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Figure 9: Various mutations observed in MPNs and their effect on epigenetic gene regulation 
(Vannucchi and Biamonte, 2011). 
1.8.7: Histone modifications and chromatin remodelling 
JAK2 has a role in modulating signalling cascades in the cytoplasm, while it has also been shown to be 
responsible for chromatin modification. JAK2 can directly phosphorylate Tyr41 on histone H3 (H3Y41) 
(Figure 10) and in doing so prevents the binding of the heterochromatin protein 1 alpha (HP1α) 
(Dawson et al., 2009). JAK2V617F has been shown to translocate to the nucleus of CD34+ cells of MPN 
patients but not to granulocytic, megakaryocytic or erythroid cells (Rinaldi et al., 2010). This could also 
be seen when K562 cells were induced via transfection to express JAK2V617F and the reverse (relocation 
to the cytoplasm) observed when cells were treated with a specific JAK2 inhibitor (Rinaldi et al., 2010).   
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Figure 10: Activation of JAK2 and translocation to the nucleus. Active JAK2 can effect gene 
expression via phosphorylation of the histone protein, H3Y41. This results in the release of the 
repressor, HP1α (Sattler and Griffin, 2009). 
 
Protein arginine methylation is a process by which protein-nucleic acid interactions can be modified. 
Liu et al., (2011) demonstrated that mutations in JAK2, including JAK2V617F and JAK2K529L (occurring in 
exon 12) resulted in the phosphorylation of protein arginine N-methyltransferase 5 (PRMT5) (Liu et 
al., 2011). PMRT5 is a type 2 arginine methyltransferase, and along with a WD40 repeat containing 
MEP50 protein and plCln, forms a 20S complex known as the methylosome (Friesen et al., 2001). This 
regulates methylation of arginine residues at several histones, including H2A, H3 and H4 (Antonysamy 
et al., 2012). The binding of the mutated JAK2 to PRMT5 was found to be stronger than in normal JAK2 
and reduced the ability of PRMT5 to form a complex with MEP50 (Figure 9). PRMT5 was also shown 
to down-regulate haematopoietic stem cell expansion and erythroid differentiation (Liu et al., 2011).  
Epigenetic modifications are also a feature of JAK2V617F negative MPN cases. Gene expression can be 
altered via chromatin remodelling or DNA methylation and several mutations have been identified 
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that have the ability to alter these processes. These can occur with or without the presence of the 
previously described JAK2 tyrosine kinase mutations (Vannucchi and Biamonte, 2011). TET2 affects 
DNA methylation through the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine (Figure 9) 
(Ko et al., 2010). Mutations in TET2 are observed in a wide range of haematological cancers 
(Delhommeau et al., 2009). 
ASXL1 is required for normal haematopoiesis and mutations in exon 12 of this gene are observed in a 
number of myeloid malignancies (Carbuccia et al., 2009, Schnittger et al., 2013). ASXL1 forms a 
complex with other proteins and affects gene expression (positive and negative) by altering chromatin 
configuration (Figure 9) (Vannucchi and Biamonte, 2011). Mutations have been identified at a 
frequency of 13% in PMF, 23% in post-PV/ET MF and 18% in blast-phase MPN (Tefferi et al., 2011). 
IDH1 and 2 affect gene expression by regulating histone and DNA methylation levels (Sasaki et al., 
2012), and have been identified in a high incidence of patients suffering from blast phase MPN but 
also in a low frequency in chronic phase MPN (Pardanani et al., 2010), although the exact mechanisms, 
if they exist, for leukaemic transformation are not yet fully understood. 
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1.9: Drug development & targets 
 
1.9.1: Allogeneic stem cell transplantation 
Allogeneic haematopoietic stem cell transplantation (ASCT) is currently the only treatment that is 
proven to be fully curative (Gupta et al., 2014), however the age profile for many MPN sufferers is 
such that the risks outweigh any potential benefits over the treatments listed below. 
1.9.2: Hydroxyurea 
Hydroxyurea (hydroxycarbamide) is the current first-line therapy of choice for treatment of MPN 
patients at high risk of thrombotic events (Harrison et al., 2005), the leading cause of morbidity and 
mortality in essential thrombocythaemia and polycythaemia vera (Falanga and Marchetti, 2012). The 
anti-myeloproliferative effects of hydroxyurea occur through inhibition of the ribonucleotide 
reductase enzyme, which is responsible for the catalytic production of deoxyribonucleotides from 
ribonucleotides (Hong and Erusalimsky, 2002). One potential mechanism of action has been proposed 
through the production of nitric oxide free radicals which target a tyrosyl free radical found in the 
reductase enzyme (Lepoivre et al., 1994). Inhibition of cell proliferation occurs primarily during the S 
phase or late G1 phase (Bertoli et al., 2013). 
1.9.3: Anagrelide 
The reduction of intracellular deoxynucleoside triphosphate pools is a double-edged sword, since DNA 
repair mechanisms are also possibly affected (Aye et al., 2015). This mutagenic and carcinogenic 
potential has been observed in animal and cellular models (Santos et al., 2011), although no significant 
link to date has been proven in human patients given therapeutic doses. Nevertheless, the theoretical 
risk has led to anagrelide being proposed as an alternative therapy in ET patients (Emadi and Spivak, 
2009), and also in use where patients are non-responsive to hydroxyurea treatment (Finazzi, 2012). 
Unlike hydroxyurea, whose action is anti-proliferative, anagrelide acts through the inhibition of 
megakaryocytopoeisis (Solberg et al., 1997).  The mechanism of inhibition is not fully understood, 
although anagrelide does act as a potent phosphodiesterase type III (PDE3) inhibitor (Gresele et al., 
2011). Phosphodiesterases are enzymes that are responsible for catalysing the hydrolysis of 
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intracellular second messengers, cyclic adenosine 3, 5-monophosphate (cAMP) and cyclic guanosine 
3, 5-monophosphate (cGMP), to the inactive 5’-AMP and 5’-GMP forms (Gresele et al., 2011). PDE3 is 
expressed in platelets, as well as vascular smooth muscle and heart cells, and acts mainly on cAMP 
(Gresele et al., 2011, Omori and Kotera, 2007). Increased concentration of cAMP can activate protein 
kinase A (PKA) by phosphorylation, which in turn can activate a signalling cascade resulting in the 
regulation of a number of genes (Zambon et al., 2005). 
1.9.4: Acetylsalicylic acid 
Acetylsalicylic acid (aspirin) is used alongside the conventional therapies listed previously as a 
preventative measure against thrombotic complications associated with myeloproliferative 
neoplasms. The major risk with this treatment is an increased risk of bleeding. The mechanism of 
action is through the suppression of platelet thromboxane A2 (TXA2) synthesis via inactivation of 
cyclo-oxygenase-1 (COX-1) (Tefferi, 2012). 
1.9.5: Interferon-α 
Experiments using JAK2V617F mice have demonstrated that prolonged treatment with interferon α 
results in the reduction of a number of symptoms, including normalisation of haemoglobin levels, 
reduction of white cell count and extramedullary haematopoiesis (Lane and Mullaly, 2013). It was also 
noted that there was a reduction in the JAK2V617F allele burden over time (Lane and Mullaly, 2013). 
Clinical studies in humans have also shown similar haematological and molecular responses, including 
the reduction of the JAK2V617F clone (Quintás-Cardama et al., 2009). The mode of action of IFN-α is via 
surface bound receptors activating JAK1 or TYK2 at the cell surface; these in turn can phosphorylate 
and dimerise STAT proteins in the cytoplasm resulting in translocation to the nucleus and transcription 
of a number of pro-apoptotic and cell growth inhibition genes (Trinchieri, 2010).  The experiments 
described above suggest that IFN-α is acting preferentially on the mutant clone.  It has also been 
shown that JAK2V617F cells treated with IFN-α have a number of cell cycle genes up-regulated both 
before and after treatment (Lane and Mullaly, 2013). This may provide an explanation as to the 
preferential responsiveness to IFN-α shown by JAK2V617F cells. However IFN-α is, for most patients, 
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poorly tolerated over a prolonged period (Quintás-Cardama et al., 2009, Lane and Mullaly, 2013), and 
cannot be considered as a curative measure on its own.  
1.9.6: Ruxolitinib and JAK2 inhibitors 
The discovery of the BCR-ABL fusion protein and identification of its tyrosine kinase activity paved the 
way for development of specific drugs targeting the src homology (SH1) domain on ABL. This has been 
identified as a key target in promoting leukaemogenicity and oncogenic transformation. One such 
drug, imatininb, works by competing for binding at the SH1 domain. With the identification of the 
central role of JAK2 signalling and constitutive activation in BCR-ABL1 negative MPN through mutant 
JAK2 and other mutations, it has been hoped that similar TK inhibiting drugs could be developed, with 
a view to selectively targeting JAK2 activity. The first, and to date only, approved drug for the 
treatment of MPN to make it to market has been ruxolitinib (INCB018424) (Mesa et al., 2012), which 
in addition to targeting JAK2 also inhibits JAK1 activity and also has a smaller effect on TYK2 and JAK3 
(Quintás-Cardama et al., 2010). The results from published clinical trial data suggests that ruxolitinib 
is effective in reducing splenomegaly and overall quality of life is improved (Harrison et al., 2016, 
Vannucchi et al., 2015a). It has also been shown to improve overall survival in MF patients versus 
either best available therapy or placebo irrespective of JAK2 mutational status (Harrison et al., 2016, 
Vannucchi et al., 2015a). 
It would seem obvious that direct targeting of JAK2V617F might be more effective than pan-JAK 
inhibitors. However the JAK2V617F mutation occurs outside the ATP binding domain on the JAK2 
enzyme meaning ATP-competitive inhibitors cannot distinguish between normal and mutant forms 
(Verstovsek, 2009). Along with the previously mentioned drugs, several others are in development 
and undergoing various stages of clinical trials. These are primarily JAK-type inhibitors similar to 
ruxolitinib, although notably one, TG101348 (SAR302503), has recently been withdrawn due to safety 
concerns (Pardanani et al., 2015). 
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1.9.7: Givinostat and histone deacetylase inhibitors 
The use of histone deacetylase (HDAC) inhibitors are another potential avenue for therapy design. 
Acetylation and de-acetylation of histone proteins provides a mechanism for controlling chromatin 
remodelling and the expression of a number of genes (Ropero and Esteller, 2007). To date, eighteen 
different mammalian HDAC enzymes have been discovered and are classed according to similarities 
in structure. Class 1 HDACs, the most well studied group, include HDAC 1, 2, 3 and 8, and are 
ubiquitously expressed (Haberland et al., 2009). Class 2 can be subdivided into two subgroups, 2a 
(HDAC 4, 7 and 9) and 2b (HDAC 6 and 10) (Haberland et al., 2009). Class 4 include the sirtuins, SIRT 1-
7 (Delcuve et al., 2012, Ropero and Esteller, 2007). Sodium butyrate, a HDAC inhibitor, was shown to 
increase the levels of SOCS 1 and 3 in K562 and HEL cells and subsequently reduce the levels of JAK2, 
STAT3, STAT5 and their phosphorylated forms (Gao et al., 2013). Givinostat (ITF2357), a novel HDAC 
inhibitor is currently in phase 2 clinical trials for PV patients unresponsive to hydroxyurea (Finazzi et 
al., 2013), and in a previous clinical trial reduced symptoms such as splenomegaly and pruritus in the 
majority of PV/ET and some MF patients (Rambaldi et al., 2010). Givinostat has been shown to down-
regulate expression of a number of genes for transcription factors involved in differentiation along the 
erythroid, megakaryocytic and myeloid lineages (Amaru Calzada et al., 2012). These include TAL1, 
NFE2 and c-MYC, of which both the latter two had protein and mRNA levels downmodulated in 
response to givinostat treatment. The effect on NFE2 was shown to be directly via acetylation of 
histone H3 protein on distal and proximal promoter sites (Amaru Calzada et al., 2012). 
1.9.8: Heat shock protein inhibitors 
Targeting heat shock proteins may provide another pathway in treating MPN. Heat shock proteins are 
chaperone proteins in the cell and provide a protective effect from degradation. JAK2 has been shown 
to associate with one heat shock protein, HSP90, and treatment with an inhibitor, PU-H71 reduces 
proliferation and results in faster proteasomal degradation (Marubayashi et al., 2010). In addition, 
treatment with PU-H71 reduced MPLW515L mutant burden in murine models (Marubayashi et al., 2010). 
Another group found that heat shock protein inhibition had a synergistic effect when used as a co-
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treatment alongside JAK2 tyrosine kinase inhibitors. Fiskus et al. (2011) demonstrated that AUY922, a 
HSP90 inhibitor, when used with TG101209 induced more apoptosis and inhibited JAK2 signalling than 
either drug alone. This treatment was shown to be selectively more active against primary MF-MPN 
haematopoietic stem cells than normal non-mutated ones (Fiskus et al., 2011). A further benefit 
observed was that the treatment with the HSP90 inhibitor could overcome previous resistance to 
tyrosine kinase inhibition treatment. Panobinostat, a class 1 and 2 HDAC inhibitor, was able to reduce 
JAK2 mRNA expression and prevent JAK2 binding with HSP90 in a MPN cell line (Wang et al., 2009). As 
before, co-treatment with a tyrosine kinase inhibitor resulted in an enhanced effect (Wang et al., 
2009). 
 
1.10: Clinical Trials 
 
Currently there are a number of ongoing or recently completed clinical trials investigating the safety 
and efficacy of novel therapies, as well as assessment of current treatment modalities in MPNs. A brief 
summary of some of the major trials are detailed below. 
1.10.1: PT-1 
 
The PT-1 trial was a large multi-centre study looking at patients with essential thrombocythaemia 
(ClinicalTrials.gov #NCT00175838). The major aims for this study were 1) Examine the incidence of 
thrombosis and major haemorrhage in low-risk patients receiving aspirin only, 2) Assess whether 
hydroxyurea with aspirin reduces risk of thrombosis and haemorrhage in intermediate risk patients, 
3) Impact of treatment selection on quality of life and 4) Follow-up of high-risk patients (> 60 years 
old) to assess frequency of thrombosis and haemorrhage events, including patients receiving 
anagrelide. Secondary objectives for the study included assessment whether treatment choice 
affected the rate of leukaemic or myelofibrotic transformation. 
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Superiority of hydroxyurea (with aspirin) over anagrelide in controlling vascular events was 
demonstrated in high-risk patients with ET (Harrison et al., 2005). This contradicts the results of 
another study, ANAHYDRET (ClinicalTrials.gov #NCT01065038), which claimed non-inferiority of 
anagrelide compared to hydroxyurea treatment (Gisslinger et al., 2013). The major differences 
between the two studies involved aspirin as a co-treatment in the PT-1 patients and the diagnostic 
criteria used. Patients in the PT-1 group were selected using the Polycythaemia Vera Study Group 
(PVSG) as opposed to the WHO criteria in the ANAHYDRET study.  
1.10.2: COMFORT I/II 
 
Ruxolitinib, a JAK2 inhibitor, has been examined in patients with myelofibrosis in the COMFORT I study 
(ClinicalTrials.gov #NCT00952289). Reductions in constitutive symptoms, including splenomegaly and 
improvements in quality of life were demonstrated over placebo (Verstovsek et al., 2012b). The 
COMFORT II study further showed these improvements over best available therapy (BAT) in addition 
to increased overall survival rates in patients receiving ruxolitinib (Cervantes et al., 2013) 
(ClinicalTrials.gov  #NCT00934544). 
A number of studies have been completed or are ongoing to evaluate the utility in treating PV or ET 
with ruxolitinib in patients who are resistant or intolerant to hydroxyurea therapy. These include the 
MAJIC trial (UKCRN ID: 11941) and RESPONSE (ClinicalTrials.gov # NCT01243944). The RESPONSE study 
showed ruxolitinib was superior to standard therapy in reducing symptoms associated with PV, 
including splenomegaly, as well as controlling the haematocrit (Vannucchi et al., 2015b). The RELIEF 
trial (ClinicalTrials.gov #NCT01632904) compared ruxolitinib directly against hydroxyurea treatment 
in PV patients. 
In a phase II clinical trial (INCB18424-256, ClinicalTrials.gov #NCT00726232) examining safety and 
efficacy of ruxolitinib in PV and ET, three patients were shown to have complete molecular remission 
in JAK2V617F allele burden after 5 years (Pieri et al., 2015).  
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1.10.3: PERSIST-I 
 
Pacritinib (SB1518) is a novel pyrimidine based small molecule with inhibitory activity against JAK2WT 
(IC50 = 22 nM), and JAK2V617F (IC50 = 19nM) (Hart et al., 2011a, William et al., 2011). It also has 
equipotent activity (IC50 = 23nM) against fms-like tyrosine kinase-3 (FLT3), a gene commonly found to 
be mutated in AML patients(Hart et al., 2011b). PERSIST-I is an ongoing study examining pacritinib 
versus BAT in myelofibrosis patients (ClinicalTrials.gov #NCT00745550). Recent results suggest that 
pacritinib is effective in reducing spleen volume (31% of patients achieved a ≥ 35% decrease by MRI / 
42% had decrease ≥ 50% by physical examination), MF symptoms (with the exception of fatigue) were 
also reduced (Komrokji et al., 2015).  
1.10.4: CYT3817 / Momelotinib 
 
CYT3817 is an aminopyrimidine derivative, ATP-competitive inhibitor of JAK1, JAK2 and TYK2 (Tyner 
et al., 2010, Pardanani et al., 2009). It inhibits growth of cell lines (HEL and Ba/F3) containing either 
the JAK2V617F (IC50 = 1500 nM) or MPLW515L (IC50 = 200 nM) mutations but has minimal effect on the 
BCR-ABL cell line K562 (IC50 = 58000 nM). Phase I/II studies with CYT3817 in MF patients demonstrated 
that 46% had a spleen reduction ≥ 50% and 68% of previously transfusion dependent patients became 
transfusion independent (Gotlib et al., 2013). This effect on anaemia is notable in contrast with that 
seen in other JAK inhibitors, including ruxolitinib (Harrison et al., 2012, Verstovsek et al., 2012b). 
Currently CYT3817 is undergoing a phase III clinical trial (ClinicalTrials.gov #NCT02101268), the 
primary endpoint for the trial is splenic response rate (> 35%) at week 24.  
1.10.5: PEGASYS 
 
Interferon alpha (IFN-α) is known to reduce the colony-forming ability of erythrocyte, granulocyte and 
megakaryocyte progenitors in MPN patients (Kiladjian et al., 2008). A pegylated form of IFN-α (Peg-
IFN-α-2a), which has lower toxicity and a better pharmacokinetic profile, has been shown to have high 
levels of molecular and haematological responses in previously untreated ET and PV patients (Quintás-
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Cardama et al., 2009). This included a subset of patients (6% and 14% for ET and PV respectively) 
where JAK2V617F was completely undetectable after treatment. A phase III trial of pegylated interferon 
(+ aspirin) versus hydroxyurea (+ aspirin) is currently ongoing (ClinicalTrials.gov #NCT01259856).  
1.11: Summary 
 
Although key advances have been made in the last decade of our understanding of the molecular 
genetics of the classical myeloproliferative neoplasms, it is debatable whether this has been translated 
into a significant increase in patient quality of life and reduced mortality, especially for myelofibrosis, 
and morbidity. None of the existing treatments provide a fully curative option, and only one JAK2 
tyrosine kinase inhibitor has been released to date. 
Combination therapy may prove, in the short term at least, the most effective development in the 
management of patients with MPN. Treatment with both conventional therapies, such as hydroxyurea, 
and HDAC inhibitors may have synergistic apoptotic effects as seen in cell model studies (Amaru 
Calzada et al., 2013), and in clinical trials (Finazzi et al., 2013). As well as targeting the different stages 
of the classical JAK/STAT pathway, other signalling cascades affected by deregulated JAK2, especially 
those described earlier (PI3K/Akt and MAPK), could provide attractive targets for drug development 
or already have specific inhibitors that could be utilised. However, it is also important to note that in 
CALR cell models, synergy between JAK2 and PI3K inhibitors was not observed compared to JAK2 cell 
models (Chachoua et al., 2016). Phenotype differences between the three main Philadelphia negative 
MPNs may be in part explained by changes at the nuclear level modulated by differential transcription 
factor and micro RNA expression profiles. These epigenetic changes may provide a key target for 
treatment or in monitoring disease progression.  
The impact of the increased number of treatments, each targeting different pathways at different cell 
cycle stages means that a key understanding of the molecular events in MPNs are more important 
than ever. This will apply in the development of new drugs as well as tailoring current regimes to fit 
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the disease profile. In the absence of a treatment to fully remove the disease allele, understanding 
the mechanisms via which MPNs progress and identifying potential key steps in the transformation of 
the disease will be crucial in improving patient quality of life. 
1.12: Aims 
 
This project aims to investigate the molecular mechanisms of deregulated JAK2 signalling in MPNs and 
identify changes to key pathways involved in haematopoiesis. It is hoped that these studies will 
identify potential targets for MPN treatment and improve our understanding into how different 
disease phenotypes can arise from mutations affecting the JAK/STAT signalling pathway. Three 
approaches will be used in this project: 
1) Investigate GATA1 expression in MPN patients. 
2) Examine the role of GATA1 in cell-line models. 
3) Proteomics to study effect of JAK2 signalling in cell models and MPN patients. 
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CHAPTER 2: 
Methodology
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2.1: Isolation of Peripheral Blood Mononuclear cells (PBMCs) from human 
donors 
 
Two patient cohort groups were recruited for this research project. Ethical approvals for the study are 
documented in the appendices. 
Cohort 1: GATA1 Expression levels in peripheral blood of patients with ET [NHS Ethics: 12/EM/0350] 
Patients diagnosed with essential thrombocythaemia according to the 2008 WHO criteria were 
recruited for this study. 
Exclusion criteria for this study were:  
 Patients with any other myeloproliferative disorder. 
Written informed consent was obtained from all patients before peripheral blood samples were taken. 
Sample collection (peripheral whole blood) was carried out by a trained phlebotomist using 
venepuncture. 
Peripheral blood was obtained from ET patients (n = 36) and healthy control donors (n = 7). Phosphate 
buffered saline solution was prepared by dissolving one Oxoid™ PBS tablet (Oxoid, Basingstoke, UK) 
in 100 mL water and adding 200 µL of a 0.5 M EDTA (Fisher Scientific, Loughborough, UK) pH 8.0 
solution. The PBS/EDTA solution was adjusted to pH 7.4. Whole blood was diluted with the PBS/EDTA 
solution (1 in 4 dilution) and layered over Ficoll-Paque Premium 1.077 g/m (GE Healthcare Life 
Sciences, Buckinghamshire, UK) in a 50 mL Falcon tube. The tube was centrifuged for 40 minutes in a 
swing bucket rotor centrifuge (Model: Allegra X-15R, Manufacturer: Beckman-Coulter, High Wycombe, 
UK) at 450 x g with the brake switched off and acceleration set to minimum. Temperature was set at 
20ºC. After centrifugation, the PBMC layer at the interface between the Ficoll-Paque and plasma layers 
was carefully extracted using a Pasteur pipette and transferred to a clean 15 mL Falcon tube. 10 mL of 
PBS/EDTA was added to the PBMCs and the tube was centrifuged for 10 minutes at 300 x g with brake 
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switched on. Supernatant was discarded after centrifugation and cells were resuspended with 10 mL 
of PBS/EDTA. This was then centrifuged for 10 minutes at 200 x g (brake on). Supernatant was 
discarded and cells were resuspended in appropriate volume (5 mL) of PBS and a cell count was taken 
using 0.4% trypan blue (Sigma-Aldrich, Poole, UK). 
Cohort 2: JAK2 in Myeloproliferative Neoplasms [NHS Ethics: 14/NW/1444] 
Patients with a myeloproliferative neoplasm, either PV, ET, or MF according to the WHO 2008 
diagnostic criteria were recruited for this study. All patients were 18 or above and had been recently 
diagnosed with an MPN or on cytoreductive therapy (hydroxyurea or anagrelide) at the time of 
sampling. 
Exclusion criteria for this study were: 
 Patients on ruxolitinib. 
 Patients who had received chemotherapy, any investigational drug or had undergone major 
surgery within the last four weeks. 
 Female patients who were pregnant or breast-feeding. 
 Patients with any other myeloproliferative disorder. 
Written informed consent was obtained from all patients before peripheral blood samples were taken. 
Peripheral blood (4 mL) was diluted with equal volume of Iscove’s MDM + 2% BSA (Stemcell 
Technologies, Vancouver, Canada) and inverted gently to mix. This was layered over 5 mL of Ficoll-
Paque Premium 1.077 g/m in a 15 mL Falcon tube. The tube was centrifuged for 30 mins at 400 x g 
with brake off and acceleration at minimum setting in a swing bucket rotor centrifuge (Model: Allegra 
X-15R, Manufacturer: Beckman-Coulter, High Wycombe, UK). A clean Pasteur pipette was used to 
transfer cells from the interface between the plasma and Ficoll layers to a fresh 15 mL tube. 10 mL of 
IMDM + 2% FBS was added to the tube containing the isolated cells. The tube was centrifuged for 10 
mins at 300 x g with the brake on. Supernatant was carefully discarded and pellet resuspended in 10 
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mL of IMDM + 2% FBS. Tube was centrifuged for 10 mins at 300 x g, the supernatant removed and 
resuspended in 2 mL of IMDM + 2% FBS. A cell count was performed using trypan blue assay. 
An aliquot (300 µL) of a 10 X cell solution (2 x 106 cells/mL) was added to 3 mL of MethoCult 
methylcellulose media, H4034 Optimum (Stemcell Technologies, Vancouver, Canada). Ruxolitinib (100 
and 250 nM) was added to the methylcellulose media. Vehicle control, dimethyl sulfoxide (DMSO), 
was also added to the methylcellulose media, at the same concentration as that of the highest drug 
concentration (250 nM) was dissolved in. The mixture was gently rolled and vortexed briefly to mix 
before allowing to settle. 1.1 mL of media was applied to each colony dish using a blunt end needle 
and syringe (Stemcell Technologies, Vancouver, Canada). Cells were incubated at 37ºC in a 5% CO2 
incubator for 14 days before colony types were identified and counted. BFU-E colonies were isolated 
and collected in 5 mL ice-cold PBS and centrifuged (300 x g for 3 minutes). Supernatant was discarded 
and pellet was resuspended in 1 mL ice-cold PBS. A cell count in 0.4% trypan blue was taken. The 
sample was then centrifuged at full speed in a microcentrifuge. Supernatant was aspirated completely 
and the pellet stored at -80ºC. 
2.2: Extraction of RNA from PBMCs using TRIzol® method 
 
PBMC cells (1 x 106) in PBS were spun down and supernatant was discarded to leave pellet in a 1.5 mL 
eppendorf. The PBMC pellet was solubilised in 1 mL TRIzol® reagent (Thermo-Fisher, Paisley, UK). 200 
µL of chloroform (Sigma-Aldrich, Dorset, UK) was added to the cells in TRIzol® and the mixture was 
shaken vigorously by hand for 15 seconds. The eppendorf was left to settle for 3 minutes before 
centrifugation (Model: Micro Star 17R, Manufacturer: VWR, Lutterworth, UK) at 12,000 x g for 15 
minutes at 4ºC. After centrifugation, the upper aqueous layer was removed and placed in a clean 
RNA/DNA free eppendorf. 0.5 µL of glycogen (20 µg/µL) (Life Technologies, Paisley, UK) was added to 
the aqueous phase followed by 500 µL of analytical grade isopropanol (Fisher Scientific, Loughborough, 
UK). The mixture was incubated at room temperature for 10 minutes. After incubation, the tube was 
centrifuged for 10 minutes at 12,000 x g at 4ºC. Supernatant was removed and pellet was washed with 
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75% ethanol (Fisher Scientific, Loughborough, UK) in DEPC water (Sigma-Aldrich, Poole, UK). Pellet 
was centrifuged at 7500 x g for 5 minutes at 4ºC. Supernatant was removed and pellet was allowed to 
air-dry for 10 minutes before dissolving in 50 µL of nuclease-free water (Sigma-Aldrich, Poole, UK). 
The tube was incubated at 55-60ºC on a block heater (Model: SBH130D/3, Manufacturer: Stuart, Stone, 
UK) for 10 minutes. 
2.3: Cleanup of RNA obtained using the TRIzol® extraction method 
 
Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany) was used to clean-up RNA after phenol-chloroform 
extraction. The sample was adjusted to 100 µL total volume with RNAse free water. 350 µL of buffer 
RLT from the RNeasy kit was added to the 100 µL sample and mixed well by pipetting. 250 µL of 
analytical grade ethanol (Fisher Scientific, Loughborough, UK) was added and mixed well by pipetting. 
The entire mixture (700 µL) was added to an RNeasy Mini kit spin column placed in a 2 mL collection 
tube and centrifuged for 15 seconds at 10,000 x g (Model: Micro Star 17R, Manufacturer: VWR, 
Lutterworth, UK). Flow-through was discarded. After centrifugation, DNase treatment was performed 
using the RNase-free DNase set (Qiagen, Hilden, Germany). 350 µL of buffer RW1 was added directly 
to the column and centrifuged for 15 seconds at 10,000 x g, flow-through was discarded. DNase 
mixture was prepared by mixing 10 µL of DNase I stock solution with 70 µL buffer RDD. The 80 µL 
mixture was added to the spin column membrane and incubated at room temperature for 15 minutes. 
Following incubation, 350 µL buffer RW1 was added to the spin column and centrifuged for 15 seconds 
at 10,000 x g, flow-through was discarded. 500 µL of buffer RPE was added to the spin column and 
centrifuged for 15 seconds at 10,000 x g, flow-through was discarded. A further 500 µL of buffer RPE 
was added to the spin column and centrifuged for 15 seconds at 10,000 x g, flow-through was 
discarded. The spin column was transferred to a clean collection tube and centrifuged at full speed 
(17,000 x g) for 1 minute to fully dry the membrane. 50 µL of nuclease-free water was added directly 
to the spin column placed in a 1.5 mL eppendorf tube for collection. This was centrifuged for 1 minute 
at 10,000 x g and flow-through collected. The purity and yield of RNA was determined by absorbance 
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readings at 230/260/280 nm on a Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Loughborough, UK). 
2.4: cDNA synthesis from PBMC RNA 
 
1000 ng of total RNA, quantified on a Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Loughborough, UK) was used in the cDNA reaction. High Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Paisley, UK) was used for RNA extracted from human peripheral blood samples. A 2X 
master mix was prepared according to the table below: 
Table 5: cDNA reaction mixture (High Capacity cDNA Reverse Transcription kit) 
Kit Component Volume per reaction (µL) 
10X RT Buffer 2.0 
25X dNTP Mix (100 mM) 0.8 
10X RT Random Primers 2.0 
MultiScribe™ Reverse Transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease-free water 3.2 
TOTAL 10 
 
10 µL of master mix was mixed with 10 µL of sample (1000 ng) in nuclease-free water. Samples were 
run in a thermocycler (Model: T100, Manufacturer: BioRad) according to the following settings: 
Step1: 25ºC 10 minutes 
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Step 2: 37ºC 120 minutes 
Step 3: 85ºC 5 minutes 
Step 4: 4ºC Hold 
2.5: Quantitative PCR (qPCR) 
 
qPCR reaction was run on MicroAmp Fast 96-well Reaction Plate (Applied Biosystems), on a StepOne 
Plus thermocycler (Applied Biosystems). Both SYBR Green chemistry and TaqMan probe methods 
were used.  
SYBR Green: cDNA was diluted 1/50 in nuclease-free water (Sigma-Aldrich, Dorset, UK). 4.5 µL of 
diluted cDNA was added to 5 µL iTaq SYBR Green (Bio-Rad, Hercules, USA) and 0.5 µL of 10 mM primer 
(Sigma-Aldrich, Dorset, UK). Primer sequences are shown in the table below. 
Table 6: List of primer sequences used 
 Forward Reverse 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
GATA1 CTGTCCCCAATAGTGCTTATGG GAATAGGCTGCTGAATTGAGGG 
FOG1 CGGTACTGCCGTCTTTGCA CGTGCGAGGAGCAGTAATACTTC 
NFE2 ACTCACTCATGCCCAACTCC TCTACCGGCAAGTTGACAATC 
FLI1 CGCTGAGTCAAAGAGGGACT AATGTGTGGAATATTGGGGG 
CALR TGTCAAAGATGGTGCCAGAC ACAACCCCGAGTATTCTCCC 
CANX ACACAGCAACCACTTCCCTT GCCTCCGCCTCTCTCTTTAC 
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 Forward Reverse 
STAT1 ATCAGGCTCAGTCGGGGAATA TGGTCTCGTGTTCTCTGTTCT 
ISG15 CGCAGATCACCCAGAAGATCG TTCGTCGCATTTGTCCACCA 
OAS1 TGTCCAAGGTGGTAAAGGGTG CCGGCGATTTAACTGATCCTG 
MX1 AGCGGGATCGTGACCAGAT TGACCTTGCCTCTCCACTTATC 
TAP1 CTGGGGAAGTCACCCTACC CAGAGGCTCCCGAGTTTGTG 
HLA-A1 AAAAGGAGGGAGTTACACTCAGG GCTGTGAGGGACACATCAGAG 
HSPA8 ACCTACTCTTGTGTGGGTGTT GACATAGCTTGGAGTGGTTCG 
HSP90AB1 AGAAATTGCCCAACTCATGTCC ATCAACTCCCGAAGGAAAATCTC 
ITGA2B GATGAGACCCGAAATGTAGGC GTCTTTTCTAGGACGTTCCAGTG 
TTRAP GACAGTGAGACTCGAACACATT CAAGGGCACAAACTCAGCAAC 
DNAJA1 GACATACAGCTCGTTGAAGCA GTGATGACGATGGTTCGGTTG 
IRF1 CTGTGCGAGTGTACCGGATG ATCCCCACATGACTTCCTCTT 
DDX3X ACGAGAGAGTTGGCAGTACAG ATAAACCACGCAAGGACGAAC 
SOCS1 TTTTCGCCCTTAGCGTGAAG CATCCAGGTGAAAGCGGC 
SOCS3 GGAGACTTCGATTCGGGACC GAAACTTGCTGTGGGTGACC 
STAT3 GAGGACTGAGCATCGAGCA CATGTGATCTGACACCCTGAA 
STAT5 TTACTGAAGATCAAGCTGGGG  TCATTGTACAGAATGTGCCGG 
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 Forward Reverse 
IRF3 TCTTCCAGCAGACCATCTCC TGCCTCACGTAGCTCATCAC 
IRF4 ATGCTTTGGAGAGGAGTTTC  CTGGATTGCTGATGTGTTC 
 
qPCR cycle times and temperatures are shown below.  
Step 1: 95ºC 30 seconds 
Step 2: 95ºC 3 seconds 
Step 3: 60ºC 30 seconds 
Repeat Step 2 – 3 x 39 
Step 4: 60ºC + 0.3ºC incremental to 95ºC 3 seconds 
TaqMan: For each well, 4.5 µL of 1/50 diluted cDNA sample was added to 0.5 µL TaqMan probe and 5 
µL of Fast Advanced Master Mix (Thermo Fisher) using a MicroAmp Fast-96 Reaction plate (Applied 
Biosystems). PCR cycle times and temperatures given below: 
Step 1: 50ºC 2 minutes 
Step 2: 95ºC 20 seconds 
Step 3: 95ºC 1 second  
Step 4: 60ºC 20 seconds 
Repeat Step 3 – 4 x 39 
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2.6: Cell culture 
 
Immortalised myeloid leukaemia cell lines in suspension were obtained from the Leibniz Institute 
DSMZ - German Collection of Microorganisms and Cell Cultures GmBH unless stated. Growth media 
used was RPMI-1640 (Invitrogen, Paisley, UK) supplemented with either 10 or 20% foetal bovine 
serum (Invitrogen, Paisley, UK). Cells were chosen on the basis of having an activating JAK2 mutation 
(HEL, SET2 and UKE1) or a previous patient MPN history (SET2 and UKE1). The first control cell line, 
K562, was selected as it also results in constitutive JAK/STAT pathway activation but does not carry a 
JAK2 mutation. The other control, HL-60, had neither a JAK2 activating mutation nor detectable 
JAK/STAT activity. 
Table 7: Cell lines used in the studies 
Cell 
line 
DSMZ # Type Culture 
conditions 
JAK2V617F 
mutation status 
(Quentmeier et 
al., 2006) 
K-562 ACC 10 Chronic myeloid 
leukaemia in blast crisis 
RPMI-1640 + 10% 
FBS.  
 
No 
HL-60 ACC 3 Acute myeloid leukaemia RPMI-1640 + 10% 
FBS. 
No 
HEL ACC 11 Erythroleukaemia RPMI-1640 + 10% 
FBS. 
Yes - 
homozygous 
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Cell 
line 
DSMZ # Type Culture 
conditions 
JAK2V617F 
mutation status 
(Quentmeier et 
al., 2006) 
SET-2 ACC 608 Essential 
thrombocythemia at 
megakaryoblastic 
leukaemic transformation 
RPMI-1640 + 20% 
FBS. 
Maintain 
between 0.2-1 x 
106 cells/mL. 
Yes -
heterozygous. 
Both JAK2WT and 
JAK2V617F 
UKE-1 Gift from 
Professor Anthony 
Green (University 
of Cambridge) 
Essential 
thrombocythemia at 
leukaemic transformation 
RPMI-1640 + 10% 
FBS. 
Yes - 
homozygous 
 
2.7: Drugs and inhibitors 
 
Anagrelide, ruxolitinib, and givinostat (Selleckchem, Newmarket, UK) dissolved in DMSO and 
hydroxyurea (Sigma-Aldrich, Poole, UK) dissolved in water, were applied to cell culture at a 1/100 
dilution of final volume. Fludarabine (Sigma, Poole, UK) was dissolved in DMSO to a working 
concentration of 100 mM. 
2.8: Trypan blue exclusion assay 
 
Cells were seeded (1 x 105 cells per well) in 12-well microtitre plates (Sarstedt, Leicester, UK) in 990 µL 
RPMI 1640 growth media + 10-20% FBS (Invitrogen, Paisley, UK). 10 µL of drug at 100 X final 
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concentration diluted in RPMI media was added to each well. DMSO, equivalent in dilution of highest 
drug concentration was added to a control well. The treated samples were mixed by gentle pipetting 
up and down ten times. At every 24-hour interval after treatment up to 96 hours, cells were removed 
fully from the wells. These were mixed by gentle vortexing and 50 µL of cell suspension was added to 
50 µL 0.4% trypan blue solution (Sigma-Aldrich, Poole, UK). The mixture was incubated at room 
temperature for 5 minutes, then vortexed briefly, before 10 µL of the mixture was pipetted onto a 
haemocytometer chamber with cover slip attached. Dead cells with permeable membranes took up 
the dye and stained blue, live cells did not stain and reflected light. Cells were counted in each of the 
16-square corner quadrants (1 mm x 1 mm x 0.1 mm). The total volume per quadrant was 0.1 µL or 1 
x 10-4 mL. Total number of cells was divided by number of quadrants counted (4) and multiplied by 
the dilution factor in trypan blue (2). This gave cell count per 1 x 10-4 mL, final cell count per mL was 
determined by multiplying by 10,000. Cell viability percentage was calculated by dividing live cells by 
total cells (dead and live) and multiplying by 100. 
2.9: 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) cell proliferation assay 
 
Cells were seeded (2 x 104 cells per well) in 96-well microtitre plates (Sarstedt, Leicester, UK) with 
drugs or peptides in 2X or 10X dilutions. Vehicle control was added to control wells at equivalent 
DMSO (dimethyl sulfoxide) or water concentration to highest drug concentration. After 72 hours, four 
negative control wells were treated with 10 µL of a 10% Triton X-100 solution for 10 minutes. All cells 
were then incubated for 2 – 4 hours in the presence of 20 µL 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent (Promega, Madison, USA) 
and phenazine methosulfate (PMS) (Sigma-Aldrich, Poole, UK). MTS/PMS mixture was prepared at a 
100:5 ratio immediately prior to adding to the wells. Absorbance was measured on a microtitre plate 
reader (Model: SpectraMax Plus, Manufacturer: Molecular Devices, Wokingham, UK) at 490 nm. 
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2.10: RNA extraction on cell lines 
 
RNA extraction was performed using the Quick RNA Mini-Prep (Zymo Research, USA).  All reagents 
unless specified were supplied with the kit.  Cell pellets were lysed in 300 µL RNA lysis using a 21G 
gauge needle and 1 mL syringe (Becton-Dickinson, Fraga, Spain), plunged up and down ten times. An 
equal volume of ethanol (Fisher Scientific, Loughborough, UK) was added to the lysate and the mixture 
transferred to a Zymo-Spin™ IIICG Column in a 2 mL collection tube. The spin column was centrifuged 
at 13,000 x g for 30 seconds and the flow through was discarded. 400 µL of RNA wash buffer was used 
to prewash the column (centrifuge at 13,000 x g for 30 seconds). 80 µL of DNase reaction mix (75 µL 
DNase digestion buffer and 5 µL DNase I) was added directly to the column membrane and incubated 
for 15 minutes at room temperature. After incubation, the tube was centrifuged (30 seconds at 13,000 
x g). 400 µL of RNA Prep Buffer was added to the spin column and centrifuged (13,000 x g for 30 
seconds). Flow-through was discarded. 700 µL of RNA Wash buffer was added to the spin column and 
centrifuged (13,000 x g for 30 seconds), flow-through was discarded. 400 µL RNA wash buffer was 
added to the spin column and centrifuged (13,000 x g for 2 minutes), flow-through was discarded. The 
spin column was then transferred to a clean RNase free eppendorf and 50 µL of nuclease-free water 
pipetted directly on to the membrane. The tube was centrifuged (13,000 x g for 30 seconds) and the 
spin column discarded and flow-through collected. The purity and yield of RNA was determined by 
absorbance readings at 230/260/280 nm on a Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Loughborough, UK).  
2.11: cDNA synthesis from cell line RNA 
 
Complementary DNA was synthesised from total RNA using the iScript cDNA synthesis kit (Bio-Rad, 
Hercules, USA). Reaction mixture was as follows: 
4 µL iScript reaction mix 
1 µL iScript Reverse Transcriptase 
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1000 ng Total RNA 
Nuclease-free H2O to 20 µL 
A no-reverse transcriptase control (NRT) was performed, substituting reverse transcriptase in the 
reaction mix for water. Nuclease-free water was used in place of RNA sample for the no-template 
control (NTC). 
The reaction mixture (20 µL) was run in a thermocycler (Model: T100, Manufacturer: Bio-Rad, Watford, 
UK) per the following settings: 
Step1: 25ºC 5 minutes 
Step 2: 42ºC 30 minutes 
Step 3: 85ºC 5 minutes 
Step 4: 4ºC Hold 
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2.12: Cell cycle analysis 
 
Cell fixation: Cells (K562 and HEL) at 2 x 105 cells/mL (5 mL total volume) were serum starved for 24 
hours prior to drug treatment (1 µM anagrelide or ruxolitinib) for up to 72 hours. After incubation, 
media was removed and cells were washed in PBS, before being resuspended in 0.5 mL of PBS. 4.5 mL 
of ice-cold 70% ethanol was added while mixing to the cell suspension. 
Propidium iodide (PI) staining: Cells in ethanol were centrifuged, supernatant was discarded and 
washed with PBS. Propidium iodide staining solution was prepared by adding 200 µL of 1 mg/mL 
propidium iodide (Sigma-Aldrich, Poole, UK) and 2 mg DNase-free RNase A (Sigma-Aldrich, Poole, UK) 
to 10 mL of a 0.1% Triton-X100 solution. 1 mL of the PI staining solution was used to stain cell pellet 
for 30 minutes at room temperature. PI emission was measured using a FACSVerse flow cytometer 
(BD Biosciences, Oxford, UK) and cell cycle analysis performed using FlowJo X software (Treestar Inc, 
Ashland, US). 
2.13: Western blotting 
 
Buffers used for SDS-PAGE and Western blot are given below: 
Table 8: Buffer formulations for SDS-PAGE and Western blot experiments 
Modified RIPA buffer 50 mM Tris (Fisher Scientific, Geel, Belgium) pH 7.5 
150 mM NaCl (Fisher Scientific, Geel, Belgium) 
1% NP-40 (Thermo Scientific, Rockford, USA) 
10% Glycerol (Fisher Scientific, Loughborough, UK) 
5 mM EDTA (Fisher Scientific, Geel, Belgium)  
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Ultrapure (18.2 MΩ) H2O (Model: Purelab Flex, Manfacturer: Elga 
Lab Water, High Wycombe, UK) 
SDS Loading buffer 10% SDS (Fisher Scientific, Geel, Belgium) 
50% Glycerol 
200 mM Tris pH 6.8 
Ultrapure H2O 
Bromophenol Blue (BDH Chemicals, Poole, UK) 
 
SDS Running Buffer 
 
25 mM Tris 
192 mM Glycine (Melford Biolaboratories, Chelsworth, UK) 
0.1% w/v SDS 
Transfer buffer 25 mM Tris 
192 mM Glycine 
20% Methanol (Fisher Scientific, Loughborough, UK) 
Tris Buffered Saline (TBS) 20 mM Tris pH 7.5 
100 mM NaCl 
TBS-Tween (TBS-T) 0.1% Tween-20 (Fisher Scientific, Loughborough, UK) 
5% Bovine Serum Albumin 
(BSA) blocking solution 
5% BSA (Roche, Mannheim, Germany) in 0.1% TBS-T 
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Primary antibody diluent 
(2.5% BSA) 
2.5% BSA in 0.1% TBS-T 
 
Cells were lysed in modified RIPA buffer with protease inhibitors (Roche, Mannheim, Germany) added 
(1 tablet per 10 mL mRIPA buffer). Total protein concentration for lysates was determined using 
Bradford reagent (Bio-Rad, Watford, UK) or by A280 spectrometer reading on a Nanodrop 
spectrophotometer (Thermo Scientific, Loughborough, UK). Lysates were loaded on a 10% SDS-PAGE 
gel and run at 100 – 120V until the dye front reached the end of the plate. Transfer of proteins to 
nitrocellulose membrane was carried out using a wet-blot apparatus with Tris/Glycine + 20% methanol 
transfer buffer. Transfer was carried out at +2 – 8ºC at 100V for 1 hour. Ponceau S (Sigma-Aldrich, 
Poole, UK) dye was used to check transfer. The nitrocellulose membrane was blocked in 5% BSA in Tris 
Buffered Saline + 0.1% Tween-20 (TBS-T). Primary antibody at the appropriate dilution was applied to 
the membrane and incubated overnight at +2 – 8ºC. Antibody dilutions are listed in Table 9 below. 
After incubation, the primary antibody was removed and membrane washed 5 times for 5 minutes 
with TBS-T. Secondary antibody, HRP-conjugated anti-rabbit IgG (Cell Signalling Technology (NEB), 
Hitchin, UK) at a 1/10,000 dilution in TBS was applied to the membrane and incubated at room 
temperature for 1 hour with gentle rocking. After incubation, the membrane was washed 5 times for 
5 minutes with TBS-T followed by rinse in TBS. Enhanced chemiluminescent substrate (Thermo-
Scientific, Loughborough, UK) was applied directly to the membrane and left for 1 minute before 
exposing to light sensitive X-ray film (FujiFilm, Tokyo, Japan) and developed using an X-ray film 
developer (Model: Compact X4 Manufacturer: Xograph, Stonehouse, UK) 
Table 9: Antibodies and dilutions used in Western blot experiments 
Antibody Host Dilution in 2.5% BSA Manufacturer 
Phospho STAT1 (Tyr701) Rabbit 1:2000 Cell Signalling Technology 
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Antibody Host Dilution in 2.5% BSA Manufacturer 
Total STAT1 Rabbit 1:5000 Cell Signalling Technology 
Phospho STAT3 (Tyr705) Rabbit 1:1000 Cell Signalling Technology 
Total STAT3 Rabbit 1:5000 Cell Signalling Technology 
Phospho STAT5 (Tyr694) Rabbit 1:1000 Cell Signalling Technology 
Total STAT5 Rabbit 1:5000 Cell Signalling Technology 
Phospho JAK2 (Tyr1007/1008) Rabbit 1:2000 Cell Signalling Technology 
Total JAK2 Rabbit 1:5000 Cell Signalling Technology 
Monoclonal α-Tubulin Mouse 1:10000 Sigma 
GAPDH Rabbit 1:20000 Amsbio, Abingdon, UK 
HRP-conjugated anti-rabbit IgG Goat 1:10000 Thermo Scientific 
HRP-conjugated anti-rabbit IgG Goat 1:10000 Cell Signalling Technology 
HRP-conjugated anti-mouse IgG Goat 1:10000 Thermo Scientific 
 
2.14: Colony-forming assays 
 
An aliquot (300 µL) of a 10 X PBMC solution (2 x 106 cells/mL) was added to 3 mL of MethoCult 
methylcellulose media, H4034 Optimum (Stemcell Technologies, Vancouver, Canada). The growth 
media contained recombinant human (rh) cytokines, including erythropoietin (rh-EPO) at a 
concentration of 0.1 U/ml. This is the concentration at which there was differential gene expression 
between JAK2V617F and JAK2WT cells (Chen et al., 2010). Ruxolitinib (100 and 250 nM) was added to the 
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methylcellulose media at a 1/1000 dilution. The mixture was gently rolled and vortexed briefly to mix 
before allowing to settle. 1.1 mL of media was applied to each colony dish using a blunt end needle 
and syringe (Stemcell Technologies, Vancouver, Canada). Cells were incubated at 37ºC in a 5% CO2 
incubator for 14 days before colony types were identified and counted. BFU-E colonies were isolated 
and collected in 5 mL ice-cold PBS and centrifuged (300 x g for 3 minutes). Supernatant was discarded 
and pellet was resuspended in 1 mL ice-cold PBS. A cell count in 0.4% trypan blue was taken. The 
sample was then centrifuged at full speed (13,000 x g) in a microcentrifuge (Model: Micro Star 17R, 
Manufacturer: VWR, Lutterworth, UK). Supernatant was aspirated completely and the pellet stored at 
-80ºC. 
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2.15: Protein extraction for Mass spectroscopy 
 
Lysis Buffer: 
Table 10:  Lysis buffer for protein extraction 
20 mM HEPES 0.476 g 
30 mM NaCl 0.193 g 
6.4 mM Sodium Pyrophosphate 0.285 g 
1 mM Sodium Orthovanidate 0.018 g 
 Made up to 100 mL with H2O and pH to 8.5 
with 1M NaOH 
 
Urea (Sigma-Aldrich, Poole, UK) was weighed (4.8 g) in a 50 mL tube and 7 mL of lysis buffer was added 
to dissolve. pH was checked to ensure it was still 8.5. Mixture was filter sterilised through 0.22 µm 
syringe filter (Sartorius). Phosphatase Inhibitor Cocktail II and III (Sigma-Aldrich, Poole, UK) were 
added at a 1/100 dilution. 20 µL Benzonase® Nuclease (Sigma-Aldrich, Poole, UK) was added to the 
mixture. 50 µL was added to each frozen lysate and cells sheared using 21G needle and 1 mL syringe 
(Becton-Dickinson, Fraga, Spain). Lysed cells were centrifuged for 15 minutes at 15,000 RPM at 4ºC. 
Total protein concentration was determined using Quick-Start Bradford dye reagent (Bio-Rad, 
Hercules, USA). Sample was diluted 1/200 with lysis buffer and 90 µL loaded on a microtitre plate. 90 
µL Bradford dye reagent was added and absorbance at 595 nm was measured using a microtitre plate 
reader. A standard curve was generated using BSA standards (Bio-Rad, Hercules, USA). Protein 
concentrations were equalised in 50 µL total volume. 500 mM DTT was prepared by adding 0.0385 g 
DTT in 500 µL water. 0.5 µL of the DTT solution was added to each tube to give a final 5 mM 
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concentration. Tubes were incubated for 30 minutes at room temperature. 1.56 µL of 500 mM 
iodoacetamide was added to each sample tube and incubated in the dark for 20 minutes. 
Lys-C Protease (Thermo-Scientific, Rockford, USA) was prepared in 20 mM HEPES buffer (pH: 8.5) to a 
final concentration of 0.1 µg/µL. This was added at a 1:100 ratio to total protein in each tube. 0.2 µg 
Lys-C was added to tube containing 20 µg protein (2 µL of 0.1 µg/µL solution). This was incubated for 
4 hours at 37ºC with shaking. After incubation, samples were diluted to final concentration of 2 M 
urea with 20 mM HEPES pH 8.5 buffer. 0.5 µL of 100 mM CaCl2 was added to each tube. Trypsin 
protease (Thermo Scientific, Rockford, USA) was added at a 1:20 ratio with total protein – 1 µg per 
tube. Samples were incubated on shaking platform overnight at 37ºC.  
Isobaric tagging and relative quantification (iTRAQ) reagent labelling: 
Each iTRAQ reagent vial was reconstituted by the addition of 50 µl of isopropanol at room temperature. 
The vials were vortexed and centrifuged briefly. The contents of each of the vials was added to sample 
tube containing 100 µg of digested protein. 
Samples were acidified to 1% with trifluoroacetic acid (TFA) and centrifuged for 20 minutes at 10,000 
x g at 4ºC. The supernatant was removed and retained. 2 x 2 mL of 80% acetonitrile/0.5% acetic acid 
was slowly pushed through a tC18 SPE 3cc cartridge (Waters, Elstree, UK). This was followed by 2 x 2 
mL methanol. 2 x 2 mL 0.1% TFA was then pushed through the column. Sample was added to the 
column and allowed to flow through by gravity. After 20 minutes, any remaining sample in the column 
was gently pushed through. 2 x 2 mL of 80% acetonitrile/0.5% acetic acid was gently pushed through. 
Aliquots were lyophilised for storage and mass spectroscopy preparation. 
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Figure 11: Workflow for iTRAQ labelling and quantification of differentially expressed proteins in 
response to ruxolitinib treatment. 
114 116 118 121 113 115 117 119 
SET2 + 0 µM RUX SET2 + 1000 µM RUX 
Digested & labelled 
peptides combined 
Treated ± drug (RUX) 
& cells harvested 
Protein extracted & 
proteolytic digestion 
carried out 
Digested peptides 
labelled with one of 8 
iTRAQ isobaric labels 
Separation of peptide 
mixture by HPLC 
followed by MS/MS 
Relative quantification determined 
from ratio of reporter ion intensities 
Peptide fragment 
sequences identified 
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2.16: Mass Spectroscopy 
 
Workflow for labelling and quantification is shown in Figure 11. Sample loading and fractionation was 
performed using an Eksigent Ekspert NanoLC 400 UHPLC. Peptides were eluted from the reverse phase 
C18 nano-column using a flow rate of 300 nL/min. Mass spectroscopy was carried out on a TripleTOF 
6600 MS/MS instrument with electrospray ionisiation (AB SCIEX, Framingham, MA, USA). The 
instrument was operated in data dependent mode. Peptides with multiple charges (2+ to 4+) with a 
charge to weight ratio (m/z) between 400 and 1600 were selected for MS/MS. Visualisation of altered 
biological processes was performed using these differentially expressed proteins and Cytoscape v3.5.0 
(Shannon et al., 2003) with ClueGO plugin (Bindea et al., 2009) with gene ontology terms. Interactions 
between the proteins were examined and demonstrated using the web program STRING (version 10.5) 
(Szklarczyk et al., 2015). 
2.17: Statistics and data analysis 
 
IC50 values from MTS assays were determined, where possible, using GraphPad Prism software v6.05. 
A log transformation of the concentration values was performed and a three-parameter non-linear 
curve fit applied. IC50 was determined as the concentration at which 50% maximal inhibition occurred 
on the curve fit. Each MTS assay was carried out on three separate occasions. 
Relative gene expression was calculated using the ΔΔCT method, where GAPDH was used as the 
control gene. Sample was cDNA derived from PBMCs from ET patients and control sample was PBMC 
cDNA from a healthy volunteer. CT values were acquired from the StepOne instrument software (v2.3). 
ΔCT         =             CT(Gene of Interest) - CT(GAPDH) 
ΔΔCT      =             ΔCT(Sample) – (Average ΔCT(Control Sample)) 
Relative quantification given by following transformation; 
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RQ      =          2-(ΔΔCt) 
Median gene expression of the 36 ET samples was compared against that of 7 healthy volunteers. 
Significance was determined using the Mann-Whitney U-test. Kruskal-Wallis with Dunn’s Multiple 
Comparison test was used to calculate significance for an independent variable between three or 
more groups. All tests were carried out using GraphPad Prism v6.05. Significance stars are given as 
follows: 
(*) p < 0.05; (**) p < 0.01; (***) p < 0.001; (****) p < 0.0001 
A post-hoc power analysis using G*Power (v 3.1.9.2) for Windows was performed for genes that were 
significantly up or downregulated in ET patient samples. Power values for GATA1, FLI1, CALR, and 
CANX were 0.89, 1.00, 0.99, and 0.58 respectively. 
Overall changes to proportions of cells in each stage of the cell cycle were determined using the chi-
square test in GraphPad Prism. In individual cell cycle stages, a t-test (α-level = 0.05) was used to 
calculate whether treatment had any significant effect. Gating of cells was done using FlowJo software 
v 10. 
Gene expression changes in cell lines were calculated as described for ET patient derived samples. A 
t-test (α-= 0.05) (GraphPad Prism) was used to determine significance. 
Output files from the mass spectroscopy instrument were processed with Protein Pilot software 
(version 5.0.1) using Paragon™ Algorithm (version 5.0.1.0, 4874). A thorough search was performed 
against human database, Human_NR_UP000005640_LastMod20Dec15.fasta. The resulting data file 
was exported to Microsoft Excel for data analysis. Proteins were filtered by unused protein score, 
where a score ≥ 1.3 corresponded to a confidence level of 95%. Proteins with an unused protein score 
< 1.3 were excluded from the analysis. Ratios between control labels (114, 116, 118, and 121) were 
compared against treated labels (113, 115, 117, and 119) and those less than 0.8 were selected. At 
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least two spectra, with p-values less than 0.05, were required for identification and relative 
quantification. 
Percentages of ruxolitinib treated cells in colony forming assay dishes were calculated relative to 
vehicle control (DMSO) treated samples. An independent t-test (α = 0.05) was used to show 
significance between untreated and treated colonies. This was carried out for four PV samples, four 
ET samples and a healthy control in triplicate.
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CHAPTER 3: GATA1 
expression levels in 
the peripheral 
blood of patients 
with essential 
thrombocythaemia
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3.1: Introduction 
 
Essential thrombocythaemia (ET) is characterised by an elevated circulating platelet count (> 450 x 
109/L) and increased numbers of megakaryocytes (Arber et al., 2016). Estimated prevalence rates in 
the UK are 18 per 100,000 (Titmarsh et al., 2014). Overall median survival (19.8 years) is longer in ET 
than seen in PV (13.5 years) but still lower than the age-matched control population (Tefferi et al., 
2014a). Reflecting the longer survival rates, the risk of disease transformation, myeloid or leukaemic, 
is low in the first decade after diagnosis (9.1% and 1.4% respectively) although it increases 
considerably into the second (28.3% and 8.1%), and third decades after diagnosis (58.5% and 24.0%) 
(Wolanskyj et al., 2006).  
Treatment of ET is aimed at reducing thrombotic events and leukaemic transformation (O'Sullivan and 
Harrison, 2017). It is based on current symptoms and risk factors, including age, platelet count, and 
the occurrence of previous thrombotic events (Beer et al., 2011). Patients with a history of previous 
thrombotic complications, very high platelet counts (> 1500 x 109/L) or of increased age (> 60 years 
old) are considered high risk, where cytoreductive therapy (hydroxyurea) is recommended to control 
platelet counts (Alimam et al., 2015). Aspirin is used in conjunction with hydroxyurea therapy or on 
its own in lower risk patients (Tefferi and Barbui, 2015). In high risk patients who are resistant to 
hydroxyurea, anagrelide is used as a second-line therapy. Anagrelide is also used concomitantly with 
hydroxyurea as a method to avoid dose limiting toxicities encountered with a single therapy or to 
overcome poor efficacy (Gugliotta et al., 2014). In pregnant women, treatment with hydroxyurea is 
avoided due to its teratogenicity in non-human mammals (Beer et al., 2011). In these cases, aspirin is 
recommended unless contraindicated, or interferon-α if a cytoreductive agent is needed (Beer et al., 
2011, Finazzi, 2012). 
Mutations in ET patients are found in JAK2V617F (Baxter et al., 2005, James et al., 2005, Kralovics et al., 
2005, Levine et al., 2005) MPLW515L/K (Tefferi, 2010, Vainchenker et al., 2011), and several in the gene 
encoding calreticulin (CALR) (Klampfl et al., 2013, Nangalia et al., 2013). Both JAK2 and MPL mutations 
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are “gain of function”, and result in constitutive activation of the JAK/STAT signalling pathway 
(Chaligné et al., 2008). Calreticulin is a protein located in the endoplasmic reticulin (ER) which 
sequesters Ca2+ (Luo and Lee, 2013). Additionally, it plays a role in post-translational modifications of 
proteins in the ER, recognising N-linked glycans on glycoproteins and processing them for further 
folding or degradation (Michalak et al., 2009, van Leeuwen and Kearse, 1996). Mutations in calreticulin 
have been identified in 33% of ET and MF patients (Andrikovics et al., 2014). 
GATA1 is a transcription factor with a critical role in haematopoiesis, specifically in erythrocyte and 
megakaryocyte development, as well as in eosinophil and mast cell lineages (Ferreira et al., 2005).  
The structure is composed of three functional domains, two zinc fingers and an N-terminal activational 
domain. One of the zinc fingers (C) is responsible for binding to the consensus sequence on the DNA 
(Crispino, 2005). The other zinc finger (N) also has DNA binding activity, specific to a palindromic 
consensus sequence, as well as being important for the recruitment and binding of a co-factor, friend 
of GATA1, (FOG1) (Tsang et al., 1997).  
The FLI-1 (friend leukaemia integration 1) transcription factor is required for normal megakaryocyte 
development. It binds to Ets promoters on megakaryocyte specific genes, including GPIX, cMPL and 
αIIb (Pang et al., 2006). Knockout of FLI1 results in moderately reduced levels of cMPL and αIIb, and a 
dramatic reduction in the late stage gene, GPIX (Hart et al., 2000). FLI-1 can also associate with GATA1 
and FOG1 elements to provide a synergistic effect on gene expression (Pang et al., 2006). 
Nuclear factor erythroid-2 (NFE2) is a haematopoietic transcription factor and is essential for normal 
platelet formation (Shivdasani et al., 1995). Overexpression of NFE2 has been found in the vast 
majority of PV patients (Goerttler et al., 2005). Increased NFE2 is also responsible for delayed 
erythroid maturation and results in an increase in the number of mature erythroid cells deriving from 
a single progenitor (Mutschler et al., 2009).  
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3.2: Aims 
 
This study will examine expression of GATA1, along with critical haematopoietic genes involved in both 
early and late stage megakaryopoiesis. It will also investigate whether changes in the levels of these 
genes correlate to each other as well as to key clinical and haematological parameters. Finally, the 
related ER chaperone proteins, calreticulin and calnexin, will be studied to determine whether their 
expression is linked to mutational status or haematological markers of disease. Correlation between 
the two may also indicate their common role in the ER is an important factor in the pathogenesis of 
ET.    
The relative expression levels of these transcription levels in ET patients and their correlation to 
clinicopathological features will hopefully provide an insight into the molecular mechanisms of MPN 
as well as determining their suitability as diagnostic and prognostic markers of disease. 
  
3.3: Methods 
 
Methods are described in brief here; for full methodology refer to Chapter 2. Mononuclear cells were 
isolated from the peripheral blood of ET patients (n = 36) and healthy donors (n = 7) using Ficoll-Paque 
separation gradient. Total RNA was obtained using TRIzol®/chloroform extraction techniques. 
Complimentary DNA (cDNA) was synthesised using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Quantitative PCR was run using either Quantinova Sybr Green dye (Qiagen, 
Manchester, UK) or Taqman probes (Life Technologies, Paisley, UK). 
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3.4: Results 
 
3.4.1: Essential thrombocythaemia clinical parameters 
 
Clinical and haematological parameters for patients enrolled in this study are listed in Table 11. Age, 
sex, platelet count, mutation type (if present) and current therapy were recorded for each patient. 
Platelet counts were measured at two points, firstly at the time of essential thrombocythaemia (ET) 
diagnosis and secondly when a peripheral blood sample was drawn for analysis in this study. The total 
population median age was 68.5 years with female patients slightly younger (median age: 65.5 years) 
compared to males (median age: 70 years). There were also more female than male patients enrolled 
(1.6:1) in the study. 47% of patients carried a mutation in JAK2, 11% had a CALR mutation and 38% 
had no identified mutation in JAK2, CALR or MPL (triple-negative). One single patient had a mutation 
in the gene encoding the thrombopoietin receptor, MPL. Treatment regimens at the time of sampling 
were also recorded. 53% of patients were being treated with the cytoreductive agent hydroxyurea, 
14% were on the platelet-lowering drug anagrelide. 17% of patients were treated with a combination 
of the two therapies, while the remainder of patients (17%) had their condition monitored and were 
not undergoing any drug treatment.  
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Table 11: ET patient cohort clinical data 
 TOTAL MALE FEMALE 
Number of patients 36 14 22 
Age 
(MEDIAN/RANGE) 
68.5 
(36-92) 
70 
(59-81) 
65.5 
(36-92) 
Platelet count 
(MEDIAN/RANGE) x109/L 
444 
(190-758) 
462.5 
(304-600) 
419 
(190-758) 
Platelet count (diagnosis) 
(MEDIAN/RANGE) x109/L 
706 
(449-1972) 
740 
(552-1972) 
681.5 
(449-956) 
Mutation 
JAK2 
MPL 
CALR 
Triple Negative 
 
17 
1 
4 
14 
 
7 
1 
1 
5 
 
10 
0 
3 
9 
Treatment 
ANA 
HU 
ANA+HU 
WW 
 
5 
19 
6 
6 
 
1 
8 
4 
1 
 
4 
11 
2 
5 
ANA: anagrelide. HU: Hydroxyurea. WW: Watch & Wait 
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3.4.2: GATA1 is significantly upregulated in the peripheral blood of ET patients with a 
moderate negative correlation to platelet counts 
 
Transcriptome analysis of RNA isolated from the mononuclear cells of ET patients against healthy 
donor controls showed that the key haematopoietic transcription factor, GATA1, was significantly 
upregulated (p < 0.05) in ET patients (n = 36) compared to healthy controls (n = 7) (Figure 12). 
Expression of GATA1 was found to be unrelated to the choice of therapy (Figure 13), which in our 
cohort of patients included anagrelide (ANA), hydroxyurea (HU), a combination of anagrelide and 
hydroxyurea, and those currently not being treated (WW). A moderate significant negative correlation 
(r = -0.4129, p < 0.05) was found between measured platelet level and GATA1 expression at the time 
the sample was taken. Samples were separated into three equal sized bins corresponding to measured 
platelet counts (Figure 14), Low: 190 – 373, Med: 375 – 500, High: 508 – 758 x 109 /L. GATA1 expression 
in the medium and high platelet groups were significantly lower than observed in the low platelet 
group (p < 0.05). These results suggest that raised GATA1 expression is a marker for ET, although it 
does not positively correlate with measured platelet counts in patients undergoing cytoreductive or 
platelet reducing therapies. 
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Figure 12: Median GATA1 expression in the peripheral blood mononuclear cells of ET patients versus 
healthy controls. GATA1 is significantly upregulated in the peripheral blood of ET patients (p = 
0.0003 – Mann Whitney U Test). 
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Figure 13: Median GATA1 expression in ET patients by current therapy. ANA: anagrelide, HU: 
hydroxyurea, WW: Watch and wait (no treatment). GATA1 expression was not affected by choice of 
therapy (Dunn’s Multiple Comparison Test with Kruskal-Wallis test; p = 0.6183). 
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Figure 14:  Median GATA1 expression plotted against platelet counts. Platelet counts were 
separated into equal sized bins (Low: 190 – 373, Med: 375 – 500, High: 508 – 758 x 109 /L) GATA1 
was significantly raised in patients (Dunn’s Multiple Comparison Test with Kruskal-Wallis test; p = 
0.0059). 
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3.4.3: GATA1 upregulation was independent from changes in FLI1 and NFE2 expression  
 
NFE2, which is a direct transcriptional target of GATA1, did not shown any change in median 
expression (p = 0.1310) relative to healthy control samples (Figure 15). This does not follow the 
expected gene expression pattern given the significant increase in GATA1 observed in Figure 12. 
Platelet counts showed a moderate positive correlation (r = 0.5075; p = 0.0019) with expression levels 
of NFE2 in ET patients (Figure 16). Therefore, higher levels of NFE2 were associated with an increased 
number of circulating platelets. This is contrary to what was observed in Figure 14, where increased 
GATA1 expression correlated with lower platelet counts. From this we can conclude that the rise in 
GATA1 expression seen in ET patients does not directly result in the upregulation of one of its key 
megakaryopoietic gene targets, NFE2. 
In contrast to GATA1 over-expression in ET patients, FLI1 was significantly downregulated (p < 0.0001) 
in the PBMCs of ET patients compared to healthy controls (Figure 17). This corresponded to a nine-
fold decrease in relative FLI1 expression. Unlike NFE2 and GATA1, there was no direct correlation 
between platelet levels and the reduced FLI1 expression in ET patients (r = 0.2332; p = 0.1710) (Figure 
18). The reduction of FLI1, critical for normal megakaryopoiesis, in PBMCs does not appear to 
negatively impact platelet production in these patients. It is not known whether this decrease could 
contribute to haematopoietic clonal cell expansion, a key characteristic of ET and other MPNs. 
These results suggest that changes in GATA1 expression observed in PBMCs do not directly affect the 
levels of other key haematopoietic transcription factors involved in both early and late 
megakaryopoiesis, FLI1 and NFE2. 
78 
 
 
Figure 15: Expression of the haematopoietic transcription factor NFE2 in ET patients relative to 
healthy controls. No significant difference between the median values in ET and controls was 
observed (p = 0.1310 – Mann Whitney U Test). 
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Figure 16: NFE2 expression plotted against measured platelet counts. A moderate positive 
correlation was observed, r = 0.5075, and this was significant, p = 0.0019.  
0 200 400 600 800
0.015625
0.03125
0.0625
0.125
0.25
0.5
1
2
4
8
16
NFE2 expression vs platelet counts in ET patients
Platelet Count (x109/L)
R
e
la
ti
ve
 f
o
ld
 c
h
an
ge
(2
-

C
t )
r = 0.5075
p = 0.0019
80 
 
 
Figure 17: Median expression of the haematopoietic transcription factor FLI1 in ET patients relative 
to healthy controls. Levels of FLI1 were significantly lower in ET patients versus controls (p < 0.0001 
– Mann Whitney U Test). 
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Figure 18: FLI1 expression in ET patients plotted against measured platelet counts. No significant 
correlation was observed (r = 0.2332; p = 0.1710). 
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3.4.4: CALR and CANX are significantly downregulated in the peripheral blood of ET 
patients and levels of CALR are higher in JAK2 mutated patients 
 
Expression of the gene for the endoplasmic reticulum chaperone protein, calreticulin, was lower in ET 
patients compared to healthy controls (Figure 19). A threefold decrease in relative CALR expression 
for ET patient samples was observed which was significant (p < 0.05; Mann-Whitney U test). JAK2 
mutations (exon 12 and JAK2V617F) were associated with a greater than twofold increase in relative 
CALR levels (median: 0.591) than those found in triple negative patients (median: 0.2045) (Figure 20); 
although no significant differences were observed between the CALR mutated and either JAK2 or 
triple-negative groups (Figure 20). Therapy choice that patients were on at the time of sampling did 
not have any significant effect (p > 0.05) on relative CALR expression (Figure 21). 
Gene expression for the related chaperone protein, calnexin (CANX), was also downregulated (p < 0.05 
– Mann-Whitney U test). There was a fivefold decrease in relative CANX expression in the ET patient 
group (median CANX expression: 0.2725 versus 1.350) (Figure 22). There was a significant moderate 
correlation (r = 0.5137; p < 0.05) between CALR and CANX expression in ET patients (Figure 23). The 
reduction of both these ER chaperone proteins, and the correlation between the two, may indicate 
that their shared role may be a factor in the pathogenesis of the disease.  
It was also shown that triple-negative patients had higher platelet counts than either JAK2V617F or CALR 
mutated, although the difference was not significant (Dunn’s Multiple Comparison Test with Kruskal-
Wallis test; p > 0.05). These results may be partly due to the low number of samples, particularly in 
the CALR mutated group.
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Figure 19: Median CALR expression in ET patient samples versus healthy controls. CALR was 
significantly downregulated in ET patient samples (p < 0.05 – Mann-Whitney U test). 
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Figure 20: Calreticulin expression by recorded mutation type (JAK2, CALR, or triple-negative) in ET 
patients. Higher levels of CALR were observed in JAK2 mutated versus TN patients (Dunn’s Multiple 
Comparison Test with Kruskal-Wallis test; p < 0.05). 
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Figure 21: Expression of CALR by current treatment in ET patients. Treatments were anagrelide 
(ANA), hydroxyurea (HU), combination ANA + HU, or watch and wait/no treatment (WW). Choice of 
therapy or combination did not significantly affect CALR levels (Dunn’s Multiple Comparison Test 
with Kruskal-Wallis test; p > 0.05). 
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Figure 22: Calnexin expression in ET patients versus controls. The median level of CANX was 
significantly lower in ET patients (p < 0.05; Mann-Whitney U test). 
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Figure 23: Correlation of CANX expression to CALR in ET patients. Levels of calnexin were moderately 
correlated (r = 0.5137) with those of CALR and this was significant (p < 0.05). 
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Figure 24: Platelet counts plotted by recorded mutation in ET patients (JAK2, CALR or triple-
negative). Mutational status did not significantly affect platelet levels (p > 0.05; Dunn’s Multiple 
Comparison Test with Kruskal-Wallis test). One sample positive for a MPL mutation (platelet count: 
557 x 109 /L) was omitted from the analysis. 
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3.5: Discussion 
 
The clinical and haematological parameters for our cohort of patients showed the expected higher 
female to male ratio as previously reported in other studies (Brière, 2007, Mesa et al., 1999), as well 
as the increased prevalence in younger females (Brière, 2007, Wolanskyj et al., 2006). The presence 
of a JAK2 mutation in these ET patients reflected the frequencies in the literature, where JAK2V617F 
mutations were found in 50 – 60% of ET patients (Alimam et al., 2015); however there was a lower 
than expected number of patients carrying a CALR mutation (11%) compared to other published 
reports (24 – 32%) (Klampfl et al., 2013, Nangalia et al., 2013, Rumi et al., 2014a, Tefferi et al., 2014b). 
In addition, there were a high number of triple-negative patients in our samples (carrying no known 
mutations in JAK2, MPL or CALR), 38%, versus expected 12 – 15% (Tefferi et al., 2014c, Tefferi et al., 
2014b, Nangalia et al., 2013). The small cohort size may be responsible for the discrepancies observed 
between the frequencies of CALR and triple-negative patients and those reported in the literature 
rather than any localised population aspect. It is also noted that the recruitment of these patients 
bridged the period during which mutations in CALR were identified in ET and MF patients (Klampfl et 
al., 2013, Nangalia et al., 2013). Although all JAK2/MPL negative patients were retested for CALR, it is 
possible that mutants may be missed in some of these patients due to limits of detection in current 
diagnostic methods in detecting low-allele burden samples (Lim et al., 2015, Luo and Yu, 2015). 
Recently, whole exome sequencing of triple-negative samples from ET and MF patients identified a 
small number of patients with activating mutations outside of exon 10 of MPL and novel JAK2 
mutations that could constitutively activate JAK2-STAT5 signalling (Milosevic Feenstra et al., 2016). 
This indicates that caution should be taken when drawing conclusions from comparisons between 
JAK2/CALR/MPL mutated, and triple-negative patients, as discrete homogenous groups.  
The results showed no significant difference in platelet counts between the mutation types, whereas 
previous groups have shown that platelet counts are significantly higher in CALR vs both JAK2V617F and 
triple-negative patients (Rotunno et al., 2014, Rumi et al., 2014a). However, it was only the JAK2V617F 
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mutation that was associated with a higher risk of thrombotic events (Rotunno et al., 2014). It should 
be noted that the results here are for patients undergoing a range of cytoreductive and platelet 
lowering therapies, which, depending on their efficacy, may have a confounding effect on the results. 
Also, as previously mentioned, the triple-negative cohort of patients is likely to be a heterogenous 
group whose activating mutations may share similarities with either JAK2V617F, CALR exon 9, or 
MPLW515K/L. It is also very likely that no significant differences were observed due to the small sample 
size. Previous studies demonstrating lower platelet counts in CALR mutated ET patients have used 
data from over 600 patients (Rumi et al., 2014a). 
This study has shown that GATA1 is overexpressed in the peripheral blood of ET patients and this 
occurs independently of mutational status. GATA1 has previously been shown to be significantly 
upregulated in the bone marrow of ET and PV patients, but not in MF (Rinaldi et al., 2008) and the 
results in peripheral blood of ET patients reflect these findings. The increase in GATA1 is independent 
of platelet-lowering and cytoreductive therapy, which may suggest a role as a marker for disease. 
Interestingly, a moderate correlation was found between increased platelet counts and lower 
(although still upregulated) GATA1 expression. Studies separating the ET category of disease into two 
distinct groups, “true-ET” and “prefibrotic-MF (pre-MF)”, have shown that the pre-MF group have 
similar (Barosi et al., 2012) or even significantly increased (Barbui et al., 2011, Rupoli et al., 2015) 
platelet counts versus true-ET. It is possible that reduced GATA1 expression (relative to other ET 
patients) may be indicative of a pre-MF phenotype. Further loss of GATA1 expression and relative 
downregulation may also point towards disease transformation to myelofibrosis, where impaired 
haematopoiesis is driven by low GATA1 levels (Gilles et al., 2017). This cohort of patients were 
recruited according to the 2008 WHO criteria for ET, it may be useful to retrospectively analyse this 
group and identify whether any fall into the recently designated pre-MF category (Arber et al., 2016). 
Samples with much higher platelet counts or existing patients whose platelet counts have increased, 
may be required to confirm whether there is any correlation with GATA1 gene expression. 
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NFE2, a key regulator of megakaryopoiesis, did not show any change in level of expression. This is 
surprising, since firstly the p45 subunit of NFE2 is a direct transcriptional target of GATA1 (Tsang et al., 
1997), and secondly, previous studies have shown that NFE2 is overexpressed in both PV and ET 
patients (Wang et al., 2010). These results were from mRNA extracted from granulocytes (Wang et al., 
2010) rather than PBMCs which were used in this study. The differences in cell populations between 
the two methods and presence of earlier progenitors in PBMCs may explain why our results did not 
reflect these findings. NFE2 is associated with late-stage megakaryocytic development and NFE2 
knockout is associated with defects in proplatelet formation and platelet shedding (Tijssen and 
Ghevaert, 2013). NFE2 did show a moderate positive correlation with platelet levels, which suggests 
that regulation of NFE2 affects disease pathogenesis. From our results, we conclude that expression 
of NFE2 and its effect on platelet levels is independent from GATA1 expression in these cells. 
FLI1 was shown to be significantly downregulated in peripheral blood mononuclear cells derived from 
ET patients. This is unusual since other research has demonstrated that it is reduced in the bone 
marrow of ET patients (Bock et al., 2006). Cross-antagonism between the erythroid specific 
transcription factor, EKLF, and FLI1 has also been shown to promote megakaryopoiesis (Siatecka et al., 
2007, Starck et al., 2003). Furthermore, FLI1 is required for transcriptional synergy between GATA1 
and FOG1 in upregulating expression of megakaryocytic specific genes (Wang et al., 2002). Given that 
the primary hallmark of ET is increased platelet count and megakaryocyte proliferation, the decrease 
in FLI1 expression in these patients does not appear to negatively impact this. FLI1, unlike both GATA1 
and NFE2, did not correlate with measured platelet counts or with the expression of either GATA1 or 
NFE2. 
The functions of calreticulin, in calcium homeostasis and as an ER chaperone protein, are understood 
(Michalak et al., 2009) but it is not yet fully known how mutations in CALR that are found in MPN 
patients result in an ET or MF (but not PV) disease phenotype. Recently, the type of calreticulin 
mutation (52bp deletion or 5bp insertion) has been shown to have differential effects on the 
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phenotype (ET versus MF) as well as the risk of myelofibrotic transformation (Cabagnols et al., 2015). 
Ruxolitinib (a JAK 1/2 inhibitor) is equally effective in treating JAK2 mutated and non-mutated MPN, 
indicating that all these mutations (JAK2V617F, exon 12, MPL and CALR) affect a common pathogenic 
pathway. The reduction in gene expression in CALR, in all mutation types, suggests that loss of CALR 
function may be responsible in part for the MPN phenotype (in contrast to the gain of function seen 
in JAK2 and MPL mutations). Other groups have reported that CALR is lower in MPN patients compared 
to healthy volunteer donors (Park et al., 2014). Interestingly this group also reported that CALR 
expression was higher (not significant) in non-JAK2 mutated than in JAK2V617F or exon 12 mutated 
patients (Park et al., 2014). This is contrary to our results which showed that JAK2 mutations were 
associated with increased CALR levels over triple-negative patients (significant). However, the 
differences in methodology between the two studies should be noted, our study examined ET patients 
only whereas the data by Park et al. (2014) included PV and MPN-unclassified as well as ET patients. 
It was also not specified in the study whether the RNA was extracted from bone marrow aspirates or 
peripheral blood. Park et al. (2014) also highlight that their results were not statistically significant, 
probably due to the low number of MPN patients studied. 
These results demonstrate that GATA1 is a useful marker of ET disease, especially since it is still 
overexpressed while patients are undergoing cytoreductive or platelet lowering therapies. Further 
investigation may be required to determine whether newer JAK2 kinase inhibitors, such as ruxolitinib, 
have any effect on GATA1 expression levels.  It has also been shown that increased GATA1 mRNA does 
not directly alter the expression of related haematopoietic genes, NFE2 and FLI1. Finally, calreticulin 
is significantly downregulated, along with another chaperone protein, calnexin, suggesting that post 
translational modifications and quality control in the endoplasmic reticulum may play a role in ET 
disease, independent of mutational status. 
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CHAPTER 4: 
Molecular 
mechanisms of 
GATA1 in MPN cell 
models
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4.1: Introduction 
 
To explore the role of GATA1 in ET patients, it was decided to study its mechanisms in cell line models 
treated with anagrelide. Unlike hydroxyurea, the gold standard therapy used in ET (Harrison and 
Keohane, 2013), anagrelide is not a cytoreductive agent and works by inhibiting megakaryopoiesis 
(Ahluwalia et al., 2010), although the exact mechanism of action is not fully understood. Anagrelide is 
a potent phosphodiesterase III (PDE3) inhibitor, which can prevent aggregation of platelets – although 
this is only observed in doses that are higher than clinically relevant (Balduini et al., 1992). Studies 
have demonstrated a possible mechanism of action involving a down-regulation of GATA1 expression 
(Ahluwalia et al., 2010). Anagrelide does not affect MPL signal transduction, JAK2 and STAT3 
phosphorylation levels are unchanged in cell lines exposed to the drug, but during TPO-induced 
megakaryopoiesis, expression levels of GATA1 and FOG1 are reduced (Ahluwalia et al., 2010).  
Five cell line models were used in these experiments, three of these (HEL, SET2 and UKE1) contain the 
JAK2V617F mutation found in 50-60% of cases of ET. Two of the cell lines (SET2 and UKE1) were derived 
from patients with a prior history of ET before transformation to AML (Uozumi et al., 2000, Fiedler et 
al., 2000). UKE1 and HEL were homozygous for the JAK2V617F mutation whilst SET2 expressed both 
JAK2V617F and JAK2WT (Quentmeier et al., 2006). 
The roles of GATA1 and FOG1 in haematopoiesis have been discussed previously in Chapter 3.  FOG1 
is co-expressed with GATA1 during haematopoiesis, and through its binding on one of the N-terminal 
fingers on GATA1, is responsible for normal erythroid and megakaryocyte development (Tsang et al., 
1998, Tsang et al., 1997). Both FOG1 knockout mouse models and mutants affecting GATA1/2 binding 
to FOG result in megakaryopoietic failure. FOG1 may also have an independent role from GATA1 in 
inhibiting differentiation in mast cell and eosinophil lineages (Chlon and Crispino, 2012), exogenous 
expression of FOG1 in these eosinophil progenitors results in erythro-megakaryocyte features 
(Querfurth et al., 2000). 
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GATA2 expression overlaps with that of GATA1 and during terminal erythroid differentiation there is 
a switch from GATA2 to GATA1 expression (Cheng et al., 1996, Suzuki et al., 2013). Cell lines with high 
levels of GATA2 show a decrease in proliferation and a shift towards a megakaryocyte lineage, 
including an increase in ploidy (Ikonomi et al., 2000). GATA2 overexpression along with GATA1 
mutations are associated with paediatric Down’s syndrome acute megakaryoblastic leukaemia (DS-
AMKL) (Huang and Crispino, 2015). It also controls cell cycle progression in GATA1 deficient cells, while 
overexpression enhances megakaryocyte development (Huang et al., 2009). 
NFE2 is a heterodimeric transcription factor containing haematopoietic specific p45 subunit and a 
smaller Maf protein (Andrews et al., 1993). p45 knockout mice do not develop platelets and die from 
haemorrhage, although there is still megakaryocyte proliferation in response to TPO (Shivdasani et al., 
1995). The p45 subunit of NFE2 is under direct transcriptional control of GATA1, platelets deficient in 
GATA1 have lower expression levels of p45 NFE2 (Vyas et al., 1999).  
PU.1 is a haematopoietic transcription factor involved in terminal myeloid cell maturation, B-cell, and 
T-cell development (Kastner and Chan, 2008). It is also expressed in early erythroid progenitor cells 
and is downregulated during terminal differentiation (Back et al., 2004). GATA1 directly interacts with 
the PU.1 protein and the two antagonise each other’s functions (Nerlov et al., 2000, Zhang et al., 2000). 
Platelet factor 4 (PF4) is a CXC family chemokine expressed by megakaryocytes and released during 
platelet aggregation (Xia and Kao, 2003). It has a high affinity for, and forms an inactivating complex 
with, heparin (Denton et al., 1983). GATA1 has been shown to interact with the promoter region of 
PF4 (Minami et al., 1998). Disruption of the GATA binding motif on the PF4 promoter reduces 
transcriptional activity of a reporter gene while overexpression of GATA1 enhances it (Minami et al., 
1998). 
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PSTPIP2 is a target gene for GATA1 and is upregulated in GATA1-mutated or low GATA1 expressing 
megakaryocytes (Liu et al., 2014). During TPA-induced megakaryopoiesis in K562 cells, PSTPIP2 is 
upregulated with a concomitant fall in the expression of GATA1 (Liu et al., 2012). 
The glycoprotein IX (GPIX) protein is found on the surface of platelets (Li and Emsley, 2013). Its 
expression is associated with late stage megakaryopoiesis (Tijssen and Ghevaert, 2013). FLI1 in synergy 
with GATA1 binds to promoter sequences upstream from the GPIX gene and enhances expression 
(Eisbacher et al., 2003). 
4.2: Aims 
 
Following on from the experiments investigating GATA1 expression in ET patients, it was decided to 
examine GATA1, associated transcription factors and markers of differentiation involved in 
megakaryopoiesis in cell models. Anagrelide was used to probe GATA1 in cell line models, as it has 
previously been reported to affect the expression of GATA1 and other haematopoietic genes 
(Ahluwalia et al., 2010). These experiments in cell lines, including AML transformed ET models, will 
provide further understanding how dysregulated GATA1 signalling can contribute to disease 
pathogenesis in ET. GATA1 regulation by anagrelide will also be studied to determine whether it is 
directly responsible for its anti-platelet activity in-vivo. 
4.3: Methods 
 
Methods are described in brief here, for full methodology refer to Chapter 2. 
MTS Assays: Cells (K562, HL-60, HEL, SET2 and UKE1) were incubated for 72 hours in the presence of 
inhibitors and vehicle control (DMSO). After incubation, 20 µL of MTS (Promega, Madison, USA) with 
PMS (Sigma-Aldrich, Poole, UK) (50:1) solution was added to 100 µL of cells in culture media. Cells 
were incubated for 2 – 4 hours and absorbance at 490 nm was measured. Control wells were treated 
with 10% Triton-X100 (Sigma) 20 minutes prior to addition of PMS for complete cell death. 
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Trypan blue exclusion assay: Cells were cultured in the presence of anagrelide for 96 hours. Samples 
were taken at each 24-hour timepoint and mixed with 0.4% trypan blue (Sigma-Aldrich, Poole, UK). 
Cell counts (live and dead) were taken with an inverted microscope and haemocytometer. 
Cell cycle analysis: Cell lines (K562 and HEL) were serum-starved overnight prior to treatment with 
anagrelide. After 48 hours of treatment, cells were collected by centrifugation and washed with ice-
cold PBS. Cell fixation and propidium iodide staining were performed as per published protocols 
(Darzynkiewicz and Juan, 2001). Cell fluorescence was measured on a FACSVerse (BD Biosciences) and 
analysis carried out using FlowJo VX software (Treestar Inc). 
Transcriptome analysis (in-vitro cell line models): Cell lines (K562 and HEL) were treated with 
anagrelide (± 1 µM). After 48 hours, RNA was isolated (Qiagen, Hilden, Germany) and cDNA was 
synthesised (Bio-Rad, Hercules, USA). Relative quantification of key haematopoietic genes was 
determined on a StepOne Plus real time PCR instrument (Applied Biosystems) using Sybr Green I 
mastermix (Bio-Rad, Hercules, USA). 
Phorbol 12-myristate 13-acetate (PMA) induced cell differentiation: K562 and HEL cells were treated 
with 1 x 10-8 M PMA to induce megakaryopoietic differentiation. After 48 hours, cell morphology was 
examined under an inverted microscope. Cells were gently dislodged from the culture plate surface 
by pipetting and light scraping. Collected cells were spun down and transcriptome analysis carried out 
as described previously. 
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4.4: Results 
 
4.4.1: Cellular proliferation in the HEL cell line is significantly reduced by anagrelide 
treatment  
 
Five cell lines (SET2, UKE1, HEL, K562, and HL-60) were exposed to increasing concentrations of the 
anti-platelet drug, anagrelide, over 72 hours. The erythroleukaemic cell line, HEL, showed significant 
reduction in proliferation at 0.01 µM (p < 0.05) and a 50% reduction compared to DMSO control at 
100 µM (Figure 25). HEL was the only JAK2V617F cell line to respond to anagrelide treatment. Neither 
SET2 (Figure 26) nor UKE1 (Figure 27) showed any significant change (p > 0.05) in proliferation to 
anagrelide. Therefore, IC50 values for this drug were unable to be calculated for both these cell lines. 
Both JAK2WT cell lines, K562 (Figure 28) and HL60 (Figure 29), did not respond to treatment. No 
significant difference (K562: p > 0.05; HEL: p > 0.05) in proliferation was observed at the highest 
concentration tested. As previous with SET2 and UKE1, IC50 values were not determined. 
The presence of a JAK2 mutation, also seen in SET2 and UKE1, does not appear to be responsible for 
the sensitivity of the HEL cell line to anagrelide. Also, loss of heterogeneity (LOH) of JAK2 in the HEL 
cell line is unlikely to have any effect on sensitivity to anagrelide since UKE1 is also homozygous for 
the JAK2V617F mutation. 
Anagrelide does not appear to have any anti-proliferative activity in the SET2, UKE1, K562, or HL60 cell 
lines and its effects on HEL are likely to be unique to this cell line and unrelated to aberrant JAK2 
signalling. 
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Figure 25: Cellular proliferation assay for anagrelide in the HEL cell line with JAK2V617F mutation. IC50 
= 100 µM. Significance (α = 0.05) between highest and lowest concentrations calculated using t-test 
(p < 0.05). Experiment carried out at three independent times (n = 3 ± SD). 
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Figure 26: Cellular proliferation assay for anagrelide in the SET2 cell line with JAK2V617F mutation. Cell 
viability, measured by MTS reduction, was not affected by anagrelide treatment. No significant 
difference (α = 0.05) at highest concentration (t-test; p > 0.05). Experiment carried out at three 
independent times (n = 3 ± SD). 
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Figure 27: Cellular proliferation assay for anagrelide in the UKE1 cell line with JAK2V617F mutation. 
Cell viability, measured by MTS reduction, was not affected by anagrelide treatment. No significant 
difference (α = 0.05) at highest concentration (t-test; p > 0.05). Experiment carried out at three 
independent times (n = 3 ± SD). 
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Figure 28: Cellular proliferation assay for anagrelide in the JAKWT cell line, K562. Cell viability, 
measured by MTS reduction, was not affected by anagrelide treatment. No significant difference (α 
= 0.05) at highest concentration (t-test; p > 0.05). Experiment carried out in triplicate (n = 3 ± SD). 
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Figure 29: Cellular proliferation assay for anagrelide in the JAKWT cell line, HL60. Cell viability, 
measured by MTS reduction, was not affected by anagrelide treatment. No significant difference (α 
= 0.05) at highest concentration (t-test; p > 0.05). Experiment carried out in triplicate (n = 3 ± SD). 
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4.4.2: Anagrelide treatment results in an increase in cells in the G0/G1 phase of the cell 
cycle 
 
Following on from the cell proliferation experiments, two cell lines (K562 and HEL) were selected for 
cell cycle analysis, using propidium iodide staining. After treatment for 48 hours with 1 µM anagrelide, 
followed by fixation in ethanol, no significant change was observed between fractions of K562 cells in 
each phase of the cell cycle (Figure 30 and Figure 31). T-test results: G0/G1: p = 0.1539; S: p = 0.6032; 
G2/M: p = 0.1464 (Figure 30).  
HEL cells, which responded to anagrelide in cell proliferation assays (Figure 24), showed a significant 
increase (Figure 32 and Figure 33) in the proportion of cells in G0/G1 phase (t-test; p = 0.0224) (Figure 
32). This was followed by decreases in the proportion of cells in both S (p = 0.0096) and G2/M phases 
(p = 0.0037) (Figure 33). Further work using the trypan blue exclusion assay resulted in a reduction in 
cell growth over 96 hours (> 4-fold) and a significant decrease in cell viability for cells treated with 
anagrelide compared to control (Figure 34). At 72 hours, cells treated with 0.3 µM anagrelide had cell 
viability of 56% versus 92% in the DMSO vehicle control group (Figure 34).  
The anti-proliferative effect of anagrelide appears to be specific to the HEL cell line and involves a 
block in cell cycle progression from G1 to S phase. This also results in cytotoxicity, only observed in 
the HEL cell line. It is not yet known whether this mechanism plays any role in the anti-
megakaryopoietic activity the drug has in MPN patients. 
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Figure 30: Effect of anagrelide on cell cycle in K562 cells. Representative experiment shown in the figure (FlowJo Software), experiment was carried out in 
triplicate. No difference was observed in the proportion of K562 cells in each stage of the cell cycle ± anagrelide. 
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Figure 31: Cell cycle analysis of K562 cells treated with 1 µM anagrelide for 48 hours. Bars show 
average percentage cells in each phase of the cell cycle with standard deviation (n = 3 ± SD). 
Anagrelide did not have any significant effect (t-test; p > 0.05) on cell cycle phases in the K562 cell 
line.
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Figure 32: Effect of anagrelide on cell cycle in HEL cells. Representative experiment shown in the figure (FlowJo Software), experiment was carried out in 
triplicate. There was a decrease in cells in S and G2M phase for HEL cells treated with anagrelide compared to control.
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Figure 33: Cell cycle analysis of HEL cells treated with 1 µM anagrelide for 48 hours. Bars show 
average percentage cells in each phase of the cell cycle with standard deviation (n =3 ± SD). In HEL 
treated cells, a significant increase (α = 0.05) was observed in number of cells in G0/G1 phase (t-test; 
p < 0.05) on anagrelide treatment. Conversely significant decreases were measured in cell numbers 
entering S (t-test; p < 0.05) and G2/M (t-test; p < 0.05) phases.  
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Figure 34: Cell viability calculated using trypan blue exclusion assay. Total (live and dead) cell counts 
taken at each 24-hour time point (n = 3 ± SD). Percentage of live cells per total cell number 
determined. There was a significant (α = 0.05) decrease in viability for cells treated with 1 µM 
anagrelide after 72 hours (t-test; p < 0.05). 
  
24 48 72 96
40
60
80
100
Cell viability for HEL cells treated with anagrelide
Time (hrs)
%
 v
ia
b
le
 c
e
ll
s
Control
0.3 µM
1 µM
***
***
111 
 
4.4.3: Anagrelide has no effect on the expression of key haematopoietic genes in cell 
models 
 
Key haematopoietic gene expression and response to anagrelide was examined in three cell lines, two 
JAK2V617F cell lines, HEL and SET2, and a control JAK2WT cell line, K562. 
HEL previously showed proliferation and cell cycle responses when exposed to 1 µM of anagrelide 
(Figure 24, Figure 31 and Figure 32). Real time PCR studies with this cell line failed to show any 
significant changes (t-test; p > 0.05) to gene expression in any of the following genes, GATA1, GATA2, 
FOG1, NFE2 and PU.1 (Figure 35). The other two cell lines tested, SET2 (Figure 36) and K562 (Figure 
37), also did not show any significant up or down regulation of these genes (p > 0.05). 
These results suggest that the factors that inhibit proliferation and induce cell death in HEL are not 
caused by direct GATA1 or haematopoietic gene regulation by anagrelide. It may also indicate that 
any activity of anagrelide on GATA1 may be restricted to certain differentiation specific events. 
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Figure 35: Relative fold change of key haematopoietic genes in the homozygous JAK2V617F cell line, 
HEL, treated with 1 µM anagrelide (72 hours) (n = 3 ± SD). Expression is relative to the housekeeping 
gene, GAPDH, and a vehicle control sample (DMSO). No significant change in expression observed 
for any gene tested (t-test; p > 0.05).
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Figure 36: Relative fold change of key haematopoietic genes in the heterozygous JAK2V617F cell line, 
SET2, treated with 1 µM anagrelide (72 hours) (n = 3 ± SD). Expression is relative to the 
housekeeping gene, GAPDH, and a vehicle control sample (DMSO). No significant change in 
expression observed for any gene tested (t-test; p > 0.05).
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Figure 37: Relative fold change of key haematopoietic genes in the JAKWT cell line, K562, treated with 
1 µM anagrelide (72 hours) (n = 3 ± SD). Expression is relative to the housekeeping gene, GAPDH, 
and a vehicle control sample (DMSO). No significant change in expression observed for any gene 
tested (t-test; p > 0.05). 
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4.4.4: Anagrelide has no effect on Phorbol 12-myristate 13-acetate (PMA) induced 
differentiation 
 
To investigate whether anagrelide may have an effect during induced differentiation, the suspension 
cell lines K562 and HEL were treated with 1 x 10-8 M PMA ± 1 µM anagrelide. PMA arrested cell growth 
and resulted in changes to cell morphology and adhesion to the culture plate surface. These were 
observed under 10X magnification on an inverted microscope. After 48 hours, no difference in cell 
adhesion to the plate surface was observed between PMA and PMA + ANA in either cell line (Figure 
38). The anti-proliferative effect of anagrelide on HEL cells, as demonstrated in Figure 25 and Figure 
34 was not observed whilst cells were induced to differentiate. Anagrelide, at the concentration tested, 
does not appear to reduce megakaryocytic differentiation induced by PMA. 
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Figure 38: Effect of anagrelide on morphology changes induced by PMA treatment. Cells (K562, HEL 
and SET2) induced to differentiate in the presence of PMA (1 x 10-8M) ± anagrelide (1 µM). 
Differentiation is noted by change in morphology and adherence to surface of culture dish.  DMSO 
used as vehicle control for PMA and anagrelide. 
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4.4.5: Anagrelide reduced gene expression of the megakaryocyte markers PF4 and 
PSTPIP2 during PMA induced differentiation 
 
GPIX, PF4 and PSTPIP2 were selected as markers for differentiation induced by PMA treatment. 
Expression of PSTPIP2 and GPIX are under direct transcriptional control by GATA1 with GPIX 
modulated by the interaction of GATA1 and its co-factor, FOG1.  
No change (p > 0.05) was observed in GATA1 expression between control (undifferentiated) cells and 
those exposed to PMA (Figure 39). Concomitant treatment with anagrelide and PMA compared to 
vehicle control (DMSO) and PMA also showed no significant change (p > 0.05) in GATA1 levels (Figure 
40). PMA treatment resulted in a 2.5-fold increase in the relative level of GPIX (p < 0.05) during induced 
differentiation (Figure 41), although on exposure to anagrelide over the 48 hours there was no 
significant change (p > 0.05) in expression (Figure 42). There was a greater than 80-fold increase (p < 
0.05) in the expression of the megakaryocytic specific gene, PF4, when cells were exposed to PMA 
(Figure 43). This increase was reduced by over 25% (p < 0.05) when treated simultaneously with 
anagrelide (Figure 44). There was a slight increase in PSTPIP2 in PMA-induced cells, although this was 
not significant (p > 0.05) (Figure 45). Similar to PF4, there was a significant (p < 0.05) 25% decrease in 
expression when cells were treated concomitantly with anagrelide (Figure 46). 
Induced differentiation of HEL cells by PMA does not alter the expression of GATA1, although the 
levels of the three GATA1 target genes are elevated, significantly in the case of GPIX and PF4. It must 
also be noted that while GATA1 expression during differentiation was unchanged when exposed to 
anagrelide, both PF4 and PSTPIP2 decreased. The downregulation of these genes in response to 
anagrelide may be due either to post-translational modifications to GATA1 or GATA1-independent 
mechanisms. As GPIX is unaffected by anagrelide, this may indicate that GATA1-independent 
mechanisms are likely to be responsible for the activity of anagrelide in this cell line.  
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Figure 39: HEL cells treated with PMA to induce differentiation. No 
difference in gene expression was observed for GATA1 (t-test; p > 0.05). 
Experiment carried out three independent times (n = 3 ± SD). 
Figure 40: HEL cells treated with PMA to induce differentiation in the 
presence of anagrelide or control (DMSO). No difference in gene 
expression was observed for GATA1 (t-test; p > 0.05). Experiment carried 
out three independent times (n = 3 ± SD). 
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Figure 41: HEL cells treated with PMA to induce differentiation. A 
significant upregulation in gene expression was observed for GPIX (t-test; 
p < 0.05). Experiment carried out in triplicate (n = 3 ± SD). 
Figure 42: HEL cells treated with PMA to induce differentiation in the 
presence of anagrelide or control (DMSO). No difference in gene 
expression was observed for GPIX (t-test; p > 0.05). Experiment carried 
out on three independent time points (n = 3 ± SD). 
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Figure 43: HEL cells treated with PMA to induce differentiation. A 
significant upregulation in gene expression was observed for PF4 (t-test; p 
< 0.05). Experiment carried out three independent times (n = 3 ± SD). 
Figure 44: HEL cells treated with PMA to induce differentiation in the 
presence of anagrelide or control (DMSO). PF4 expression was 
significantly downregulated when treated with anagrelide (t-test; p < 
0.05). Experiment carried out three times (n = 3 ± SD). 
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Figure 45: HEL cells treated with PMA to induce differentiation. No 
difference in gene expression was observed for PSTPIP2 (t-test; p > 0.05). 
Experiment carried out three times (n = 3 ± SD). 
Figure 46: HEL cells treated with PMA to induce differentiation in the 
presence of anagrelide or control (DMSO). PSTPIP2 expression was 
significantly downregulated when treated with anagrelide (t-test; p < 
0.05). Experiment carried out three times (n = 3 ± SD).
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4.5: Discussion 
 
Cell proliferation in K562, HL60, SET2 and UKE1 cell lines (Figure 26 - Figure 29) as measured by the 
MTS assay was unchanged by anagrelide treatment. This was expected, since the drug is not believed 
to be cytotoxic, unlike other therapies (e.g. hydroxyurea) used to control platelet counts in ET patients 
(Hong and Erusalimsky, 2002). Interestingly, the HEL cell line did respond significantly (Figure 25) to 
anagrelide with an IC50 of 100 µM. It is notable that a drug whose main mode of effect is in halting 
differentiation (Hong et al., 2006) should also prevent proliferation at high concentrations. 
Unfortunately, it was not possible to determine the concentration at which total inhibition of 
proliferation occurred, as the stock dilution and DMSO toxicity prevented concentrations greater than 
100 µM. 
Reductions in proliferation in HEL were confirmed using trypan blue exclusion assays, viability was also 
reduced. This suggests that anagrelide does have a cytotoxic effect, at least in the HEL cell line. 
Following on from cell proliferation experiments, propidium iodide staining was used to determine 
the stage of the cell cycle at which anagrelide inhibited proliferation in HEL. Cell cycle studies showed 
that anagrelide resulted in a G0/G1 block in the HEL cells affected, with corresponding decreases in 
cells in S and G2/M stages. No changes were observed in K562. Megakaryocyte development is 
characterised by endomitosis, a change in the normal process of mitosis (Wen et al., 2011). This is 
where DNA is repeatedly duplicated but cytoplasmic duplication does not occur, leading to an increase 
in cell ploidy. Cell cycle kinetics are altered with a shorter G1 phase, normal S phase, short G2 phase 
and a truncated mitotic phase (Wen et al., 2011). Therefore, regulation of key cell cycle checkpoints 
is critical for normal megakaryopoiesis. Anagrelide is known to reduce both diameter and ploidy of 
megakaryocytes (Espasandin et al., 2015), suggesting a possible role in regulating cell cycle genes 
involved in endomitosis. Upregulation of Cyclin E, critical for progression through G1 phase, in 
transgenic animals results in polyploidisation (Eliades et al., 2010), and knockout results in defective 
megakaryocyte endoreplication (Geng et al., 2003). Another cyclin protein family member, cyclin D1, 
123 
 
is responsible for G1/S transition (Sun et al., 2001). Overexpression of cyclin D1 leads to increased 
polyploidisation (Sun et al., 2001). In addition, cyclin D1 has been demonstrated to be a direct GATA1 
target in megakaryocytes but not erythroid cells (Muntean et al., 2007). The role of anagrelide in 
inhibiting cyclic AMP phosphodiesterase 3 (cAMP PDE3) may also be a factor. Inhibition of 
megakaryopoiesis by cAMP has been shown to be controlled by downregulation of E2A and its target 
CDKN1A/p21, which is negatively regulated by anagrelide (Rubinstein et al., 2012). Research using 
other PDE3 inhibitors does not show any changes in megakaryocyte maturation in-vitro (Espasandin 
et al., 2015). 
These results suggest that anagrelide does have an effect on cell cycle progression, although it is 
uncertain as to whether these mechanisms are responsible for its anti-platelet activity or the reasons 
why it is only observed with the HEL cell line.  
It is noted that the concentration used in cell cycle experiments (1 µM) was typically greater than the 
plasma concentration of the drug in patients. This is approximately 5-50 ng/mL (Mazur et al., 1992), 
or 20-200 nM. There was significant reduction in proliferation from 10 nM (Figure 25) and viability at 
100 nM (Figure 34), which are within or lower than the therapeutic dose range.  
No changes in gene expression, including GATA1, were observed when K562, HEL or SET2 were treated 
with anagrelide. Anagrelide has previously been demonstrated to affect the expression of several 
genes, including GATA1, FOG, FLI1 and NFE2, during TPO-induced megakaryopoiesis in cultured UT-
7/mpl or primary haematopoietic cell lines (Ahluwalia et al., 2010), but has no reported impact on 
JAK2 phosphorylation status. This was a key rationale behind using this drug to probe changes in 
GATA1 and its role in essential thrombocythaemia. It is unknown whether the mechanism for the 
inhibition for proliferation in HEL cells is the same as that observed in megakaryocyte differentiation. 
The antiproliferative activity of anagrelide on this cell line is therefore not directly linked to 
modulation of GATA1 expression. 
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To investigate whether GATA1 expression was altered by anagrelide during megakaryopoiesis, the 
phorbol ester, PMA, is a protein kinase C activator and induces p21 expression in a p53 independent 
manner (Park et al., 2001). Elevated levels of cyclic AMP induced by anagrelide inhibits 
megakaryopoiesis by targeting E2A-p21 transcriptional axis (Rubinstein et al., 2015). PMA was used to 
induce megakaryocytic changes in the HEL cell line. When exposed to PMA with and without 
anagrelide, there was no difference in proliferation or cell adhesion to the plate surface (Figure 38). 
Experiments using CD34+ haematopoietic cells induced to differentiate with TPO in the presence of 
anagrelide have shown reduction in megakaryocyte numbers but not in mononuclear cells (McCarty 
et al., 2006). 
Inducing differentiation using PMA did not result in any change in the expression levels of GATA1 and 
this was unaltered when anagrelide was used concomitantly. The previously mentioned study by 
(Ahluwalia et al., 2010) showed GATA1 increasing when primary haematopoietic cells were cultured 
under megakaryocytic differentiation conditions, this was reduced when treated with anagrelide. This 
is likely to be a result of key differences in the experimental setup of both studies. The results 
presented here used PMA to induce differentiation in transformed immortalised HEL cells as opposed 
to TPO in primary haematopoietic cells. GATA1 has multifunctional roles during haematopoiesis and 
its expression levels are linked to each particular stage of differentiation (Ferreira et al., 2005). 
The presence of anagrelide (Figure 27) resulted in reduced expression of two megakaryocytic genes, 
PF4 and PSTPIP2 but not in GATA1 or the megakaryocytic specific GPIX. The decrease in PF4 is 
noteworthy since it acts as a negative regulator of megakaryopoiesis in both in-vitro and in-vivo 
models (Lambert et al., 2007) but has also been shown to induce megakaryopoiesis and platelet 
accumulation in lung-tumour bearing mice (Pucci et al., 2016). In ET patients, levels of PF4 released 
from platelets are higher than controls and treatment with anagrelide resulted in a significant 
reduction which was not observed with either HU or IFN-α (Cacciola et al., 2004). Recently, gene 
expression analysis on CD34+ cord blood derived cells showed that anagrelide was responsible for 
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downregulating genes associated with megakaryocyte proteins but had no effect on GATA1 (Sakurai 
et al., 2016), reflecting the results found here. 
The clinical efficacy of anagrelide in reducing platelet counts in patients with ET is known, but the full 
molecular mechanism is not well-understood. These results, in a cell line responsive to anagrelide, 
indicate that GATA1, which is overexpressed in ET, is not a direct target of anagrelide activity. 
Downstream targets of GATA1 involved in megakaryopoiesis are affected by anagrelide during PMA-
induced megakaryocytic differentiation indicating that direct transcriptional control of GATA1 is 
unlikely to be responsible but GATA1-independent mechanisms or post-translational modifications 
may play a role in the disease. This may also be a potential mechanism for the activity of anagrelide in 
ET patients and a possible target for novel therapies.
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CHAPTER 5: 
Molecular 
mechanisms of JAK2 
dysregulation
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5.1: Introduction 
 
Mutations in the non-receptor tyrosine kinase, JAK2, have been identified in over 95% of PV and 
between 50-60% of ET and MF cases (O'Sullivan and Harrison, 2017). Constitutive activation of the 
JAK/STAT pathway is a hallmark of myeloproliferative neoplasms, yet it is not fully understood how 
JAK/STAT pathway dysregulation gives rise to phenotypically different disorders in PV, ET, and MF, or 
the factors which determine disease progression and leukaemic transformation.  
Ruxolitinib is a JAK1/JAK2 inhibitor which prevents activation of JAK/STAT signalling by blocking the 
ATP binding site on the kinase domain of JAK2 (Ostojic et al., 2011). It is not specific for the JAK2V617F 
mutated form and has activity against JAK2WT (Vandenberghe, 2012). Clinical trials have demonstrated 
its efficacy in reducing some of the symptoms associated with MPNs, including splenomegaly, as well 
as an improvement in overall survival (Verstovsek et al., 2012a). 
While gene expression analysis is an invaluable tool in studying the effects of JAK/STAT pathway 
dysregulation, mRNA levels do not always accurately correlate with expressed protein levels 
(Greenbaum et al., 2003). Post-translational modifications can dynamically alter the function, activity, 
and half-life of proteins in a manner that is not reflected in transcriptional analysis. These 
modifications may involve the addition of a chemical group and are reversible, e.g., 
acetylation/deacetylation and phosphorylation, or are irreversible, e.g., proteolysis. A global 
quantitative proteomic analysis coupled with investigation of key post-translational modifications is 
therefore a complementary method of studying JAK/STAT signalling dysregulation. 
5.2: Aims 
 
The following experiments will aim to characterise the effect of JAK2 inhibition (using ruxolitinib) on 
MPN patient derived cells. Model JAK2V617F and JAK2WT cell lines will also be used to study the impact 
on cell proliferation, STAT phosphorylation and signalling, and changes to the global proteome. 
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5.3: Methods 
 
Methods are described in brief here. For full descriptions refer to Chapter 2.  
Experiments using model JAK2V617F and JAK2WT cell lines: 
MTS Assays: Cells (K562, HL-60, HEL, SET2 and UKE1) were incubated for 72 hours in the presence of 
inhibitor or vehicle control (DMSO). After incubation, 20 µL of MTS (Promega) with PMS (Sigma) (50:1) 
solution was added to 100 µL of cells in culture media. Cells were incubated for 2 – 4 hours and 
absorbance at 490 nm was measured. Control wells were treated with 10% Triton-X100 (Sigma) 20 
minutes prior to addition of PMS for complete cell death. 
Cell Cycle Analysis: Cell lines (K562 and HEL) were serum-starved overnight prior to treatment with 
ruxolitinib (Selleckchem). After 48 hours of treatment, cells were collected by centrifugation and 
washed with ice-cold PBS. Cell fixation and propidium iodide staining were performed as per published 
protocols (Darzynkiewicz and Juan, 2001). Cell fluorescence was measured on a FACSVerse (BD 
Biosciences) and analysis carried out using FlowJo VX software (Treestar Inc). 
Western Blotting: Cell culture and drug treatment was performed as previously described in Chapter 
2. Total protein (10 mg/µL) was obtained from cells lysed in mRIPA buffer and run on a 10% SDS-PAGE 
gel. Proteins were transferred to a nitrocellulose membrane and probed with primary antibodies for 
pSTAT1, pSTAT3, pSTAT5, STAT1, STAT3, STAT5 and GAPDH. Secondary antibodies (anti-rabbit IgG) 
with a HRP conjugate were used for detection with a chemiluminescent reagent (Thermo ECL). 
Experiments using cells from donor patients: 
Colony-Forming-Cell (CFC) Assays: Peripheral blood mononuclear cells from donors were isolated 
using MethoCult media containing 0.1 µM EPO according to the Stemcell protocol for CFC assays 
(Stemcell Technologies). Cells were plated (2 x 105 cells per dish). Plates were examined after 10 days 
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and enumerated after 14 days in culture. Individual BFU-E colonies were trypsinised and taken from 
the plates, washed two times with PBS and the cell pellet stored at -80ºC. 
Experiments using model cell lines and patient samples: 
Quantitative Proteomics:  8-plex iTRAQ labelling was used to identify differentially expressed proteins 
in ruxolitinib treated HEL and SET2 cell lines, as well as cells from MPN patients treated o/n with 
ruxolitinib. Digested and labelled peptides were separated using a NanoLC with electrospray ionisation 
coupled to a Triple TOF 6600 mass spectrometer. The instrument was operated in data dependent 
mode. Peptides with multiple charges (2+ to 4+) with a charge to weight ratio (m/z) between 400 and 
1600 were selected for MS/MS. Output files were processed using Protein Pilot software (version 
5.0.1). Data analysis was carried out using Microsoft Excel, Cytoscape v3.5.0 with ClueGO plugin and 
GraphPad Prism v 6.0. 
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5.4: Results 
 
5.4.1: Ruxolitinib selectively inhibits the growth of JAK2V617F mutated cell lines 
 
Cell lines exposed to increasing concentrations of the tyrosine kinase inhibitor, ruxolitinib, showed 
different growth responses depending on whether the JAK2V617F mutation was present. All JAK2V617F 
cell lines (Figure 47 - Figure 49) demonstrated reduced proliferation after 72 hours exposure to the 
drug. In contrast, there was no effect on JAK2WT cell lines (Figure 50 and Figure 51), indicating that the 
increased JAK2 activity in the mutant cell lines was responsible for their sensitivity to JAK inhibition by 
ruxolitinib. IC50 values in the JAK2V617F expressing cell lines do not appear to be directly related to loss 
of heterogeneity. SET2, which expresses both mutant and wild-type JAK2, had a similar IC50 (132 nM) 
to the homozygous UKE1 cell line (109 nM), whereas HEL was 565 nM. Both SET2 and UKE1 cell lines 
were derived from patients with a previous history of ET, but HEL cell line had no recorded MPN or 
MDS prior to AML (Martin and Papayannopoulou, 1982, Quentmeier et al., 2006). It is not known 
whether this may influence sensitivity to JAK/STAT targeting by ruxolitinib. 
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Figure 47: Cellular proliferation assay in the JAK2V617F cell line, HEL + ruxolitinib. Viability, measured 
by MTS reduction, was reduced in response to increasing concentrations of ruxolitinib. IC50 value 
determined using GraphPad Prism software: 565 nM (n = 3 ± SD). 
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Figure 48: Cellular proliferation assay in the JAK2V617F cell line, SET2 + ruxolitinib. Viability, measured 
by MTS reduction, was reduced in response to increasing concentrations of ruxolitinib. IC50 value 
determined using GraphPad Prism software: 132 nM (n = 3 ± SD). 
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Figure 49: Cellular proliferation assay in the JAK2V617F cell line, UKE1 + ruxolitinib. Viability, measured 
by MTS reduction, was reduced in response to increasing concentrations of ruxolitinib. IC50 value 
determined using GraphPad Prism software: 109 nM (n = 3 ± SD).  
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Figure 50: Cellular proliferation assay in the JAK2WT cell line, K562 + ruxolitinib. Cell viability, 
measured by MTS reduction, was not affected by ruxolitinib treatment. There was no significant 
difference (t-test; p > 0.05) in proliferation at highest tested concentration (10,000 nM) (n = 3 ± SD). 
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Figure 51: Cellular proliferation assay in the JAK2WT cell line, HL60 + ruxolitinib. Cell viability, 
measured by MTS reduction in HL60, was not affected by ruxolitinib treatment. No IC50 
concentration determined. There was no significant difference (t-test; p > 0.05) in proliferation at 
highest tested concentration (10,000 nM) (n = 3 ± SD). 
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5.4.2: G0/G1 increase in HEL cells treated with ruxolitinib 
 
The proportion of K562 and HEL cells in each stage of the cycle stage was measured in response to 
ruxolitinib treatment (1 µM) over 72 hours. No differences were observed between the vehicle control 
and 1 µM RUX-treated K562 cells (Figure 52 and Figure 53). Chi-square test results: χ2 = 3.656, df = 3, 
p > 0.05.   
There was an increase in cells in the sub G0 (t-test; p < 0.05) and G0/G1 (t-test; p < 0.05) phases after 
HEL cell were treated with ruxolitinib, as well as a corresponding decrease in S (t-test; p < 0.05) and 
G2/M (t-test; p < 0.05) (Figure 54 and Figure 55). Chi-square test results: χ2 = 420.1, df = 3, p < 0.05.   
These results reflect the findings from the previous MTS experiments showing cells carrying a JAK2V617F 
mutation (Figure 47 - Figure 49) were more sensitive to JAK/STAT inhibition than those with wild type 
JAK2 (Figure 50 and Figure 51). The mechanism for inhibited proliferation by ruxolitinib in JAK2 
mutated cells is associated with a G0/G1 block by ruxolitinib. This is consistent with its inhibition of 
JAK/STAT signalling and its impact on the cell cycle. 
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Figure 52: Effect of ruxolitinib on cell cycle in K562 cells. Representative experiment shown in the figure (FlowJo Software), experiment was carried out in 
triplicate. No difference was observed in the proportion of K562 cells in each stage of the cell cycle ± ruxolitinib. 
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Figure 53: Cell cycle analysis of K562 cells treated with ruxolitinib for 48 hours. Bars show average 
percentage cells in each phase of the cell cycle with standard deviation (n = 3 ± SD). Ruxolitinib did 
not have any significant effect (t-test; p > 0.05) on cell cycle phases in the K562 cell line.
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Figure 54: Effect of ruxolitinib on cell cycle in HEL cells. Representative experiment shown in the figure (FlowJo Software), experiment was carried out in 
triplicate. An increase in the proportion of cells in G0/G1 was observed in response to ruxolitinib treatment, along with a corresponding decrease in the 
number of cells in S and G2/M phases. 
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Figure 55: Cell cycle analysis of HEL cells treated with ruxolitinib for 48 hours. Bars show average 
percentage cells in each phase of the cell cycle with standard deviation (n = 3 ± SD). In HEL treated 
cells, a significant increase (p < 0.05) was observed in number of cells in Sub G0 phase (t-test; p < 
0.05) and G0/G1 phase (t-test; p < 0.05) on ruxolitinib treatment. Conversely significant decreases 
were measured in cell numbers entering S (t-test; p < 0.05) and G2/M (t-test; p < 0.05) phases. 
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5.4.3: Ruxolitinib reduces phosphorylation of STAT3 and STAT5 in JAK2V617F cell lines 
and increases phosphorylation of JAK2 
 
Constitutive activation of the JAK-STAT pathway is a characteristic feature of MPNs. Over-activation 
of this pathway, as indicated by STAT3 and STAT5 phosphorylation, is seen in the model MPN cell lines 
HEL and SET2 when compared to the CML cell line, K562 (Figure 56). As a result of treatment with the 
JAK2 inhibitor, ruxolitinib, a dose-dependent inhibition of downstream signalling pathways was 
indicated by a reduction in phosphorylation of STAT3 and STAT5. The greatest effect was observed 
with STAT5 phosphorylation, with 1.0 µM ruxolitinib enough to completely knockdown pSTAT5 in HEL 
and SET2. The reduction in STAT3 phosphorylation was more modest in HEL and SET2, although lower 
than observed in the JAK2WT cell line, K562. Conversely, the level of JAK2 phosphorylation was 
enhanced with increasing doses of ruxolitinib in the JAK2V617F cell lines. Phosphorylated JAK2 was 
barely detectable in the vehicle control samples for HEL and SET2, and any of the K562 samples 
(control and treated). 
Ruxolitinib indirectly affects phosphorylation levels of the key signalling proteins, STAT3 and STAT5 by 
targeting JAK2. The drug is an ATP mimetic, which competes for binding at the kinase domain of JAK2. 
This action renders JAK inaccessible for recruitment, phosphorylation and dimerisation of STAT 
proteins. These results demonstrate that ruxolitinib, despite increased catalytic activity in the kinase 
domain characterised by increased phosphorylation at Tyr1007 on JAK2, does not result in 
phosphorylation of downstream JAK/STAT signalling pathway targets. The long-term effects, such as 
resistance like that seen with other tyrosine kinase inhibitors, of constant JAK activation are not fully 
understood but other studies have suggested that it may contribute towards acquired persistence to 
drug therapy.  Ruxolitinib treatment did not affect the total protein levels of either STAT3 or STAT5. 
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Figure 56: Western blots of phosphorylated and total STAT3, STAT5, and JAK2 proteins in K562 
(JAK2WT), HEL, and SET2 (JAK2V617F) after 24 hours in response to ruxolitinib treatment. Both 
phosphorylated STAT3 and STAT5 decreased with increasing concentrations of ruxolitinib in JAK2V617F 
cell lines. Phosphorylated levels of JAK2 increased in in JAK2V617F cell lines when exposed to 
ruxolitinib. 
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5.4.4: Ruxolitinib treatment of peripheral blood mononuclear cells from patient samples 
results in a decrease in numbers of myeloid and erythroid progenitor cells 
 
All four patients had elevated levels of haemoglobin, above the WHO diagnostic threshold for PV (> 
165/160 g/L in men/women). ET samples had increased levels of circulating platelets (> 455 x 109 /L). 
Patients were not receiving any JAK inhibitor therapy, which could affect results for experiments 
where isolated PBMCs were treated with ruxolitinib. PBMCs from patients with high levels of either 
haemoglobin or platelet counts, and control patient samples, were treated with either 100 nM or 250 
nM RUX in methylcellulose culture media for 14 days. Numbers of all colony types were significantly 
lower with 100 or 250 nM ruxolitinib treatments (Figure 58 - Figure 60). Relative reduction in all colony 
types was lowest for the control sample treated with ruxolitinib, followed by ET, and then PV groups. 
In addition to reduced numbers of colonies, ruxolitinib treatment resulted in smaller BFU-E colony size 
in culture (Figure 57). Sensitivity to ruxolitinib treatment in PBMCs does not appear to be related to 
the presence of a JAK2 mutation or increased haematopoietic markers (haemoglobin or platelets) in 
PV and ET. 
 
Figure 57: Typical colony sizes (40x) observed for BFU-E in untreated (A), 100 nM RUX (B) and 250 
nM RUX (C). Colony size was markedly reduced in ruxolitinib treated cells. 
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Figure 58: Colonies counted using the Stemcell Human CFU assay. A decrease in all colony types was 
seen in ruxolitinib treated PBMCs from PV patients (n = 4 independent patient samples ± SD). 
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Figure 59: Colonies counted using the Stemcell Human CFU assay. A decrease in all colony types was 
seen in ruxolitinib treated PBMCs from ET patients (n = 4 independent patient samples ± SD). 
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Figure 60: Colonies counted using the Stemcell Human CFU assay. A decrease in all colony types was 
seen in ruxolitinib treated PBMCs from a control patient. 
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5.4.5: Ruxolitinib treatment of SET2 cells results in the differential expression of 187 
unique proteins  
 
To determine the molecular effects of ruxolitinib inhibition on JAK2 signalling, high resolution 
quantitative mass spectrometry was employed on the MPN cell model SET2. An overlay of the total 
ion chromatograms for each instrument run is shown in Figure 61 for the fractionated samples. A 
representative total ion chromatogram is shown in Figure 62. 
Relative quantification mass spectrometry was employed to identify pathways affected by ruxolitinib 
inhibition of JAK2. Its effects on 3113 proteins were quantified with high confidence and a false 
discovery rate <1%; indicating good coverage of the total cellular proteome. The labelling efficiency 
was > 98%, determined by comparing the total number of potential reactive sites (i.e., N-termini and 
lysine side chains) with the iTRAQ modification present, with two iTRAQ tags required for proteins to 
be quantified. Upon ruxolitinib treatment (1 µM), 187 total proteins were identified as being 
significantly differentially expressed, of which 26 were upregulated and 161 were downregulated (< 
0.8 versus sample treated with vehicle control for at least two labels (113, 115, or 117) with a p-value 
< 0.05) (Table 13 in Chapter 7: Appendices).
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Figure 61: Overlay of total ion chromatograms for SET2 ± 1 µM RUX replicates labelled with iTRAQ reagent. Retention time is shown on the x-axis, (0 – 120 minutes). Intensity 
of peaks is displayed on the y-axis 
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Figure 62: Representative TIC from one iTRAQ run from overlay shown in Figure 61. Time in minutes is on the x-axis (0 – 120) and % intensity is on the y-axis. 
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5.4.5.1: Functional characterisation of downregulated proteins in SET-2 upon ruxolitinib treatment.  
 
Figure 63: Pie chart of overrepresented gene ontology (GO) biological process terms for downregulated proteins (< 0.8) in SET2 cells treated with 1 µM 
ruxolitinib measured by mass spectroscopy. 
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The molecular functions, localisation and expression of individual proteins are well characterised and 
curated in databases such as Uniprot (UniProt, 2015). However, proteins rarely act alone in 
modulating cell and biological processes (De Las Rivas and Fontanillo, 2010). With the large number 
of differentially expressed proteins from iTRAQ experiments (Table 13 in Chapter 7: Appendices), it is 
necessary to examine the networks these proteins belong to as well as how they affect other processes, 
directly and indirectly. To determine how these proteins interact with each other and other molecular 
pathways, a program called STRING was utilised (Szklarczyk et al., 2015). STRING applies weighting to 
protein-protein interactions dependent on known experimental data, as well as computationally 
predicted interactions. STRING analysis was used to map protein-protein interactions from the 
differentially expressed data set (Figure 64). Minimum interaction score was set at > 0.700 for high 
confidence. A maximum of five node separation was used to calculate indirect associations. 
The analysis highlighted eight interacting proteins with functional enrichment in ribosome pathway 
(false discovery rate: 0.000195). These were connected to a group of aminoacyl-tRNA synthetase (ARS) 
proteins, IARS, QARS, and DARS. ARSs are involved in the initial stages of protein synthesis, they 
catalyse esterification reactions ligating transfer RNAs with their cognate amino acids (Park et al., 
2008). In addition to their canonical roles in transcription, these proteins have also been reported to 
control functions such as tumorigenesis, angiogenesis, and inflammation (Kim et al., 2011). 
Mammallian ARS proteins form a large multi-protein complex (along with NS1 associated protein, 
ribosomal protein L13a, and GAPDH) in monocytes exposed to interferon-γ, called the gamma-
interferon induced inhibitor of translation (GAIT) (Ribas de Pouplana and Geslain, 2008). The GAIT 
complex binds to a RNA motif in the 3’ untranslated region of target inflammatory mRNAs, thereby 
preventing translation by blocking the interaction between eukaryotic translation initiation factor 4G1 
(eIF4G) and eIF3 (Carpenter et al., 2014). 
The group of eight ribosomal proteins are also linked to guanine nucleotide-binding protein, β2-like 1 
(GNB2L1), also known as receptor for activated C kinase 1 (RACK1) (Adams et al., 2011). Originally 
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identified as a scaffolding binding protein for protein kinase C (Adams et al., 2011), it is now also 
known to interact with non-receptor tyrosine kinases, such as Src kinases (Mamidipudi et al., 2007a, 
Mamidipudi et al., 2007b, Chang et al., 2002b), as well as receptor tyrosine kinases, insulin-like growth 
receptor factor 1 (IGF-R1) (Kiely et al., 2002), and type I interferon receptor (Usacheva et al., 2001). 
RACK1 mediates STAT3 recruitment and activation through IGF-R1 and insulin receptor (Zhang et al., 
2006). RACK1 has also been found to interact with STAT1, through the type I interferon receptor 
(Usacheva et al., 2001, Kubota et al., 2002).
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Figure 64: STRING analysis of protein-protein interactions identified from SET2 cells treated with 1 µM ruxolitinib. Minimum required interaction score was 
> 0.700 (high confidence).  Proteins associated with ribosome pathway (in red) were significantly enriched.
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5.4.6: STAT1 protein levels, but not STAT3/5, decrease in response to ruxolitinib 
treatment in JAK2V617F cell lines 
 
Following on from the global proteomic analysis, where ruxolitinib was shown to affect levels of 
proteins involved in antigen processing and presentation, it was decided to examine expression of 
STAT signalling proteins. Relative protein quantification using iTRAQ labelled peptide digests of SET2 
cells treated with ruxolitinib showed that only STAT1 expression was significantly reduced (p < 0.05) 
compared to a control protein, GAPDH (Figure 65). There was a 2.5-fold reduction in STAT1 compared 
to GAPDH (Table 12). No significant (p < 0.05) change was observed for STAT3 (p = 0.6867) and STAT5A 
(p = 0.6574) (Table 12 and Figure 65). 
Table 12: Relative protein quantification for STAT proteins measured by mass spectroscopy 
Name Uniprot ID 
Unused 
protein 
score 
113 FC 115 FC 117 FC 119 FC Avg FC 
GAPDH P04406 42.26 0.8790 0.9290 1.0000 1.0965 0.9360 
STAT1 P42224 22.01 0.5346 0.4365 0.2270 0.0673 0.3994 
STAT3 P40763 11.82 1.0186 0.9120 1.4191 0.0667 1.1166 
STAT5A K7EK35 19.88 1.0000 1.0568 1.0093 0.9376 1.0220 
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Figure 65: STAT protein levels measured by iTRAQ using LC-MS/MS. Treated samples (1 µM RUX) 
labelled with 113, 115, 117, and 119 isobaric tags. Ratios between all tags compared to 121 labelled 
control sample. T-test between GAPDH (control protein) and STAT protein ratios, STAT1: p < 0.05, 
STAT3: p > 0.05, STAT5A: p > 0.05. 
 
In SET2, exposure to ruxolitinib resulted in dephoshorylation of STAT1, but also a reduction in the total 
level of STAT1 (Figure 66). This was also confirmed in the HEL cell line (Figure 67), which showed that 
as well as protein dephosphorylation in STAT1/3/5, there was a decrease in total STAT1 after 48 hours 
treatment. The reduction in both total and phosphorylated STAT1 was dose-dependent, with higher 
concentrations of ruxolitinib eliciting a greater response (Figure 66 and Figure 67). These western blot 
results reflect what was found in the mass spectroscopy analysis of STAT protein expression (Figure 
65). 
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While phosphorylated STAT1 and STAT5 levels were decreased after 15 minutes exposure to 
ruxolitinib, total protein levels were unaffected up to 6 hours post-treatment in both HEL and SET2 
cell lines (Figure 68).  
Additionally, examination of STAT1 protein levels from the PBMCs of MPN patients treated overnight 
with ruxolitinib showed some interesting results. All patients showed a decrease in overall STAT1 
protein, but this was insignificant for the two ET patients (Figure 70 and Figure 71) tested (p > 0.05). 
However, the sole PV patient (Figure 69) did have a significantly lower amount of STAT1 (p < 0.05) in 
PBMCs exposed to ruxolitinib. Further samples would be required to confirm these findings but initial 
results may suggest a link between response to ruxolitinib and JAK2V617F allele burden, which is 
typically higher in PV patients (Passamonti and Rumi, 2009). 
 
Figure 66: Protein expression in SET2 cells treated with ruxolitinib (0, 500, or 1000 nM) for 72 hours. 
Levels of phosphorylated STAT proteins decreased along with total STAT1 expression. Total STAT1 
protein was reduced after 48 hours with 500 and 1000 nM. 
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Figure 67: Protein expression in HEL cells treated with ruxolitinib (0, 500, or 1000 nM) for 72 hours. 
Levels of phosphorylated STAT proteins decreased along with total STAT1 expression. Total STAT1 
protein was reduced after 48 hours with 500 and 1000 nM, confirming the findings with SET2 in 
Figure 66. There was no decrease in the level of total STAT3 or STAT5.  
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Figure 68: Cell lines (HEL and SET2) treated with ruxolitinib for 6 hours. Decrease in phosphorylated STAT1 and STAT5 was observed for both cell lines after 
15 minutes treatment.
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Figure 69: Relative protein levels of STAT1 measured by LC-MS/MS for PBMCs extracted from a 
polycythaemia vera patient blood sample in at least four mass spectroscopy runs (t-test; p < 0.05). 
PBMCs were treated overnight with ruxolitinib before extraction for mass spectroscopy. 
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Figure 70: Relative protein levels of STAT1 measured by LC-MS/MS for PBMCs extracted from an 
essential thrombocythaemia patient blood sample in four mass spectroscopy runs. PBMCs were 
treated overnight with ruxolitinib before extraction for mass spectroscopy (t-test; p > 0.05). 
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Figure 71: Relative protein levels of STAT1 measured by LC-MS/MS for PBMCs extracted from an 
essential thrombocythaemia patient blood sample. PBMCs were treated overnight with ruxolitinib 
before extraction for mass spectroscopy. Four mass spectroscopy runs carried out (t-test; p > 0.05). 
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5.4.7: STAT1 mRNA is reduced in JAK2V617F, but not JAK2WT cell lines 
 
STAT1 total protein expression was shown to be reduced in Figure 65 - Figure 67. To determine 
whether STAT1 downregulation occurred during translation or transcription, the levels of STAT1 mRNA 
were measured in three cell lines using quantitative PCR upon RUX treatment. STAT1 was decreased 
in both HEL (0.67 x control) and SET2 (0.37 x control) cell lines, but slightly increased in the K562 cell 
line (Figure 72). The greater knockdown of STAT1 in the SET2 cell line compared to HEL, corresponds 
to its increased sensitivity to ruxolitinib treatment, shown in Figure 47 and Figure 48. Total STAT1 
protein reduction in response to ruxolitinib in these cell lines is likely to be because of inhibition of 
STAT1 transcription.  
 
Figure 72: STAT1 gene expression in K562 (JAK2WT), HEL and SET2 (JAK2V617F) treated with 1 µM 
ruxolitinib for 48 hours (n = 3 ±SD). Gene expression normalised using the housekeeping gene, 
GAPDH and a vehicle control treated sample. STAT1 levels were reduced in both JAK2V617F cell lines 
compared to samples treated with vehicle control. 
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5.4.8: SOCS3 is downregulated in SET2 cells treated with ruxolitinib 
 
Next, the expression levels of cytokine-inducible negative regulators of cytokine signalling (SOCS 
proteins) were measured. Expression of SOCS1 was increased 1.5-fold whereas there was a two-fold 
reduction in SOCS3 (Figure 73). Both these proteins reduce cytokine signalling in a classical negative 
feedback loop, where their expression is induced along with the target cytokine or downstream target 
(Krebs and Hilton, 2001). The downregulation of SOCS3 is consistent with the decrease in STAT1 
activity in response to ruxolitinib (Figure 67). The increase in SOCS1 may be as a result of paradoxical 
JAK2 phosphorylation by ruxolitinib. Differential response to type I or type II interferon signalling may 
also be responsible for the differences between SOCS1 and SOCS3 expression. 
 
Figure 73: Gene expression of inflammatory cytokines (IL-6, IL-1b) and SOCS proteins relative to 
GAPDH reference gene and vehicle control treated sample. Levels of IL-1b and its downstream 
target, IL-6, were upregulated (p < 0.05) in response to ruxolitinib treatment of SET2 cells. There was 
an increase in the level of SOCS1 and a decrease in SOCS3 expression (p < 0.05) (n = 3 ± SD). 
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5.4.9: Ruxolitinib is a more potent inhibitor of STAT1 transcription than fludarabine 
 
The effect of fludarabine, a chemotherapy drug used in the treatment of CLL and a STAT1 inhibitor at 
RNA and protein level, was examined in the SET2 cell line (Figure 74). 50% inhibition of proliferation 
in the SET2 cell line was achieved using 5.5 µM of the drug over 72 hours (Figure 74). Both ruxolitinib 
and fludarabine treatment in SET2 cells resulted in a downregulation of STAT1 (Figure 75). Ruxolitinib 
treatment in SET2 at 1 µM resulted in a two-fold reduction of STAT1. The reduction induced by 
fludarabine was more modest (0.7x control), although this was at a level equivalent to the IC50 
calculated in Figure 74. 
 
Figure 74: Cellular proliferation assay of the STAT1 inhibitor, fludarabine, on the JAK2V617F cell line 
SET2. Proliferation was reduced in response to increasing concentrations of fludarabine. IC50 value 
determined using GraphPad Prism software: 5.5 µM (n = 3 ± SD). 
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Figure 75: STAT1 mRNA expression in response to ruxolitinib or fludarabine treatment. STAT1 is 
downregulated by ruxolitinib (1 µM) and the STAT1 specific inhibitor, fludarabine (5.5 µM).
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5.5: Discussion 
 
Ruxolitinib, a JAK1/2 inhibitor, reduced proliferation on all JAK2V617F cell lines (HEL, SET2 and UKE1) 
(Figure 47 - Figure 49), but not on JAK2WT cells, K562 and HL60 (Figure 50 and Figure 51). At the 
concentrations tested, the inhibition appeared specific to cells bearing the JAK2V617F mutation, despite 
the mechanism of ruxolitinib being targeted against all JAK2 activity, regardless of mutational status. 
Other proliferation assays using WST1 reagent, have shown similar IC50 values for HEL (790 nM) and 
SET2 (160 nM) when treated with ruxolitinib (Bogani et al., 2013) as these results have shown (565 
and 132 nM respectively). As reported by Quintás-Cardama et al. (2010), cells bearing the JAK2V617F 
appear to selectively undergo apoptosis when treated with ruxolitinib, although clinically the drug is 
equally effective in patients with or without the JAK2V617F mutation. The exact cause for this is not fully 
understood and given that non-JAK2V617F patients do not display constitutive JAK/STAT activation 
(Schwemmers et al., 2007), it would appear that ruxolitinib may have direct effects downstream from 
this signalling pathway, common to both JAK2V617F and non-mutated JAK2. 
Ruxolitinib did not affect the distribution of K562 cells in each phase of the cell cycle (Figure 52 and 
Figure 53). In K562 cells, STAT5 is constitutively activated through tyrosine phosphorylation by BCL-
ABL (de Groot et al., 1999, Hantschel et al., 2012), thereby negating the effect of targeting JAK2 kinase 
activity upstream. After 48 hours, there was a significant increase (p < 0.05) in HEL cells in the G0/G1 
phase and a decrease in cells in S phase indicating that this drug may cause a G0/G1 block in the cell 
cycle (Figure 54 and Figure 55). Similar results have also been demonstrated in Ba/F3-EPOR VF cells 
containing the JAK2V617F mutation (Bogani et al., 2013). A key regulator of G1/S progression CDC25A 
has been reported to be a target for constitutive JAK2V617F activity and is overexpressed in murine and 
human cells (including HEL and SET2) bearing the JAK2V617F mutation (Gautier et al., 2012). JAK2 has 
also been shown to bind and phosphorylate p27(Kip1), a cyclin dependent kinase inhibitor (Jäkel et al., 
2011). 
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Ruxolitinib also inhibited the growth of haematopoietic progenitor cells in colony-forming unit assays 
from ET, PV, and control patients, indicating that it is effective against the mutant clone (Figure 33 -
Figure 35). This effect has also been shown in mononuclear cells from both PV and ET (JAK2V617F and 
JAK2WT) (Barrio et al., 2013), although notably this group found wild type JAK2 in ET patients was more 
sensitive to ruxolitinib treatment. The sizes of BFU-E colonies were also significantly reduced on 
ruxolitinib treatment. BFU-E development and proliferation in these colonies is as a result of IL-3 
stimulation of the JAK/STAT pathway (Callus and Mathey-Prevot, 1998, Dai et al., 1991), which is 
inhibited on ruxolitinib treatment. 
Both STAT3 and STAT5 phosphorylation was decreased in JAK2V617F cells (Figure 56 and Figure 67) 
when treated with ruxolitinib. Constitutive STAT3 and STAT5 activation is a hallmark of MPNs with 
JAK2V617F or exon 12 mutations. Levels of phosphorylation of the respective STAT proteins has been 
linked to disease phenotype (Teofili et al., 2007). High levels of both phospho-STAT3 and phospho-
STAT5 were found in bone marrow biopsies of PV patients, whereas high pSTAT3 and lower pSTAT5 
was associated with an ET phenotype (Teofili et al., 2007). Lower overall pSTAT3 and pSTAT5 was 
indicative of myelofibrosis (Teofili et al., 2007). In the cell lines tested, SET2 was isolated from a patient 
with a previous history of ET, it was observed that STAT5 phosphorylation was weaker than pSTAT3. 
Ruxolitinib treatment was also able to completely knockdown pSTAT5, but only resulted in a partial 
reduction in pSTAT3. Similar STAT3/STAT5 phosphorylation patterns were seen in the HEL cell line, 
whose MPN status is unknown. It is not known why ruxolitinib did not fully inhibit STAT3 
phosphorylation in the cell lines tested, since previous groups have shown this effect in the HEL 
(Quintás-Cardama et al., 2010) and SET2 (Meyer et al., 2015) cell lines. Insensitivity of these cells to 
type I JAK inhibitors is a possible explanation, although the IC50 value in cell-proliferation assays for 
the SET2 cells was 132 nM. This is similar to that found in naïve SET2 cells (70 nM) compared to 900 
nM in ruxolitinib persistent SET2 (Meyer et al., 2015). Both JAK2V617F cell lines (HEL and SET2) showed 
hyper-phosphorylation of JAK2 when exposed to ruxolitinib (Figure 56). Ruxolitinib is a type I JAK 
inhibitor, and it targets the active kinase confirmation of JAK2 in an ATP-competitive manner. The 
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paradoxical phosphorylation of JAK2 and dephosphorylation of downstream STAT proteins has been 
observed by other groups (Andraos et al., 2012, Meyer et al., 2015). The mechanism for this is not 
fully understood, however experiments suggest that conformational changes induced by ruxolitinib 
may result in protection of the Tyr1007/1008 sites on JAK2 from phosphatases (Gorantla et al., 2013). 
Type II JAK inhibitors, such as CHZ868, do not have this effect (Meyer et al., 2015). As with type I 
inhibitors, type II JAK inhibitors bind to the ATP-binding site but also to an induced hydrophobic pocket. 
This has the effect of stabilising JAK2 in an inactive confirmation (Meyer et al., 2015, Andraos et al., 
2012). Treatment with type II JAK inhibitors can also overcome persistence to type I inhibitors in SET2 
cells. This occurs due to reactivation of the JAK/STAT pathway through heterodimerisation between 
JAK2 and JAK1/TYK2 (Koppikar et al., 2012, Meyer et al., 2015). CHZ868 can overcome persistence to 
type I JAK inhibitors in SET2 cells (Meyer et al., 2015). 
Global proteomic analysis using mass spectroscopy identified 162 proteins which were downregulated 
on ruxolitinib treatment (Table 13 in Chapter 7: Appendices). Using an analysis of GO terms relating 
to biological processes, it was found that there was an overrepresentation of terms relating to several 
processes involved in ribonucleoprotein complex assembly, protein glycosylation, and cytosolic 
transport (Figure 63 and Table 14).  
STRING analysis of protein-protein interactions showed an enhancement of differentially regulated 
proteins associated with the ribosome pathway. These were separated by a single node to STAT1. 
STAT1 plays a key role in signal transduction from IFN-γ signalling via its membrane-bound receptor. 
IFN-γ is important in modulating cellular immunity to intracellular pathogens, inflammation, 
macrophage recruitment, and tumour suppression (Hu et al., 2009). Activation of STAT1 is responsible 
for the transcription of a large number of downstream IFN-γ target genes (Krause et al., 2006). It has 
also been shown in GATA1 knockdown mouse models that STAT1 production is impaired along with 
impaired terminal megakaryopoiesis and this can be part rescued through ectopic expression of STAT1 
or its target interferon receptor factor 1 (IRF1)  (Huang et al., 2007). In addition, loss of STAT1 
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promotes erythropoiesis over megakaryopoiesis in JAK2V617F mouse models (Duek et al., 2014). STAT1 
and JAK2 expression are downregulated in GATA1 knockdown murine megakaryocytes (Muntean and 
Crispino, 2005). Ectopic expression of STAT1 or its target effector, IRF1, can rescue megakaryopoiesis 
defects in these GATA1 deficient mice (Huang et al., 2007). 
Relative protein quantification between STAT proteins (1, 3, and 5A) and a control gene (GAPDH) 
showed that only STAT1 was significantly downregulated, 2.5-fold lower than GAPDH, in response to 
ruxolitinib (Table 12 and Figure 65). In western blot experiments using cells treated over 6 hours, no 
change in total STAT for either STAT1 or STAT5 was observed. Phosphorylated levels of these proteins 
were reduced after 15 minutes. Longer experiments over 72 hours did match the results observed in 
mass spectroscopy experiments. Levels of total STAT1 reduced after 48 hours, while STAT3 and STAT5 
remained unchanged. Differences in STAT expression, between STAT1 (normally involved in the 
upregulation of apoptotic genes) and STAT5, is one potential mechanism proposed to explain how 
distinct phenotypes can arise from the same somatic mutation (Chen et al., 2010). This may also have 
implications in the design of drugs that target JAK2 and by association STAT phosphorylation and 
signalling.  
STAT1 and STAT3 have contrasting roles in controlling cell cycle progression and tumourigenesis. 
STAT1 negatively regulates the cell cycle through expression of cyclin-dependent kinase (CDK) 
inhibitors, including p21waf/cip1 and p27Kip1, as well as the G1/S phase blocker, KLF4 (Avalle et al., 2012). 
STAT3 is responsible for activating CDKs, through increased expression of cyclin D2 as well as 
downregulating p21, a CDK inhibitor (Thomas et al., 2015). In multiple myeloma cells, STAT1 can 
attenuate IL-6 induced STAT3 activation and increases expression of pro-apoptotic genes (Dimberg et 
al., 2012). These STAT proteins also have contrasting effects on cancer immunity and inflammation. 
STAT1 is mainly activated through interferon (α, β, and γ) signalling and results in the expression of 
TH1 immunostimulatory and pro-apoptotic genes (Yu et al., 2009). Interleukins-6, 10, 11, 21, and 23, 
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stimulate STAT3 and increases expression of TH17 type genes, which are involved in the inflammatory 
response (Yu et al., 2009). 
Changes in STAT1 gene expression in cell lines treated with ruxolitinib was observed only in those 
carrying a JAK2V617F mutation (Figure 66) suggesting that the reduction in total STAT1 may occur at the 
transcriptional level, rather than post translational modifications such as increased proteolytic 
processing. 
SOCS proteins are important negative regulators of JAK/STAT signalling and are upregulated in 
response to cytokine binding in a classical negative feedback loop (Krebs and Hilton, 2001). The activity 
of SOCS1 is mostly targeted at modulating IFN-γ signalling, whereas IL-6 induction of JAK/STAT is 
primarily regulated by SOCS3. Both of these inhibitors have different mechanisms in how they 
negatively regulate JAK/STAT. SOCS1 binds directly to activated JAK2 at the autophosphorylation site 
(1001-1013) and targets it for ubiquitin-dependent proteolytic degradation (Ungureanu et al., 2002, 
Waiboci et al., 2007). SOCS3 mechanism is slightly different, it can bind simultaneously to JAK2 as well 
as to the membrane bound receptor, catalysing the ubiquitination of both (Babon et al., 2012). SOCS3 
can directly inhibit JAK proteins in the absence of receptor binding, although this is with much poorer 
affinity than SOCS1 (Babon et al., 2012). When SET2 cells were exposed to ruxolitinib, contrasting 
results were observed between expression levels of SOCS1 and SOCS3 (Figure 73). Despite increased 
levels of transcription for genes encoding the pro-inflammatory and STAT3 stimulating IL-6 and IL-1b 
(Samavati et al., 2009), there was a twofold decrease in expression of SOCS3. SOCS1 did not decrease, 
with levels increasing 1.5-fold. One potential explanation for these results may lie in the previously 
described binding mechanisms for SOCS1 and SOCS3, as well as the paradoxical phosphorylation of 
JAK2 in the presence of ruxolitinib. Both JAK2 and membrane receptor activation in proximity are 
needed to stimulate SOCS3 (Babon et al., 2012), and this is blocked with ruxolitinib. SOCS1, however, 
is primarily induced by JAK2 activation alone, which occurs due to autophosphorylation of 
Tyr1007/1008 in the activation loop (Andraos et al., 2012). 
172 
 
Ruxolitinib was compared to the STAT1 specific inhibitor, fludarabine. Fludarabine reduces STAT1 
phosphorylation, mRNA and protein expression, but does not affect the levels of other STAT proteins, 
including STAT3 and STAT5 (Frank et al., 1999). JAK2 phosphorylation is also unaffected, although total 
levels of JAK2 decrease 5 days after STAT1 inhibition, indicating that total JAK2 suppression is 
secondary to anti-STAT1 activity (Torella et al., 2007). SET2 was less sensitive to fludarabine (IC50 = 5.5 
µM) (Figure 74) compared to ruxolitinib (IC50 = 132 nM) (Figure 48) in cell proliferation assays. 
Ruxolitinib was also a more potent inhibitor of STAT1 gene expression, treatment with 1 µM RUX 
resulted in a three-fold reduction of STAT1 in SET2 cells (Figure 75). Fludarabine dosed at a greater 
concentration (5.5 µM) only resulted in a downregulation of STAT1 by 30%. These results suggest that 
targeting JAK2 inhibition, upstream from STAT1 signalling, has a greater effect on cell proliferation and 
STAT1 expression than targeting STAT1 directly. 
These experiments highlight the crucial role that STAT1 plays in modulating JAK signalling in MPNs. 
Differential expression of STAT proteins, including STAT1, and responses to JAK inhibitors are 
important factors in predicting how MPNs may progress and respond to treatment. Interactions with 
other molecular pathways, including immunity and inflammatory responses (modulated by STAT1) are 
significant considerations when examining potential treatment side-effects during targeted JAK/STAT 
inhibition.
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CHAPTER 6: 
Overview
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Knowledge and understanding of the molecular mechanisms underpinning the BCR-ABL negative 
myeloproliferative neoplasms has improved greatly in the last 12 years. The discovery of the JAK2V617F 
mutation in MPN patients (Baxter et al., 2005, James et al., 2005, Kralovics et al., 2005, Levine et al., 
2005) has been perhaps the most important advance since the classification of these disorders by 
Dameshek in the 1950s (Dameshek, 1951). More recently, the identification of calreticulin mutations 
in ET and MF has provided an almost complete picture of the genetic landscape of MPN (Klampfl et 
al., 2013, Nangalia et al., 2013). Regardless of differences in phenotype or mutation type, 
dysregulation of the JAK/STAT pathway is a shared feature. Therefore, this project aimed to 
investigate what impact changes at a nuclear level (independent of JAK2) had in MPNs, as well as 
investigating whether these changes affected disease pathogenesis. Global proteomic changes and 
modifications in ruxolitinib treated cells were also examined in order to determine the impact of JAK2 
dysregulation as well as identifying potential pathways for treatment.  
Changes at the nuclear level, affecting transcription of critical haematopoietic transcription factors, 
were studied in ET patients. The haematopoietic transcription factor, GATA1, is a key modulator of 
cell differentiation and lineage commitment (Crispino, 2005). It was found that GATA1 was 
significantly upregulated in these patients, which was independent of mutational status. Notably, the 
correlation with one of the clinicopathological indicators for ET, platelet counts, was negative.  
To further investigate the role of GATA1 expression, changes in MPN cell line models were studied 
using anagrelide. The rationale for selecting this drug were; 1) its use as a platelet-reducing agent in 
ET, 2) it was not known to affect JAK/STAT pathway signalling, and 3) previous experiments have 
shown a potential link between GATA1 downregulation and the mechanism of this drug. Therefore, 
changes elicited in cell proliferation, cell cycle stages, and gene expression would be independent from 
JAK/STAT signalling, but instead result from GATA1 downregulation. Haematopoietic gene expression, 
including GATA1, was not significantly affected by anagrelide treatment but the JAK2V617F cell line, HEL, 
responded to the drug in cellular proliferation assays. This cell line was derived from a patient with no 
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known history of MPN, but with the JAK2V617F mutation. Whilst proliferation was reduced, and 
evidence of a block in cell cycle progression from G1 to S phase was shown, this did not impact on the 
expression of key haematopoietic genes in this cell line. GATA1 has multifunctional roles, often 
dependent on presence of co-factors expressed at different stages of development (Chang et al., 
2002a, Crispino, 2005). In the experiments by Ahluwalia et al. (2010), GATA1 downregulation in 
response to anagrelide was shown in primary cells during TPO-induced differentiation. Therefore, to 
simulate the effect of GATA1 downregulation during megakaryocyte differentiation, the phorbol ester, 
PMA, was used. Whilst GATA1 expression was unchanged, transcription of genes involved in 
megakaryocyte differentiation under GATA1 transcriptional control were affected. It is not known 
whether these results are specific to this cell line. 
Chapters 3 and 4 investigated nuclear changes downstream and independent from JAK/STAT signalling. 
Chapter 5 examined how the JAK/STAT pathway is directly responsible for global proteomic changes 
as well as functional protein modifications. Ruxolitinib, the first JAK inhibitor drug to be licensed for 
use in MPN patients, was used to target JAK/STAT signalling. At concentrations up to 1 µM, this drug 
was selective (inhibiting cell proliferation) against those cell lines containing the JAK2V617F mutation. 
Despite this apparent specificity, there is no complete reduction in the clonal burden in patients 
treated with ruxolitinib (Verstovsek et al., 2014). In clinical trials, it has been shown to be equally 
effective against both JAK2-mutated and non-JAK2-mutated patients, indicating that all mutations 
found in MPN result in dysregulated signalling via JAK2/STAT pathways (Verstovsek et al., 2014). 
Targeted drugs against JAK2 should therefore, in theory, be effective against all MPNs. However in the 
CALR-mutated MARIMO, a cell line derived from an AML patient with previous history of ET, ruxolitinib 
does not have any effect on proliferation (Kollmann et al., 2015). This group have also shown that the 
cell line does not depend on JAK2/STAT5 signalling and CALR expression is 10-fold higher than seen in 
JAK2V617F cell lines. The results in this study (Chapter 3) indicate that downregulation of CALR is 
common to all MPNs, although proteomics in Chapter 5 did not show any significant reduction in 
calreticulin protein levels.  
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Phosphorylated levels of all the STAT proteins (1/3/5) were decreased with ruxolitinib treatment in 
JAK2V617F cell lines.  Interestingly total STAT1 levels also decreased, a finding confirmed with global 
proteomics studies. Gene expression experiments suggest that downregulation of STAT1 induced by 
ruxolitinib may be responsible, but decreased protein synthesis or increased proteolytic degradation 
may also play a role. 
The enhanced effectiveness of ruxolitinib in STAT1 inhibition compared to fludarabine in the SET2 cell 
line was demonstrated. As fludarabine is associated with significant immunosuppressive activity, 
these results should highlight the importance of monitoring patients undergoing ruxolitinib therapy. 
Indeed, there have already been several case reports where ruxolitinib treatment has been associated 
with opportunistic viral and intracellular infections (Wysham et al., 2013, von Hofsten et al., 2016, 
Heine et al., 2013). It is not yet known whether other JAK inhibitors undergoing clinical trials will inhibit 
STAT1 in a similar manner as ruxolitinib. As more tyrosine kinase inhibitors are developed which seek 
to target JAK/STAT signalling in MPN, there will be a greater need to understand differential STAT1 
responses to these drugs.
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CHAPTER 7: 
Conclusions & 
future work
180 
 
7.1: Conclusions: 
This project has demonstrated that GATA1 may have potential as a biomarker in ET, independent from 
mutational or treatment status. This was shown in PBMCs isolated from MPN donor samples. 
Experiments utilising model JAK2 cell lines then showed that pathways directly linked to GATA1 could 
regulate gene expression involved in terminal megakaryopoiesis, which has implications for the 
disease and the mechanism of anagrelide.  Direct JAK2 inhibition, in both cell line models and patient 
samples, highlighted the importance of STAT1, in MPN disease pathogenesis as well as potential 
implications in immune responses arising from the use of JAK/STAT inhibitors. 
7.2: Future Work: 
Monitoring of patient platelet levels and disease progression over time along with GATA1 expression 
may determine whether GATA1 has potential as a surrogate diagnostic and/or prognostic biomarker 
for the disorder. The recently discovered mechanism by which mutant CALR interacts with the TPO 
receptor (MPL) should also be studied to determine whether there is any link between this and the 
decreased CALR expression observed in my studies. Although decreased CALR gene expression was 
observed across all ET disease mutations, it is not known whether this is reflected in the CALR protein 
levels and whether there are changes in the proportion of mutant calreticulin located in the ER. As 
with GATA1, it may be worth examining how CALR expression levels vary during the progression of 
these disorders and whether this has any prognostic or diagnostic significance. 
Primary cell lines should also be used to confirm whether changes in GATA1 expression levels lead to 
changes downstream of genes involved in regulating megakaryopoiesis, as observed in experiments 
with cultured cell lines. Further experiments using primary cell lines undergoing megakaryocytic 
differentiation in the presence of anagrelide should be carried out to confirm these findings. Gene 
expression experiments using other PDE III inhibitors during induced megakaryopoiesis may also 
demonstrate whether this particular mechanism is responsible for the reduction of PSTPIP2 and PF4. 
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Proteomic studies should be carried out, using cell models where JAK2 and STAT1 are induced to 
overexpress, to complement the studies here where JAK2 has been negatively regulated by ruxolitinib. 
More patient samples are required to confirm the differential STAT1 protein expression patterns 
observed between ET and PV patients. Further work examining patient to patient variations in STAT1 
expression, and any changes during the course of the disease would also be valuable. These studies 
may help to predict the likely response to ruxolitinib therapy, side effects, and whether patient is at 
greater risk of disease transformation. 
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CHAPTER 8:  
Appendices 
184 
 
 
Figure 76: Representative images of A) CFU-GEMM, B) BFU-E, C) CFU-E and D) CFU-GM from colony forming unit assays. Images were taken after PBMCs 
were cultured for 14 days in methylcelluose media 
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Table 13: Differential protein expression (< 0.8) measured by iTRAQ in SET2 cells treated with 1 µM ruxolitinib. 
Uniprot 
code 
Gene symbol Gene name 
unused 
protein 
score 
113 FC 
113 
p-value 
115 FC 
115 
p-value 
117FC 
117 
p-value 
Median 
fold 
change  
(< 0.8) 
Median  
p-value 
(< 0.05) 
Q9P1F3 ABRACL ABRA C-terminal like(ABRACL) 2.58 0.0105 0.0172 0.0540 0.1320 0.0105 0.0172 0.0105 0.0172 
E9PNC7 DRAP1 DR1 associated protein 1(DRAP1) 2.01 0.0106 0.0186 0.0773 0.1502 0.0106 0.0186 0.0106 0.0186 
Q8WTS1 ABHD5 
abhydrolase domain containing 
5(ABHD5) 
4 0.0111 0.0232 1.0280 0.9462 0.0111 0.0232 0.0111 0.0232 
Q9BR61 ACBD6 
acyl-CoA binding domain containing 
6(ACBD6) 
2.7 0.0111 0.0207 0.3981 0.2553 0.0111 0.0207 0.0111 0.0207 
O43747 AP1G1 
adaptor related protein complex 1 
gamma 1 subunit(AP1G1) 
2 0.0111 0.0228 0.0111 0.0228 0.0111 0.0228 0.0111 0.0228 
O95782 AP2A1 
adaptor related protein complex 2 
alpha 1 subunit(AP2A1) 
6.2 0.0111 0.0229 0.4406 0.2861 0.0111 0.0229 0.0111 0.0229 
P02649 APOE apolipoprotein E(APOE) 2.03 0.4529 0.2945 0.0111 0.0212 0.0111 0.0212 0.0111 0.0212 
Q15392 DHCR24 
24-dehydrocholesterol 
reductase(DHCR24) 
2.14 0.0111 0.0211 0.0111 0.0211 0.2884 0.1961 0.0111 0.0211 
Q9H6R0 DHX33 DEAH-box helicase 33(DHX33) 4.28 0.0111 0.0231 0.2148 0.1599 0.0111 0.0231 0.0111 0.0231 
H0YK61 EMC4 
ER membrane protein complex 
subunit 4(EMC4) 
4 0.0111 0.0226 0.4246 0.2762 0.0111 0.0226 0.0111 0.0226 
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Uniprot 
code 
Gene symbol Gene name 
unused 
protein 
score 
113 FC 
113 
p-value 
115 FC 
115 
p-value 
117FC 
117 
p-value 
Median 
fold 
change  
(< 0.8) 
Median  
p-value 
(< 0.05) 
H3BS72 HACD3 
3-hydroxyacyl-CoA dehydratase 
3(HACD3) 
1.35 0.0111 0.0206 0.4966 0.3392 0.0111 0.0206 0.0111 0.0206 
P53701 HCCS holocytochrome c synthase(HCCS) 2.11 0.0111 0.0207 0.8166 0.7359 0.0111 0.0207 0.0111 0.0207 
P31937 HIBADH 
3-hydroxyisobutyrate 
dehydrogenase(HIBADH) 
3.86 0.0111 0.0231 1.1169 0.8158 0.0111 0.0231 0.0111 0.0231 
Q53FT3 HIKESHI 
Hikeshi, heat shock protein nuclear 
import factor(HIKESHI) 
4 0.0111 0.0219 0.0111 0.0219 0.2377 0.1700 0.0111 0.0219 
Q14145 KEAP1 
kelch like ECH associated protein 
1(KEAP1) 
2.37 0.0111 0.0229 0.0111 0.0229 0.0111 0.0229 0.0111 0.0229 
O14733 MAP2K7 
mitogen-activated protein kinase 
kinase 7(MAP2K7) 
4.38 0.0111 0.0233 1.5136 0.4744 0.0111 0.0233 0.0111 0.0233 
Q9Y316 MEMO1 mediator of cell motility 1(MEMO1) 4 0.0111 0.0210 0.0111 0.0210 0.9204 0.8784 0.0111 0.0210 
Q9Y483 MTF2 
metal response element binding 
transcription factor 2(MTF2) 
2.01 0.0111 0.0233 1.3183 0.5976 0.0111 0.0233 0.0111 0.0233 
Q8IXK0 PHC2 polyhomeotic homolog 2(PHC2) 4.01 1.0471 0.9108 0.0111 0.0223 0.0111 0.0223 0.0111 0.0223 
Q9HCU5 PREB 
prolactin regulatory element 
binding(PREB) 
2.02 0.0111 0.0227 0.5970 0.4167 0.0111 0.0227 0.0111 0.0227 
Q9UNN8 PROCR protein C receptor(PROCR) 3.04 0.0111 0.0206 0.0809 0.2434 0.0111 0.0206 0.0111 0.0206 
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H0Y8D1 PRSS1 protease, serine 1(PRSS1) 2.78 0.0111 0.0184 0.0111 0.0184 0.0111 0.0184 0.0111 0.0184 
Q5T8U5 SURF4 surfeit 4(SURF4) 2 0.0111 0.0195 0.0560 0.1540 0.0111 0.0195 0.0111 0.0195 
J3QQW9 SUZ12 
SUZ12 polycomb repressive complex 2 
subunit(SUZ12) 
4.44 0.0111 0.0222 0.9638 0.9619 0.0111 0.0222 0.0111 0.0222 
P49754 VPS41 VPS41, HOPS complex subunit(VPS41) 2.11 0.0111 0.0206 0.0111 0.0206 0.0111 0.0206 0.0111 0.0206 
Q9UIV1 CNOT7 
CCR4-NOT transcription complex 
subunit 7(CNOT7) 
1.77 9.0365 0.1202 0.0127 0.0226 0.0127 0.0226 0.0127 0.0226 
O00623 PEX12 
peroxisomal biogenesis factor 
12(PEX12) 
2.03 11.8032 0.0999 0.0129 0.0255 0.0129 0.0255 0.0129 0.0255 
P69891 HBG1 hemoglobin subunit gamma 1(HBG1) 2 0.0138 0.0171 0.0402 0.1348 0.0138 0.0171 0.0138 0.0171 
Q9UMX0 UBQLN1 ubiquilin 1(UBQLN1) 10 0.0194 0.0350 0.0863 0.1615 0.0203 0.0351 0.0203 0.0351 
O75122 CLASP2 
cytoplasmic linker associated protein 
2(CLASP2) 
8.13 0.0111 0.0230 0.0223 0.0343 0.4130 0.0532 0.0223 0.0343 
P18085 ARF4 ADP ribosylation factor 4(ARF4) 3.91 0.1047 0.0354 0.0254 0.0066 0.0180 0.0054 0.0254 0.0066 
Q9BWJ5 SF3B5 splicing factor 3b subunit 5(SF3B5) 2.86 0.0275 0.0351 0.0294 0.0358 0.0305 0.0361 0.0294 0.0358 
Q8TDB8 SLC2A14 
solute carrier family 2 member 
14(SLC2A14) 
4.29 0.0316 0.0383 0.0334 0.0389 0.0281 0.0370 0.0316 0.0383 
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Q9Y5M8 SRPRB SRP receptor beta subunit(SRPRB) 5.1 0.0231 0.0136 0.0316 0.0325 0.0540 0.0237 0.0316 0.0237 
G3V5Q1 APEX1 
apurinic/apyrimidinic 
endodeoxyribonuclease 1(APEX1) 
4.68 0.0337 0.0398 0.1343 0.2702 0.0316 0.0395 0.0337 0.0398 
P63244 RACK1 
receptor for activated C kinase 
1(RACK1) 
16.8 0.0377 0.0108 0.0560 0.0250 0.0360 0.0079 0.0377 0.0108 
Q9BPX3 NCAPG 
non-SMC condensin I complex subunit 
G(NCAPG) 
8.04 0.0384 0.0012 0.0832 0.0038 0.0363 0.0012 0.0384 0.0012 
Q15269 PWP2 
periodic tryptophan protein homolog 
(yeast)(PWP2) 
5.54 0.0402 0.0397 0.0863 0.1500 0.0136 0.0330 0.0402 0.0397 
C9JVN9 L2HGDH 
L-2-hydroxyglutarate 
dehydrogenase(L2HGDH) 
6 0.0425 0.0393 0.5495 0.3982 0.0406 0.0388 0.0425 0.0393 
P00352 ALDH1A1 
aldehyde dehydrogenase 1 family 
member A1(ALDH1A1) 
5.19 0.0466 0.0179 0.1722 0.0493 0.0394 0.0199 0.0466 0.0199 
O95714 HERC2 
HECT and RLD domain containing E3 
ubiquitin protein ligase 2(HERC2) 
8.42 0.0474 0.0431 0.1406 0.2410 0.0398 0.0412 0.0474 0.0431 
Q9NUQ2 AGPAT5 
1-acylglycerol-3-phosphate O-
acyltransferase 5(AGPAT5) 
2.14 0.0483 0.0348 0.0384 0.0362 0.3981 0.3551 0.0483 0.0362 
Q15637 SF1 splicing factor 1(SF1) 11.52 0.0492 0.1844 0.7656 0.0485 0.0238 0.0356 0.0492 0.0485 
Q13616 CUL1 cullin 1(CUL1) 4.19 0.2938 0.0054 0.0535 0.0207 0.0107 0.0006 0.0535 0.0054 
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Q9BYD3 MRPL4 
mitochondrial ribosomal protein 
L4(MRPL4) 
4 0.0182 0.0220 0.2992 0.3884 0.0570 0.0392 0.0570 0.0392 
Q9Y512 SAMM50 
SAMM50 sorting and assembly 
machinery component(SAMM50) 
3.23 0.0570 0.0398 0.1923 0.1639 0.0363 0.0377 0.0570 0.0398 
O00764 PDXK 
pyridoxal (pyridoxine, vitamin B6) 
kinase(PDXK) 
5.05 0.0586 0.0429 0.4742 0.3344 0.0560 0.0424 0.0586 0.0429 
P62891 RPL39 ribosomal protein L39(RPL39) 4.11 0.0637 0.0037 1.1376 0.1743 0.0483 0.0032 0.0637 0.0037 
Q9Y277 VDAC3 
voltage dependent anion channel 
3(VDAC3) 
9.46 0.0377 0.0059 0.0718 0.2028 0.0649 0.0007 0.0649 0.0059 
Q969X6 UTP4 
UTP4, small subunit processome 
component(UTP4) 
1.77 0.1854 0.0413 0.0340 0.0228 0.0661 0.0228 0.0661 0.0228 
P05387 RPLP2 
ribosomal protein lateral stalk subunit 
P2(RPLP2) 
13.41 0.0530 0.0242 0.1820 0.0005 0.0685 0.0305 0.0685 0.0242 
J3KSZ5 DCXR 
dicarbonyl and L-xylulose 
reductase(DCXR) 
6.02 0.2249 0.0061 0.0109 0.0007 0.0724 0.0032 0.0724 0.0032 
Q8NE86 MCU mitochondrial calcium uniporter(MCU) 2 0.0780 0.0217 0.0780 0.0217 0.8091 0.6450 0.0780 0.0217 
Q86UX7 FERMT3 fermitin family member 3(FERMT3) 34.81 0.0817 0.0026 0.1271 0.0072 0.0437 0.0015 0.0817 0.0026 
P31946 YWHAB tyrosine 3-
monooxygenase/tryptophan 5-
4.94 0.0912 0.0347 0.1644 0.0896 0.0938 0.0327 0.0938 0.0347 
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monooxygenase activation protein 
beta(YWHAB) 
Q14376 GALE UDP-galactose-4-epimerase(GALE) 4.85 0.2148 0.1697 0.0912 0.0399 0.0991 0.0409 0.0991 0.0409 
Q9Y6K5 OAS3 
2'-5'-oligoadenylate synthetase 
3(OAS3) 
2.03 0.1009 0.0458 0.0766 0.0433 0.1076 0.0463 0.1009 0.0458 
Q9BQ52 ELAC2 elaC ribonuclease Z 2(ELAC2) 8.92 0.0111 0.0236 0.1019 0.0440 0.1107 0.0447 0.1019 0.0440 
Q05086 UBE3A ubiquitin protein ligase E3A(UBE3A) 4.18 0.8630 0.7841 0.1019 0.0448 0.1009 0.0447 0.1019 0.0448 
Q15102 PAFAH1B3 
platelet activating factor 
acetylhydrolase 1b catalytic subunit 
3(PAFAH1B3) 
6.16 0.0310 0.0019 0.3733 0.0674 0.1028 0.0120 0.1028 0.0120 
O75964 ATP5L 
ATP synthase, H+ transporting, 
mitochondrial Fo complex subunit 
G(ATP5L) 
6.2 0.0331 0.0176 0.1038 0.0365 0.1854 0.0651 0.1038 0.0365 
B0I1T2 MYO1G myosin IG(MYO1G) 9.2 0.1038 0.0423 0.0817 0.0440 0.1047 0.0423 0.1038 0.0423 
P61086 UBE2K 
ubiquitin conjugating enzyme E2 
K(UBE2K) 
6.41 0.1096 0.0197 0.3373 0.0884 0.0780 0.0266 0.1096 0.0266 
P00491 PNP purine nucleoside phosphorylase(PNP) 14.2 0.1127 0.0368 0.1076 0.0327 0.1803 0.0712 0.1127 0.0368 
I3L0U5 CCDC137 
coiled-coil domain containing 
137(CCDC137) 
4 0.0982 0.0458 0.1236 0.0453 0.1159 0.0447 0.1159 0.0453 
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Q9H6D7 HAUS4 
HAUS augmin like complex subunit 
4(HAUS4) 
1.49 0.2249 0.9671 0.0370 0.0327 0.1236 0.0435 0.1236 0.0435 
Q08211 DHX9 DExH-box helicase 9(DHX9) 37.96 0.1294 0.0094 0.2489 0.0088 0.1294 0.0128 0.1294 0.0094 
P82930 MRPS34 
mitochondrial ribosomal protein 
S34(MRPS34) 
3.26 0.0817 0.0387 0.1306 0.0448 0.1318 0.0455 0.1306 0.0448 
O15144 ARPC2 
actin related protein 2/3 complex 
subunit 2(ARPC2) 
9.55 0.1047 0.0419 0.3802 0.1331 0.1380 0.0042 0.1380 0.0419 
Q9H7M9 VSIR 
V-set immunoregulatory 
receptor(VSIR) 
2.05 0.0363 0.0386 0.3467 0.2495 0.1393 0.0427 0.1393 0.0427 
Q9Y3T9 NOC2L 
NOC2 like nucleolar associated 
transcriptional repressor(NOC2L) 
6.03 0.1419 0.0448 0.2312 0.0518 0.1047 0.0461 0.1419 0.0461 
P51149 RAB7A 
RAB7A, member RAS oncogene 
family(RAB7A) 
15.52 0.1330 0.0191 0.1419 0.0109 0.2208 0.0479 0.1419 0.0191 
I3L1P8 SLC25A11 
solute carrier family 25 member 
11(SLC25A11) 
3.08 0.0839 0.0435 0.4742 0.3309 0.1472 0.0480 0.1472 0.0480 
P55884 EIF3B 
eukaryotic translation initiation factor 
3 subunit B(EIF3B) 
24.19 0.1500 0.0153 0.2421 0.0727 0.1247 0.0093 0.1500 0.0153 
A6NJA2 USP14 ubiquitin specific peptidase 14(USP14) 8.52 0.1528 0.0373 0.0213 0.0203 0.3281 0.1835 0.1528 0.0373 
C9JFR7 CYCS cytochrome c, somatic(CYCS) 4.36 0.0863 0.0219 0.4093 0.2869 0.1542 0.0341 0.1542 0.0341 
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O95563 MPC2 
mitochondrial pyruvate carrier 
2(MPC2) 
1.55 0.1600 0.0405 0.2168 0.1754 0.1472 0.0401 0.1600 0.0405 
Q9Y6C9 MTCH2 mitochondrial carrier 2(MTCH2) 8.01 0.2466 0.0689 0.1127 0.0410 0.1629 0.0361 0.1629 0.0410 
P41252 IARS isoleucyl-tRNA synthetase(IARS) 26.08 0.2489 0.0041 0.1644 0.0003 0.0904 0.0171 0.1644 0.0041 
P46977 STT3A 
STT3A, catalytic subunit of the 
oligosaccharyltransferase 
complex(STT3A) 
5.22 0.1556 0.0477 0.2489 0.0651 0.1644 0.0439 0.1644 0.0477 
Q86VP6 CAND1 
cullin associated and neddylation 
dissociated 1(CAND1) 
14.33 0.1854 0.0003 0.1690 0.0047 0.1294 0.0213 0.1690 0.0047 
O43264 ZW10 zw10 kinetochore protein(ZW10) 4.9 0.1820 0.0043 0.1722 0.0904 0.1009 0.0391 0.1722 0.0391 
Q9NVI7 ATAD3A 
ATPase family, AAA domain containing 
3A(ATAD3A) 
25 0.1820 0.0002 0.2606 0.0002 0.1419 0.0455 0.1820 0.0002 
P57740 NUP107 nucleoporin 107(NUP107) 8.68 0.1854 0.0051 0.4365 0.2990 0.1393 0.0061 0.1854 0.0061 
A6NFX8 NUDT5 nudix hydrolase 5(NUDT5) 7.67 0.1977 0.1476 0.2884 0.0358 0.1977 0.0109 0.1977 0.0358 
Q9NVI1 FANCI 
Fanconi anemia complementation 
group I(FANCI) 
3.55 0.6427 0.2721 0.1803 0.0048 0.2014 0.0056 0.2014 0.0056 
Q15393 SF3B3 splicing factor 3b subunit 3(SF3B3) 21.92 0.2188 0.0869 0.2014 0.0086 0.1225 0.0162 0.2014 0.0162 
P47897 QARS glutaminyl-tRNA synthetase(QARS) 33.72 0.1786 0.0080 0.4093 0.0081 0.2089 0.0079 0.2089 0.0080 
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Q5SZR4 TDRKH 
tudor and KH domain 
containing(TDRKH) 
2.03 0.4742 0.1446 0.2148 0.0226 0.2070 0.0226 0.2148 0.0226 
Q13200 PSMD2 
proteasome 26S subunit, non-ATPase 
2(PSMD2) 
17.78 0.4285 0.0251 0.2168 0.0530 0.1459 0.0167 0.2168 0.0251 
Q15020 SART3 
squamous cell carcinoma antigen 
recognized by T-cells 3(SART3) 
14.66 0.3698 0.0193 0.2228 0.0166 0.0832 0.0872 0.2228 0.0193 
Q9NZ45 CISD1 CDGSH iron sulfur domain 1(CISD1) 4.15 0.1472 0.0108 0.2512 0.0250 0.2249 0.0254 0.2249 0.0250 
P00338 LDHA lactate dehydrogenase A(LDHA) 19.36 0.2249 0.0531 0.2399 0.0137 0.0912 0.0131 0.2249 0.0137 
P55060 CSE1L chromosome segregation 1 like(CSE1L) 24.03 0.2070 0.0367 0.3873 0.0003 0.2270 0.0242 0.2270 0.0242 
Q92769 HDAC2 histone deacetylase 2(HDAC2) 13.68 0.2188 0.0055 0.5916 0.2198 0.2291 0.0056 0.2291 0.0056 
P14868 DARS aspartyl-tRNA synthetase(DARS) 25.02 0.2312 0.0112 0.3597 0.0273 0.1472 0.0962 0.2312 0.0273 
O95870 ABHD16A 
abhydrolase domain containing 
16A(ABHD16A) 
6.12 0.7311 0.1746 0.2333 0.0062 0.2249 0.0064 0.2333 0.0064 
Q9NQ55 PPAN 
peter pan homolog 
(Drosophila)(PPAN) 
2.06 0.1169 0.0223 0.3733 0.0868 0.2333 0.0402 0.2333 0.0402 
P08240 SRPRA SRP receptor alpha subunit(SRPRA) 19.52 0.1941 0.0129 0.3597 0.0432 0.2333 0.0713 0.2333 0.0432 
P04818 TYMS thymidylate synthetase(TYMS) 8 0.2355 0.0249 0.5248 0.1973 0.0661 0.0126 0.2355 0.0249 
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Q9BQG0 MYBBP1A MYB binding protein 1a(MYBBP1A) 15.81 0.2421 0.0187 0.3499 0.0833 0.2355 0.0212 0.2421 0.0212 
P41091 EIF2S3 
eukaryotic translation initiation factor 
2 subunit gamma(EIF2S3) 
14.19 0.3105 0.0025 0.2443 0.0022 0.2051 0.0029 0.2443 0.0025 
P01023 A2M alpha-2-macroglobulin(A2M) 8.27 0.4365 0.0049 0.2489 0.0005 0.0817 0.0013 0.2489 0.0013 
P62266 RPS23 ribosomal protein S23(RPS23) 6.24 0.2535 0.0554 0.3048 0.0037 0.2377 0.0048 0.2535 0.0048 
P40429 RPL13A ribosomal protein L13a(RPL13A) 15.21 0.2051 0.1156 0.3873 0.0062 0.2630 0.0058 0.2630 0.0062 
P06744 GPI glucose-6-phosphate isomerase(GPI) 41.16 0.2655 0.0136 0.3076 0.0470 0.2208 0.0580 0.2655 0.0470 
J9JIE6 TMCO1 
transmembrane and coiled-coil 
domains 1(TMCO1) 
4 0.2655 0.0407 0.2466 0.0397 0.3467 0.0414 0.2655 0.0407 
Q6P2Q9 PRPF8 pre-mRNA processing factor 8(PRPF8) 31.89 0.2679 0.0046 0.5012 0.0004 0.2399 0.0632 0.2679 0.0046 
P02774 GC GC, vitamin D binding protein(GC) 7.5 0.6427 0.0971 0.2858 0.0361 0.2355 0.0026 0.2858 0.0361 
P16435 POR 
cytochrome p450 
oxidoreductase(POR) 
5.83 0.2992 0.0451 1.5417 0.7547 0.3020 0.0451 0.3020 0.0451 
P21796 VDAC1 
voltage dependent anion channel 
1(VDAC1) 
23.01 0.2089 0.0045 0.3373 0.0138 0.3020 0.0143 0.3020 0.0138 
Q10567 AP1B1 
adaptor related protein complex 1 
beta 1 subunit(AP1B1) 
14.59 0.4966 0.0011 0.3020 0.0217 0.3076 0.0017 0.3076 0.0017 
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Q9NYB0 TERF2IP TERF2 interacting protein(TERF2IP) 3.93 0.3105 0.0490 2.8576 0.3646 0.2704 0.0477 0.3105 0.0490 
P20645 M6PR 
mannose-6-phosphate receptor, 
cation dependent(M6PR) 
5.69 0.3192 0.0088 0.3597 0.0115 0.1445 0.0098 0.3192 0.0098 
P45880 VDAC2 
voltage dependent anion channel 
2(VDAC2) 
5.03 0.2754 0.0154 0.3192 0.0161 0.3597 0.0191 0.3192 0.0161 
P13051 UNG uracil DNA glycosylase(UNG) 6.81 0.3342 0.0482 2.4434 0.9188 0.3404 0.0484 0.3404 0.0484 
H7C2I1 PRMT1 
protein arginine methyltransferase 
1(PRMT1) 
3.84 0.3698 0.0112 0.3565 0.0118 0.1570 0.2385 0.3565 0.0118 
O75165 DNAJC13 
DnaJ heat shock protein family 
(Hsp40) member C13(DNAJC13) 
3.93 0.3698 0.0038 0.3837 0.0049 0.8872 0.9262 0.3837 0.0049 
P42566 EPS15 
epidermal growth factor receptor 
pathway substrate 15(EPS15) 
7.78 0.4613 0.0534 0.4130 0.0237 0.2911 0.0111 0.4130 0.0237 
B4DWR3 VBP1 VHL binding protein 1(VBP1) 2.15 0.6730 0.0728 0.3499 0.0299 0.4169 0.0406 0.4169 0.0406 
F8VYN9 ARL1 
ADP ribosylation factor like GTPase 
1(ARL1) 
2 0.4487 0.1530 0.4285 0.0429 0.3945 0.0419 0.4285 0.0429 
P49257 LMAN1 lectin, mannose binding 1(LMAN1) 5.71 0.4325 0.0194 0.6668 0.1564 0.3631 0.0133 0.4325 0.0194 
O75643 SNRNP200 
small nuclear ribonucleoprotein U5 
subunit 200(SNRNP200) 
43.52 0.4365 0.0084 0.4207 0.0131 0.4656 0.0058 0.4365 0.0084 
196 
 
Uniprot 
code 
Gene symbol Gene name 
unused 
protein 
score 
113 FC 
113 
p-value 
115 FC 
115 
p-value 
117FC 
117 
p-value 
Median 
fold 
change  
(< 0.8) 
Median  
p-value 
(< 0.05) 
Q9Y678 COPG1 
coatomer protein complex subunit 
gamma 1(COPG1) 
10 0.4487 0.0068 0.4406 0.0069 0.3767 0.0052 0.4406 0.0068 
O43143 DHX15 DEAH-box helicase 15(DHX15) 19.03 0.4406 0.0030 0.4831 0.0162 0.4169 0.0017 0.4406 0.0030 
Q9UL25 RAB21 
RAB21, member RAS oncogene 
family(RAB21) 
3.27 0.4406 0.0205 0.4365 0.0205 0.5702 0.0408 0.4406 0.0205 
F8W727 RPL32 ribosomal protein L32(RPL32) 6.19 0.4406 0.0206 0.3436 0.0168 0.4831 0.0989 0.4406 0.0206 
Q9NPA8 ENY2 
ENY2, transcription and export 
complex 2 subunit(ENY2) 
4.45 0.4487 0.0414 0.4285 0.0030 0.9204 0.0790 0.4487 0.0414 
Q9UNM6 PSMD13 
proteasome 26S subunit, non-ATPase 
13(PSMD13) 
11.2 0.4786 0.0040 0.6081 0.0063 0.2992 0.1025 0.4786 0.0063 
P51398 DAP3 death associated protein 3(DAP3) 7.68 0.5200 0.0440 0.4875 0.0561 0.3532 0.0287 0.4875 0.0440 
P39656 DDOST 
dolichyl-diphosphooligosaccharide--
protein glycosyltransferase non-
catalytic subunit(DDOST) 
12.57 0.4571 0.0125 0.6918 0.0720 0.4875 0.0484 0.4875 0.0484 
P23396 RPS3 ribosomal protein S3(RPS3) 19.62 0.4875 0.0040 0.5105 0.0091 0.4571 0.0050 0.4875 0.0050 
B1ANR0 PABPC4 
poly(A) binding protein cytoplasmic 
4(PABPC4) 
18.35 0.5105 0.0281 0.4966 0.2103 0.3467 0.0303 0.4966 0.0303 
Q01970 PLCB3 phospholipase C beta 3(PLCB3) 9.83 0.5297 0.0468 0.4966 0.0461 0.4966 0.0461 0.4966 0.0461 
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p-value 
117FC 
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(< 0.05) 
Q01518 CAP1 
adenylate cyclase associated protein 
1(CAP1) 
16.53 0.5445 0.0125 0.5012 0.0122 0.3837 0.0249 0.5012 0.0125 
Q01813 PFKP phosphofructokinase, platelet(PFKP) 24.3 0.5248 0.0231 0.5012 0.0068 0.2911 0.0276 0.5012 0.0231 
Q9HB71 CACYBP calcyclin binding protein(CACYBP) 8.18 0.5495 0.0181 0.5495 0.0238 0.2399 0.1684 0.5495 0.0238 
P42224 STAT1 
signal transducer and activator of 
transcription 1(STAT1) 
22.01 0.6792 0.0294 0.5546 0.1963 0.2780 0.0019 0.5546 0.0294 
O00221 NFKBIE NFKB inhibitor epsilon(NFKBIE) 2.06 0.5649 0.0417 0.5702 0.0419 0.5152 0.0406 0.5649 0.0417 
P11388 TOP2A topoisomerase (DNA) II alpha(TOP2A) 23.87 0.4487 0.0037 0.6368 0.0057 0.5754 0.0256 0.5754 0.0057 
Q9C0C9 UBE2O 
ubiquitin conjugating enzyme E2 
O(UBE2O) 
10.03 0.5754 0.0051 0.5346 0.0040 0.7047 0.1137 0.5754 0.0051 
E7EUC7 UGP2 
UDP-glucose pyrophosphorylase 
2(UGP2) 
10.12 0.6138 0.0162 0.5754 0.0253 0.5152 0.0119 0.5754 0.0162 
Q99832 CCT7 
chaperonin containing TCP1 subunit 
7(CCT7) 
32.84 0.5808 0.0030 0.5970 0.0230 0.4920 0.0201 0.5808 0.0201 
F1T0B3 DDX1 DEAD-box helicase 1(DDX1) 14.33 0.5808 0.0190 0.5346 0.0340 0.6081 0.0524 0.5808 0.0340 
P42704 LRPPRC 
leucine rich pentatricopeptide repeat 
containing(LRPPRC) 
40.71 0.5808 0.0396 0.6138 0.0408 0.4406 0.0179 0.5808 0.0396 
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Q14149 MORC3 
MORC family CW-type zinc finger 
3(MORC3) 
4.09 0.5395 0.0054 0.6982 0.0317 0.6026 0.0147 0.6026 0.0147 
Q8N2G8 GHDC GH3 domain containing(GHDC) 2.07 0.6138 0.0435 0.6982 0.3476 0.5754 0.0426 0.6138 0.0435 
P46940 IQGAP1 
IQ motif containing GTPase activating 
protein 1(IQGAP1) 
22.02 0.6138 0.0480 0.6730 0.0506 0.4529 0.0333 0.6138 0.0480 
P78527 PRKDC 
protein kinase, DNA-activated, 
catalytic polypeptide(PRKDC) 
89.73 0.6138 0.0000 0.6194 0.0000 0.5808 0.0000 0.6138 0.0000 
O00178 GTPBP1 GTP binding protein 1(GTPBP1) 3.88 0.6194 0.0479 0.9727 0.9695 0.5916 0.0473 0.6194 0.0479 
Q71DI3 HIST2H3A 
histone cluster 2 H3 family member 
a(HIST2H3A) 
14.79 0.5546 0.0026 0.6486 0.0026 0.6792 0.0028 0.6486 0.0026 
O95864 FADS2 fatty acid desaturase 2(FADS2) 1.9 0.5808 0.0399 0.8241 0.6198 0.6546 0.0422 0.6546 0.0422 
Q92616 GCN1 
GCN1, eIF2 alpha kinase activator 
homolog(GCN1) 
59.66 0.7311 0.0275 0.6668 0.0004 0.5152 0.0017 0.6668 0.0017 
P05388 RPLP0 
ribosomal protein lateral stalk subunit 
P0(RPLP0) 
24.07 0.7516 0.0032 0.6607 0.0001 0.6668 0.0910 0.6668 0.0032 
O75083 WDR1 WD repeat domain 1(WDR1) 28.74 0.7047 0.0046 0.7311 0.0440 0.6486 0.0147 0.7047 0.0147 
Q9HCS7 XAB2 XPA binding protein 2(XAB2) 3.05 0.5754 0.0029 0.7112 0.0449 0.8395 0.0531 0.7112 0.0449 
P36776 LONP1 lon peptidase 1, mitochondrial(LONP1) 13.47 0.7244 0.0183 0.6918 0.0383 0.8318 0.1162 0.7244 0.0383 
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Q9UBC3 DNMT3B 
DNA methyltransferase 3 
beta(DNMT3B) 
5.53 0.3698 0.0054 1.2589 0.2856 0.7311 0.0074 0.7311 0.0074 
P06400 RB1 RB transcriptional corepressor 1(RB1) 1.91 1.0000 0.4375 0.7516 0.0330 0.4130 0.0177 0.7516 0.0330 
O95433 AHSA1 
activator of Hsp90 ATPase activity 
1(AHSA1) 
3.43 0.8241 0.0063 0.7656 0.1277 0.6918 0.0079 0.7656 0.0079 
Q00610 CLTC clathrin heavy chain(CLTC) 59.08 0.7727 0.0021 0.7870 0.0037 0.7727 0.0143 0.7727 0.0037 
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Table 14: Gene ontology terms and groupings for downregulated proteins in SET2 cells treated with 1 µM ruxolitinib. 
GO: ID GO: Term 
Term PValue 
Corrected with 
Bonferroni step 
down 
Group PValue 
Corrected 
with 
Bonferroni 
step down 
GOLevels GOGroups 
% Associated 
Genes 
Nr. 
Genes 
Associated Genes 
Found 
GO:0042987 
amyloid precursor 
protein catabolic 
process 
21.0E-3 2.2E-3 [5, 6] Group0 13.04 3 
[APEX1, APOE, 
DHCR24] 
GO:0018279 
protein N-linked 
glycosylation via 
asparagine 
15.0E-3 2.1E-3 [5, 7, 8, 9] Group1 8.89 4 
[DDOST, LMAN1, 
PSMD2, STT3A] 
GO:0044724 
single-organism 
carbohydrate 
catabolic process 
13.0E-3 2.4E-3 [4, 5] Group2 4.40 7 
[ALDH1A1, DCXR, 
GALE, GPI, LDHA, 
NUDT5, PFKP] 
GO:0019320 
hexose catabolic 
process 
40.0E-3 2.4E-3 [6, 7] Group2 6.25 4 
[ALDH1A1, GALE, 
GPI, PFKP] 
GO:0019080 
viral gene 
expression 
2.3E-3 32.0E-6 [5] Group3 4.48 9 
[EIF3B, NUP107, 
RPL13A, RPL32, 
RPL39, RPLP0, 
RPLP2, RPS23, 
RPS3] 
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GO: ID GO: Term 
Term PValue 
Corrected with 
Bonferroni step 
down 
Group PValue 
Corrected 
with 
Bonferroni 
step down 
GOLevels GOGroups 
% Associated 
Genes 
Nr. 
Genes 
Associated Genes 
Found 
GO:0006614 
SRP-dependent 
cotranslational 
protein targeting 
to membrane 
9.7E-6 32.0E-6 
[7, 8, 9, 10, 11, 
12] 
Group3 8.91 9 
[RPL13A, RPL32, 
RPL39, RPLP0, 
RPLP2, RPS23, 
RPS3, SRPRA, 
SRPRB] 
GO:0022618 
ribonucleoprotein 
complex assembly 
960.0E-6 220.0E-6 [4, 5, 6] Group4 4.48 10 
[CNOT7, DDX1, 
EIF3B, 
LOC102724159, 
PPAN, PRPF8, 
RPL13A, SART3, 
SF1, SNRNP200] 
GO:0000245 
spliceosomal 
complex assembly 
42.0E-3 220.0E-6 
[5, 6, 7, 8, 9, 10, 
11, 12] 
Group4 5.36 3 
[DDX1, SF1, 
SNRNP200] 
GO:0007093 
mitotic cell cycle 
checkpoint 
16.0E-3 480.0E-6 [3, 4, 5, 6, 7] Group5 4.19 7 
[CNOT7, FANCI, 
PRKDC, PRMT1, 
RB1, TOP2A, 
ZW10] 
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GO: ID GO: Term 
Term PValue 
Corrected with 
Bonferroni step 
down 
Group PValue 
Corrected 
with 
Bonferroni 
step down 
GOLevels GOGroups 
% Associated 
Genes 
Nr. 
Genes 
Associated Genes 
Found 
GO:1901991 
negative 
regulation of 
mitotic cell cycle 
phase transition 
4.0E-3 480.0E-6 [5, 6, 7, 8] Group5 4.13 9 
[CNOT7, CUL1, 
FANCI, PRKDC, 
PRMT1, PSMD13, 
PSMD2, RB1, 
ZW10] 
GO:0072431 
signal 
transduction 
involved in mitotic 
G1 DNA damage 
checkpoint 
45.0E-3 480.0E-6 
[6, 7, 8, 9, 10, 
11, 12] 
Group5 4.48 3 
[CNOT7, PRKDC, 
PRMT1] 
GO:0032770 
positive regulation 
of 
monooxygenase 
activity 
38.0E-3 2.9E-3 [4, 5, 6] Group6 10.34 3 
[APOE, POR, 
VDAC2] 
GO:0060191 
regulation of 
lipase activity 
37.0E-3 2.9E-3 [5] Group6 4.90 5 
[ABHD5, ARF4, 
ARL1, POR, 
VDAC2] 
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GO: ID GO: Term 
Term PValue 
Corrected with 
Bonferroni step 
down 
Group PValue 
Corrected 
with 
Bonferroni 
step down 
GOLevels GOGroups 
% Associated 
Genes 
Nr. 
Genes 
Associated Genes 
Found 
GO:0050810 
regulation of 
steroid 
biosynthetic 
process 
45.0E-3 2.9E-3 [5, 6, 7] Group6 4.44 4 
[APOE, POR, SF1, 
VDAC2] 
GO:0060193 
positive regulation 
of lipase activity 
28.0E-3 2.9E-3 [6] Group6 4.11 3 
[ABHD5, ARF4, 
ARL1] 
GO:0016197 
endosomal 
transport 
980.0E-6 220.0E-6 [4, 5] Group7 4.07 11 
[AP1G1, AP2A1, 
ARL1, CLTC, 
DNAJC13, EPS15, 
M6PR, RAB21, 
RAB7A, UBE2O, 
VPS41] 
GO:0016482 cytosolic transport 200.0E-6 220.0E-6 [4, 5] Group7 6.16 9 
[AP1G1, AP2A1, 
ARL1, CLTC, 
DNAJC13, EPS15, 
RAB21, RAB7A, 
UBE2O] 
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GO: ID GO: Term 
Term PValue 
Corrected with 
Bonferroni step 
down 
Group PValue 
Corrected 
with 
Bonferroni 
step down 
GOLevels GOGroups 
% Associated 
Genes 
Nr. 
Genes 
Associated Genes 
Found 
GO:0019886 
antigen processing 
and presentation 
of exogenous 
peptide antigen 
via MHC class II 
34.0E-3 220.0E-6 [5] Group7 5.15 5 
[AP1B1, AP1G1, 
AP2A1, CLTC, 
RAB7A] 
GO:0032802 
low-density 
lipoprotein 
particle receptor 
catabolic process 
4.5E-3 220.0E-6 [5, 6, 7] Group7 23.08 3 
[AP2A1, APOE, 
CLTC] 
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